



US009981048B2

(12) **United States Patent**
Fox et al.

(10) **Patent No.:** US 9,981,048 B2
(45) **Date of Patent:** May 29, 2018

(54) **METHODS FOR THE TREATMENT AND PREVENTION OF LIVER DISEASE**

(71) Applicant: **University of Pittsburgh—of the Commonwealth System of Higher Education**, Pittsburgh, PA (US)

(72) Inventors: **Ira Jacob Fox**, Pittsburgh, PA (US); **Aaron W. Bell**, West Mifflin, PA (US); **Taichiro N. Nishikawa**, Pittsburgh, PA (US); **Alejandro Soto-Gutierrez**, Pittsburgh, PA (US); **Yoram Vodovotz**, Sewickley, PA (US)

(73) Assignee: **UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**, Pittsburgh, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 350 days.

(21) Appl. No.: **14/177,928**

(22) Filed: **Feb. 11, 2014**

(65) **Prior Publication Data**

US 2014/0249209 A1 Sep. 4, 2014

Related U.S. Application Data

(60) Provisional application No. 61/763,744, filed on Feb. 12, 2013.

(51) **Int. Cl.**

A61K 48/00 (2006.01)
A61K 31/343 (2006.01)
C07K 14/47 (2006.01)
A61K 45/06 (2006.01)
A61K 31/05 (2006.01)
A61K 31/085 (2006.01)
A61K 31/11 (2006.01)
C12N 15/86 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 48/005** (2013.01); **A61K 31/05** (2013.01); **A61K 31/085** (2013.01); **A61K 31/II** (2013.01); **A61K 31/343** (2013.01);
A61K 45/06 (2013.01); **C07K 14/4702** (2013.01); **C12N 15/86** (2013.01); **C12N 2750/14141** (2013.01); **C12N 2750/14171** (2013.01)

(58) **Field of Classification Search**

CPC .. **A61K 31/7088**; **A61K 35/407**; **C12N 5/067**; **C12N 2501/12**

See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

OTHER PUBLICATIONS

Poynard et al. Impact of Pegylated Interferon Alfa-2b and Ribavirin on Liver Fibrosis in Patients With Chronic Hepatitis C. *Gastroenterology*, 2002, vol. 122, pp. 1303-1313.*

Song et al. Intrasplenic transplantation of syngenic hepatocytes modified by IFN- γ gene ameliorates hepatic fibrosis in rats. *Transplant International*, 2002, vol. 15, pp. 472-478.*

Nishikawa, 2015, JCI, 125:1533-1544.*

Kay, *Nature Reviews Genetics*, advance online publication, pp. 1-13, published online Apr. 6, 2011.*

Misra, *JAPI*, 61: 127-133, 2013.*

Villeneuve (2000, *Hepatology*, 31:207-210).*

Butterworth (2002, *Metabolic Brain Disease*, 17:221-227).*

Berasian, et al., "Expression of Wilms' tumor suppressor in the liver with cirrhosis" Relation to hepatocyte nuclear factor 4 and hepatocellular function, *Hepatology*, 38(1):148-157 (2003).

Berry, et al., "High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study", *J. Cell Biol.*, 43(3):506-520 (1969).

Bolotin, et al., "Integrated approach for the identification of human hepatocyte nuclear factor 4 α target genes using protein binding microarrays", *Hepatology*, 51(2):642-653 (2010).

Bures, et al., "Techniques and basic experiments for the study of brain and behavior", *Elsevier*, pp. 37-45 (1976).

Cawthon, "Telomere measurement by quantitative PCR", *Nucleic Acids Res.*, 30(10):e47 (2002).

Durrand, et al., "Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD", *J. Hepatol.*, 42(Suppl):S 100-S 107 (2004).

Friedman, "Liver fibrosis—from bench to bedside", *J. Hepatol.*, 38(Suppl 1):S38-S53 (2003).

Gines, et al., "Management of Cirrhosis and Ascites", *The New England Journal of Medicine*, 350:1646-1654 (2004).

Gonzalez, "Regulation of hepatocyte nuclear factor 4 α -mediated transcription", *Drug Metabolism Pharmacokinet*, 23(1):2-7 (2008).

Grimm, et al., "In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses", *JVI*, 82(12):5887-5911 (2008).

Guevel, "Identification of small molecule regulators of the nuclear receptor HNF4 α based on naphthofuran scaffolds", *Bioorganic & Medicinal Chemistry*, 17:7021-7030 (2009).

Hayhurst, et al., "Hepatocyte nuclear factor 4 α (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis", *MCB*, 21(4):1393-1403 (2001).

Kobayashi, et al., "Hepatocyte transplantation in rats with decompensated cirrhosis", *Hepatology*, 31(4):851-857 (2000).

Kirmizi, et al., "Plasticity and expanding complexity of the hepatic transcription factor network during liver development", *Genes & Development*, 20(16):2293-2305 (2006).

Limaye, et al., "Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development", *Lab. Invest.*, 88(8):865-872 (2008).

Liu, et al., "The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis", *Hepatology*, 55:1529-1539 (2012).

(Continued)

Primary Examiner — Valarie E Bertoglio

(74) **Attorney, Agent, or Firm — Baker Botts L.P.**

(57) **ABSTRACT**


The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (HNF4 α ; also known as NR2A1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.

(56)


References Cited**OTHER PUBLICATIONS**

- Locker, "Transcriptional Control of Hepatocyte Differentiation", *Molecular Pathology of Liver Diseases*, 5:193-211 (2011).
- Lopez, et al., "Update on liver transplantation: Indications, organ allocation, and long-term care", *Mt. Sinai J. Med.*, 73(8):1056-1066 (2006).
- Marrow, et al., "Direct lineage conversion of terminally differentiated hepatocytes to functional neurons", *Cell Stem Cell*, 9(4):374-382 (2011).
- Martinez-Hernandez, et al., "The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis", *Hepatology*, 14(5):864-874 (1991).
- Matsuhashita, et al., "Adeno-associated virus vectors can be efficiently produced without helper virus", *Gene Ther.*, 5(7):938-945 (1998).
- Michalopoulos, "Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas", *Am. J. Pathol.*, 176(1):2-13 (2010).
- Nagata, et al., "Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation", *Gastroenterology*, 124(2):422-431 (2003).
- Odom, et al., "Core transcriptional regulatory circuitry in human hepatocytes", *Molecular Systems Biology*, Article No. 2006.0017 (5 pages) (2006).
- Parviz, et al., "Hepatocyte nuclear factor 4 α controls the development of a hepatic epithelium and liver morphogenesis", *Nature Genetics*, 34(3):292-296 (2003).
- Pessayre, et al., "Mechanism for reduced drug clearance in patients with cirrhosis", *Gastroenterology*, 74(3):566-571 (1978).
- Schuppan, et al., "Liver Cirrhosis", *Lancet*, 371(9615):838-851 (2008).
- Seglen, "Preparation of isolated rat liver cells", *Methods Cell Biol.*, 13:29-83 (1976).
- Sladek, et al., "Hepatocyte Nuclear Factor 4 α ", *Book Chapter in Nuclear Receptor and Genetics Disease*, Academic Press, London, 2001.
- Sladek, et al., "Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily", *Genes & Development*, 4(12B):2353-2365 (1990).
- Takahashi, et al., "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", *Cell*, 131(5):861-872 (2007).
- Vaubourdolle, et al., "Evidence of the intact hepatocyte theory in alcoholic cirrhosis", *Scand J. Gastroenterol.*, 24(4):467-474 (1989).
- Yue, et al., "Hepatocyte nuclear factor 4 α attenuates hepatic fibrosis in rats", *Gut*, 59(2):236-246 (2010).
- Nishikawa, et al., "Rescue of hepatic function in rats with advanced cirrhosis and end-stage liver failure following delivery of HNF4a," AASLD Abstracts No. 1284, *Hepatology*, 56(4) Suppl.:800A-801A (Oct. 2012).
- Takagi, et al., "MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4 α , Modulating the Expression of Metabolic Enzymes and Cell Cycle*", *The Journal of Biological Chemistry*, 285(7):4415-4422 (2010).
- Wertheim, "Novel Technology for Liver Regeneration and Replacement," *Liver Transplantation* (S1): S41-S46 (2016).
- Giannone, et al., "Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CC1(4)-induced advanced cirrhosis," *Lab Invest* 92:384-395 (2012).
- Jiang, et al., "Metallothionein Gene Therapy for Chemical-Induced Liver Fibrosis in Mice," *Mol Ther.* 10(6):1130-1139 (2004).
- Lin, et al., "Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes," *Liver Int.* 25:796-807 (2005).
- Salgado, et al., "Liver Cirrhosis is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy," *Mol Ther.* 2(6):545-551 (2000).
- Sayyed, et al., "Comparison of the therapeutic effectiveness of human CD34+ and rat bone marrow mesenchymal stem cells on improvement of experimental liver fibrosis in Wistar rats," *Int J Physiol Pathophysiol Pharmacol* 8(3):128-139 (2016).
- Siller-Lopez, et al., "Treatment with Human Metalloproteinase-8 Gene Delivery Ameliorates Experimental Rat Liver Cirrhosis," *Gastroenterology* 126:1122-1133 (2004).
- Sobreval, et al., "Insulin-Like Growth Factor I (IGF-I) Expressed from an AAV1 Vector Leads to a Complete Reversion of Liver Cirrhosis in Rats," *PLoS One* 11(9):e0162955 (2016).
- Xu, et al., "Metallothionein Gene Transfection Reverses the Phenotype of Activated Human Hepatic Stellate Cells," *J Pharmacol Exp Ther* 346:48-53 (2013).

* cited by examiner



*p<0.05, **p<0.001, statistical analysis among isolated normal, compensated and decompensated cirrhotic hepatocytes








Figure 4




*p<0.05, **p<0.01, statistical analysis between isolated hepatocytes from decompensated cirrhotic w/o AAV and with AAV-HNF4α treatment

Figure 5



*p<0.05, **p<0.001, statistical analysis between isolated hepatocytes from decompensated cirrhotic w/o AAV and with AAV-HNF4a treatment



GI: 385298690 (SEQ ID NO: 1)

ggtttgaagaa gaggcagag agggactgg gaggaggcag tgggaggcg gagggcgggg 61
gccttcgggg tggcgccca gggtagggca ggtggccgcg gcgtggaggc agggagaatg 121
cgactctcca aaaccctcg tgcacatggac atggccgact acatgtcgc actggaccca 181
gcctacacca cccttggaaatt tgagaatgtg cagggtttga cgatggcggaa tgacacgtcc 241
ccatcagaag gcaccaaccc caacgcgccc aacagcctgg gigtcajgc cctgtgigcc 301
atcttcgggg accggggcac gggcaaacac tacgggtgcct cgagctgtga cggctgcaag 361
ggcttcctcc ggaggagcgt gcggaaaacac cacatgtact cctgcagatt tagccggcag 421
tgcgttgtgg acaaagacaa gaggaaaccag tgccgctact gcaggcicaa gaaatgttc 481
cgggctggca tgaagaagga agccgtccag aatgagcggg accggatcag cactcgagg 541
tcaagctatg aggacagcag cctgccctcc atcaatgcgc tcctgcaggc ggagggtcc 601
tccccacaga tcacccccc cgttccggg atcaacggcg acattcgggc gaagaagatt 661
gccagcatcg cagatgttg tgagtccatg aaggagcagc tgctggttt ctgttgagtgg 721
gccaagtaca tcccaacgtt ctgcgagctc cccctggacg accagggtggc cctgtcaga 781
gccccatgtg gcgagcacct gctgctcgga gccaccaaga gatccatgtt gtcaaggac 841
gtgctgtcc taggcaatga ctacattgtc ctcggcact gcccggagct ggccggagatg 901
agccgggtgtt ccatacgcac ctttgcacgag ctgggtgcgtgc ccttccaggc gcgtcgatc 961
gtgtacaatg agtatgccta cttcaaaagcc atcattttt ttgaccaggc tgccaagggg 1021
ctgagcgtc caggaaagat caagcggctg ctttcccagg tgcagggtgg ctggaggac 1081
tacatcaacg accggccatg tgactcgcgt gcccgcctttg gagagcgtc gcgtcgatg 1141
cccaccttgc agagcatcac ctggcagatg atcgagcaga tccagttcat caagctttc 1201
ggcatggcca agattgacaa cctttgcag gatgtcgtc tgggagggtc ccccgatcgat 1261
gcaccccatg cccaccaccc cctgcacccct cacctgtatgc aggaacatgtt gggaccaac 1321
gtcatcggtt ccaacacaat gcccactcac ctcaacgc gacagatgtc cacccttgc 1381
accccacatgc ccttcacccgc aggtggctca gggctcgac cctataaagct cctgggggg 1441
gccttcggca caatcgtaa gcccctcttgc gccatcccccc agccgaccat caccacgc 1501
gaagttatct agcaagcgcg tgggcttgg gggctccact ggctcccccc agccccctaa 1561
gagagcacct ggtgtatcag tggtcacggc aaggaaagac gigatgcac gaccgtccc 1621
agagcaggaa tgggaaaggat gaaggccccg agaacatggc ctaaggccca catccccatg 1681
ccaccccttgc cggccctgtc tggataacaa gactttgact tggggagacc tctactgcct 1741
tgacaactt ttctcatgtt gaagccactg cttcacctt caccatcatc catgtccaa 1801
ccccgacttc atcccaaagg acagccgcg ggagatgact tgaggccttta cttaaaccca 1861
gtctcccttct tcccttagctt ggtgttctc ctctccctgc ccctgtcatg gtgtccagac 1921
agagccctgtt gaggctgggtt ccaattgtgg cacttggggc accttgciccc tccctctgt 1981
gtctcccttc cctctgtgc ctccctctgc tgtcaccttgc tccagccatc ccgttcttc 2041
caacaccacc tctccagagg ccaaggaggc citggaaacg attccccccatc tcatctggg 2101
aacatgttgtt aagcactgac tgggaccagg caccaggcag ggtctagaag gtgtgggtga 2161
ggaaagacgc ctittcttc ccaaccaacc tcatcccttct tcttcaggga ctgggtggg 2221
tacttgggtg agatccctg aaggccctca acccgagaaa acaaaccctg gtggggcact 2281
gcaacaggaa ctggagttgg agaggaaaag catcagaag aggcaacca tccaccaggc 2341
ctttgagaaa gggtagaaatt ctggctggta gaggcaggta gatgggacat tccaaagaac 2401
aggctgagcc aaggccctgtt ggttagtaaga atcttagcaag aatggggaa gaatgggttg 2461
ggagagggat gatgaagaga gagagggct gctggagagc atagggtctg gaacaccagg 2521
ctgaggcttgc tgcacatcc aaggatgtt caggagatgtt ggcttccaga aatgaacac 2581
agcgttctg cagaggacgg gaggctggaa gctgggggtt cagggtgggtt ggtatgtata 2641

FIG. 7A1

atgcgggtga gagtaatgag gctggggct ggagaggaca agatggtaa accctcacat 2701
cagagtgaca tccaggagga ataagctccc agggccgtc tcaagcttt ccttactccc 2761
aggcactgtc ttaaggcatc tgacatgcat catctcaitt aatctccct tcctccctat 2821
taaccttagag attgttttg ttttttatttc tcctccccc tccccgcctt caccgcctcc 2881
actccctctt aaccttagaga ttgttacaga agctgaaatt gcgttctaag aggtgaatg 2941
atttttttc taaaactcac acaacttagga agtggctgag tcaggacttg aacccaggtc 3001
tccctggatc agaacaggag ctcttaacta cagtggtgaa atagcttctc caaggctcc 3061
ctgtgttctc accgtgatca agttgagggg ctcccggtc ccttctacag cctcagaaac 3121
cagactcggtt ctctggaa ccctgcccac tcccagggacc aagattggcc tgaggctgca 3181
ctaaaatca cttagggtgcg agcatctgtt ttgctgataa atattaagga gaattcatga 3241
ctcttgacag ctttctctc ttcactcccc aagtcaaggg gagggtggc aggggtctgt 3301
ttccctggaaat tcaggtcat ctggccgtt ggcattgggg tggacagtg tgacagtg 3361
gggggcagggg gagggtcaag caggccctggg tttagggct gctccggaga ccgtcactcc 3421
aggtgcattc tggaaagcatt agacccagg atggagcgac cagcatgtca tccatgtgga 3481
atcttgggtt ctttggggac aitctggaaa atgccactga ccagtgtgaa caaaaggat 3541
gtgttatggg gctggagggtg tgatttaggtt ggagggaaac tggggaccg actccctgccc 3601
cctgctcaac actgaccctt ctgagtgggtt ggaggcagtg ccccaatgtcc cagaaatccc 3661
accattagtg attgtttttt atgagaaaaga ggcgtggaga agtattgggg caatgtgtca 3721
gggaggaaatcc accacatcccc tacggcagtc ccagccaagc ccccaatccc agcggagact 3781
gtgccctgtc cagactcccc aagccctcccc ccaccaccc actcaagtgc ccctgaaatc 3841
cctgccagac ggctcagcct ggtctgggt aaggcaggga ggctggadcc atttctggc 3901
atttgtgtca ttccactgtt gttccctccac ctccctccctc cagcgttgcg cagaccctcg 3961
tcttggggaga aagggtgaga taagaatgtc ccatggagtg cctggggcaa cagtggccct 4021
tcatggggac aatctgttgg agcagggggt cagttctctg ctggaaatct accccctttt 4081
ggaggagaaaa cccatcccc cttaaaactt ttatgtaat gtgagaaaaca caaaacaaag 4141
tttactttt tgactctaag ctgacatgtat attagaaaat ctctcgctt cttttttttt 4201
ttttttttt ttttggcta cttaggttgcg ggtccaaaa cataaaatct gatggacaaa 4261
cagagggttgc ctggggggac aagcgtgggc acatttcccc cacaagaca ccctgtatcc 4321
caggcgggtc tcaggagctt cttaaaatcc gcatggctt cctggagagtg gacagaggag 4381
aggaggggtt cagaaatgaa cgctttctta ttcttgcata ttaccaagcc aattactttt 4441
gccaatttt tctgtatct gcccgttattt agatgttgcg tgaattttac atcaagcaat 4501
tatcaaagcg ggctgggtcc catcagaacg acccacaatct ttctgtgggt gtgaatgtca 4561
tttaggttttgc cgctgacccc tgagccccca tcactggccgc ctgtatggggc aaagaaaacaa 4621
aaaacatttc ttacttttctt gtgttttaac aaaagttat aaaacaaaat aaatggcgca 4681
tatgttttctt aaaaaaaaaaaaaaaa aaaaaaaaaaaa

GI: 385298689 (SEQ ID NO: 2)

gggttgaag gaaggcagag agggcactgg gaggaggcag tgggaggcg gagggcggg 61
gccttcgggg tgggcgccca gggttagggca ggtggcccg gcgtggaggc agggagaatq 121
cgactctcca aaacccttgt cgacatggac atggccact acagigcgc actggacc 181
gcctacacca cccttggatt tgagaatgtg caggtgttga cgatggc 1gacacgtcc 241
ccatcagaag gcaccaacct caacgcgc 1aacagcctgg gtgtcagcgc cctgtgtgcc 301
atctgcgggg accggggcac gggcaaaacac tacggtgct cgagctgtga cggctgcaag 361
ggcttcttcc ggagggagcgt gcggaagaac cacatgtact cctgcagatt tagccggcag 421
tgcggttgtgg acaaagacaa gaggaaccag tgccgtact gcaggtctaa gaaatgttc 481

FIG. 7A2

cgggctggca	tgaagaagga	agccgtccag	aatgagcggg	accggatcag	cactcgaaagg	541
tcaagctatg	aggacagcag	cctgcctcc	atcaatgcgc	tcctgcaggc	ggaggtcctg	601
tcccgcacaga	tcacccccc	cgtctccggg	atcaacggcg	acattcgggc	gaagaagatt	661
gccagcatcg	cagatgtgtg	ttagtccatg	aaggagcagc	tgctggttct	cgttgagtgg	721
gccaagtaca	tcccagctt	ctgcgagtc	ccccctggacg	accaggtggc	cctgctcaga	781
gcccattgtq	gctggcacct	gttgtccgg	gcccccaaga	gatccatggt	gttcaaggac	841
gtgtctgtcc	taggcaatga	ctacatgtc	cctcggcact	gccccggagct	ggcggagatg	901
agccgggtgt	ccatacgcgt	ccttgacgag	ctggggctgc	ccttccagga	gctgcagatc	961
gatgacaatg	agtatgccta	cctcaaaagcc	atcatctct	ttgacccaga	tgccaaagggg	1021
ctgagcgatc	cagggaaagat	caagcggctg	cgttcccagg	tgcaggtgag	citggaggac	1081
tacatcaacg	accggccatg	tgacatcggt	ggccgccttg	gagagctgct	gtgtctgtq	1141
ccccacccgtc	agagcatcac	ctggcagatg	atcgagcaga	tccagttcat	caagctttc	1201
ggcatggcca	agattgacaa	cctgttgcag	gagatgtgc	tgggagggtc	ccccagcgat	1261
gcaccccatg	cccacccaccc	cctgcacccct	cacctgtatc	aggAACATAT	ggggAACCAAC	1321
gtcatcggtt	ccaacacaat	gcccaactcac	ctcagcaacg	gacagatgtg	tgagtggccc	1381
cgaccccgagg	gacaggcagc	cacccctgtg	accccaacgc	cctcaccggc	agggtggctca	1441
gggtctgtgc	cctataagct	cctgcgggta	gcccgtccca	caatcgtaa	gccccctctct	1501
gccatcccccc	agccgaccat	caccaagcag	gaagttatct	agcaagccgc	tggggcttgg	1561
gggctccact	ggctcccccc	agccccctaa	gagagcacct	ggtgtatcag	tggtcacggc	1621
aaaggaagac	gtgtatgcag	gaccagtccc	agagcagaaa	tgggaaaggat	aaaggggccc	1681
agaacatggc	ctaagggcc	catccccatg	ccaccccttg	cgccctgtct	tggataaacaa	1741
gactttgact	tggggagacc	tctactgcct	tggacaactt	ttctcatgtt	gaagccactg	1801
ccttcacctt	cacccatc	catgtccaaac	ccccgacttc	atcccaaagg	acagccgcct	1861
ggagatgact	tgaggcctt	ctttaaaaaaa	gtcccttct	tccctagcct	gtgtcttctc	1921
ctctccctagc	ccctgtcatg	gtgtccagac	agagccctgt	gaggctgggt	ccaattgtgg	1981
cacttggggc	acccatgtcc	tccttctgt	gtgtccccca	cctctgtctc	ctccctctgc	2041
tgtcaccttq	ctcagccatc	ccgtcttctc	caacaccacc	tctccagagg	ccaaggaggg	2101
cttggaaacg	attccccca	tcattctggg	aacatgttgt	aagcactgac	tgggaccagg	2161
caccaggcag	ggtctagaag	gctgtggiga	ggaaagacgc	ctttctctc	caacccaaacc	2221
tcatccctct	tcttcaggga	cttgggtggg	tacttgggt	aggatccctg	aaggccttca	2281
accccgagaaa	acaaaaccag	gttggcgact	gcaacagaa	cttggagtgg	agaggaaaag	2341
catcagaaaq	aggcagacca	tccaccaggc	ctttgagaaa	gggtagaatt	ctggctggta	2401
gagcagggtg	gatgggacat	tccaaagaac	agcctgagcc	aaggccttagt	gttagtaaga	2461
atctagcaag	aattgaggaa	gaatgggtg	ggagaggat	gatgaagaga	gagaggccc	2521
gctggagagc	atagggtctg	gaacaccagg	ctgaggctt	gatcagcttc	aggagatatg	2581
cagggagctg	ggcttccaga	aaatgaacac	agcagtctg	cagaggacgg	gaggctggaa	2641
gctgggaggt	caggtgggg	ggatgtata	atgcgggtg	gagtaatgag	gcttggggct	2701
ggagaggacca	agatggtaa	accctcacat	caagtgaca	tccaggagga	ataagctccc	2761
agggccgtgc	tcaagctctt	ccttactccc	aggcactgtc	ttaaggcatc	tgacatgtat	2821
catctcattt	aatcccttct	tcctccat	taacctagag	atttttttgc	tttttttattc	2881
tcctccctcc	tccccggccct	cacccggcccc	actcccttct	aaccttagaga	ttgttacaga	2941
agctgaaatt	gcgttctaag	aggtaatgt	attttttttc	tgaaactcac	acaacttagga	3001
agtggctgag	tcaggacttg	aacccaggtc	tccctggatc	agaacaggag	ctcttaacta	3061
cagtggctga	atagcttctc	caaaggctcc	ctgtgttctc	accgtatca	agttgaggg	3121

FIG. 7A3

cttccggctc ctttctacag ctcagaaac cagactcggtt ctctggaa ccctgcccac 3181
 tccccaggacc aagattggcc tgaggctgcataaaatca cttagggtcg agcatcctgt 3241
 ttgtgtataat atattaagga gaattcatga ctcttgacag cttttcttc ttcaactcccc 3301
 aagtcaagggg gagggtggc aggggtctgt ttcttggaa tcaggctcat ctggcctgtt 3361
 ggcattgggg tgggacagtg tgacagtggtt gggggcagggg gagggttaag cagggctggg 3421
 tttgagggtct gctccggaga ccgtcaactcc aggtgcattc tggaaagcatt agaccccagg 3481
 atggagcgac cagcatgtca tccatgtgga atcttgggtt ctgttggggcatttggaaa 3541
 atgcactgtca ccagtgtgaa caaaaaggat gtgttatggg gctggagggtt tgatttaggtt 3601
 ggaggggaaac tggggccgg actccctgccc cctgctcaac actgaccctt ctgagtgggtt 3661
 ggaggccatgtg ccccaatccc cagaaatccc accattatgtt atgtttttt atgagaaaga 3721
 ggcgtggaga agtattgggg caatgtgtca gggaggaaatc accacatccc tacggcagtc 3781
 ccagccaagc ccccaatccc agcggagact gggccctgtt cagactccc aaggcttccc 3841
 ccaccaccc actcaatgtc ccctgaaatc cctgcccac ggttcagctt ggtctgcgggt 3901
 aaggcaggga ggctggaaacc atttctggc attgtggtca ttccactgtt gttccctccac 3961
 ctccctccctc cagcgttctt cagacccttc tcttgggaga aagggttggaa taagaatgtc 4021
 ccatggatgtc ccgtggccat cagtgccctt tcatgggaaac aatctgttggg aacgggggggt 4081
 cagttctctg ctggaaatct acccccttctt ggaggagaaaa cccatccac cttataact 4141
 ttatgttaat gtgagaaaca caaaaacaaag tttactttt tgactctaag ctgacatgtat 4201
 attagaaaat ctctcgctt ctttttttt tttttttttt tttttggctt ctgagttgtt 4261
 ggtcctaaaa cataaaatctt gatggacaaa cagagggttgg ctggggggac aacgggtggc 4321
 acaatttccc caccaagaca ccctgtatctt caggcgggtt ctaggatctt ctaaaaatcc 4381
 gcatggctt cctgagatgtt gacagaggag aggagagggtt cagaatgtt cgtctttctt 4441
 ttcttgtca ttaccaagcc aattactttt gccaatttt tctgtatctt gcccgttattt 4501
 agatgaattt gtaaattttt atcaagcaat tatcaaagcg ggctgggtcc catcagaacg 4561
 acccacatctt ttcgtgggtt gtgtatgtca tttaggtttt cgttgcaccc ttggccccc 4621
 tcaactgcgc cttgtggggc aaagaaacaa aaaacatitc ttactttctt gtgttttaac 4681
 aaaagttat aaaacaaaat aaatggcgca tatgtttttt aaaaaaaaaa aaaaaaaaaa

GI: 385298691 (SEQ ID NO: 3)

gtttggaaag gaaggcagag agggcactgg gaggaggcag tgggagggcg gaggggcg 61
 gccttcgggg tgggcggccca ggttggggca gggtggcccg gctgtggggc agggagaatg 121
 cgactctcca aaaccctctgt cgacatggac atggccgact acagtgttc actggaccca 181
 gcctacacca ccctggaaattt tgagaatgtt caggtgttgc cgttggcaaa tgacacgtcc 241
 ccatcagaag gacccaaacctt caacggccccc aacagccctgg gtgtcagcgc cctgtgtgcc 301
 atctgcgggg accggggccac gggcaaaacac tacgggtgcctt ctagtgcgttgc cggctgc 361
 ggcttcttcc ggaggagatgtt gcgaaagaac cacaatgtt cctgcagatt tagccggcag 421
 tgcgtgggtt acaaaagacaa gaggaaaccag tgccgtactt ctaggttcaaa gaaatgtttt 481
 cgggtggca tgaagaaggg aacgggtccatg aatggggggc accggatcg cactcgaagg 541
 tcaagctatgtt aggacagcgatgtt cctgccttcc atcaatgttc tccgtggggc ggagggtcc 601
 tcccgacaga tcacccccc cgttccggg atcaacggcg acattccggc gaagaagattt 661
 gccagcatcg cagatgtgtt tggtttttt aaggaggcagc tgctgtttt cttttttttt 721
 gccaagtaca tcccaatgtt ctgtggatgtt cccctggacg accagggtggc cctgttcaga 781
 gcccatgtt gcgagccatgtt gctgttcggaa gccaccaaga gatccatgtt gttcaaggac 841
 gtgtgtttttt taggtttttt ttatgtttttt cttttttttt gttttttttt 901
 accgggggtgtt ccatacgtatgtt ctttgcgtttt cttttttttt gttttttttt 961

FIG. 7A4

gatgacaatg agtatgccta cctcaaagcc atcatcttct ttgaccaga tgccaagggg 1021
 ctgagcgatc cagggaaatg caagcggtcg cgttcccagg tgcagggtgag cttggaggac 1081
 tacatcaacg accgcgcata tgactcgcgt ggccgcttgc gagagctgct gctgtgtcg 1141
 cccaccttc agagcatcac ctggcagatg atcgagcaga tccagttcat caagcttc 1201
 ggcattggcca agattgacaa cctgttgca gatatgtctgc tgggagggtcc gtgccaagcc 1261
 caggaggggc ggggttggag tggggactcc ccaggagaca ggcctcacac agtgagcica 1321
 cccctcaget ccttggctc cccactgtgc cgcttggc aagttgttta acctgtgt 1381
 gcctcagttt cctcaccaga aaaatgggaa caaggcaatg gtctatttgt tcaggcaccg 1441
 agaaccttagc acgtgcccagt cactgttcta agtgtggca attcagcaaa gaacaagatc 1501
 tttgccctcg gggagggtgt gtgtgtgtga gtatgtatgg atgcgtggat atctgtgtat 1561
 atgcccgtat gtgcgtcat gtgtatataa agccctcacat ttatgtattt tggaaaataaac 1621
 aggttaata

GI: 385298688 (SEQ ID NO: 4)

ggccatggtc agcgtgaacg cgccccctcg ggctccagtg gagagtctt acgacacgtc 61
 cccatcgaa ggcaccaacc tcaacgcgcc caacagcctg ggtgtcagcg ccctgtgtgc 121
 catctgcggg gaccggggca cggggaaaca ctacggtgcc tcgagctgtg acggctgcac 181
 ggctcttc cggaggagcg tgcggaaagaa ccacatgtac tcctgcagat tttagccggca 241
 gtgcgtgtg gacaaagaca agaggaacca gtgccgtac tgcaggctca agaaatgttt 301
 ccgggctggc atgaagaagg aagccgtcca gaatgagcgg gaccggatca gcaactcgaag 361
 gtcaagctat gaggacagca gcctgcccic catcaatgcg ctctgcagg cggagggtct 421
 gtcccacacg atcacctccc ccgttcccg gatcaacggc gacattcggg cgaagaagat 481
 tgcagcatac gcagatgtgt gtgagttccat gaaggagcag ctgctgttgc tcgttgatgt 541
 ggccaagtac atccccatgtt tctgcgagct cccctggac gaccagggtgg ccctgtctcg 601
 agcccatgtc ggcgagcacc tgctgctcg ggccaccaag agatccatgg ttttcaagga 661
 cgtgtgtctc cttaggcatac actacattgt ccctcggtac tgcccgagc tggcgagat 721
 gagccgggtg tccatacgca tccttgacga gctgggtgtc cccttcagg agtgcagat 781
 cgtatgcataat gatgtgcct acctcaaaacg catcatcttc tttgaccag atgccaagg 841
 gctgagcgt ccaggaaaga tcaagcggt gcgttcccaag gtgcagggtga gcttggagga 901
 ctacatcaac gaccggcaatg atgactcggt tggccgtt ggagagctgc tgctgtgt 961
 gcccacccatg cagagcatca cctggcagat gatcgagcag atccaggatca tcaagcttt 1021
 cggcatggcc aagattgaca acctgttgca ggagatgtgt ctgggggggt ccccccagcga 1081
 tgcacccatg gcccacccacc ccctgcaccc tcacctgtatc caggaacata tggaaaccaa 1141
 cgtcatcgat gccaacacaa tgcccaactca cctcagcaac ggacagatgt gtgagttggcc 1201
 ccgaccagg ggacaggcag ccacccctga gaccccacag ccctcaccgc cagggtggctc 1261
 aggtcttagt ccctataaagc tcctgcccggg agccgtcgcc acaatgtca agcccttc 1321
 tgcacatcccc cagccgacca tcaccaagca ggaagttatc tagcaagccg ctgggggttgc 1381
 gggctccac tggctccccc cagccccata agagagcacc tggtgatcact gttggcacgg 1441
 caaaggaaga cgtgtgcata ggaccaggcc cagagcagga atgggaaggaa tggaaaggccc 1501
 gagaacatgg cctaaaggccc acatcccact gccacccttg acggccctgtct ctggataaca 1561
 agactttgac ttggggagac ctctactgccc ttggacaact ttctctatgt tggatccact 1621
 gccttcacct tcacccatc ccatgtccaa ccccccactt catccccaaag gacagccgccc 1681
 tggagatgac ttggggccctt acttaaaccctt acgtcccttc ttcccttagcc tgggtgttct 1741
 ccttccttag cccctgtcat ggtgtccaga cagagccctg tgaggctggg tccaaattgtg 1801
 gcacttgggg caccttgctc ctcccttcgtc tgctgcccccc acctctgtcg cctccctctg 1861

FIG. 7A5

FIG. 7A6

GI: 385298686 (SEQ ID NO: 5)

ggccatggtc agcgtgaacg cgcccctcg ggctccagtg gagaggctt acgacacgtc 61
ccccatcgaa ggcaccaacc tcaacgcgcc caacagcctg ggtgtcagcg ccctgtgtc 121
catctgcggg gaccggggca cggggaaaca ctacggtgcc tcgagctgtg acggctgcaa 181
gggccttc cggaggagcg tgcgaaagaa ccacatgtac tcctgcagat ttggccggca 241
gtgcgtggt gacaaagaca agagaacca gtgcgcgtac tgcaaggctca agaaatgctt 301
ccgggctggc atgaagaagg aagccgtcca gaatgagcgg gaccgatca gcactcqaaq 361
gtcaagctat gaggacagca gcctgcctc catcaatgcg ctccigcagg cggaggicci 421
gtccccacag atcacctccc ccgtctccgg gatcaacggc gacattcggg cgaagaagat 481
tgccagcatac gcagatgtgt gtgagtccat gaaggagcag ctgctggttc tcgttgtgtg 541
ggccaagtac atccccatgc tctgcgagct cccctggac gaccagggtgg ccctgcctcag 601
agcccatgtc ggcgagcacc tgctgctcg ggccaccaag agatccatgg ttgtcaagga 661
cgtgctgctc ctggcaatg actacattgt ccctcggcac tgccggagc tggcggagat 721
gagccgggtg tccatacga tcctgacga gctggtgetg cccttccagg agctgcagat 781
cgatgacaat gatgtgcct acctcaaagc catcatcttc ttgaccagg atgccaagg 841
gctgagcgtat ccagggaaaga tcaagcggct gcgttcccgat gtgcaggtga gettggagga 901
ctacatcaac gaccgcgtt atgactcgcg tggccgcattt ggagagctgc tgctgctgct 961
gcccacccgt cagagcatca cctgcagat gatcgagcag atccagttca tcaagctt 1021
cgccatggcc aagattgaca acctgttgca ggagatgctg ctgggagggt ccccccagcga 1081
tgccacccat gcccaccacc ccctgcaccc tcacctgtatc caggaacata tggaaaccaa 1141
cgtcatcggtt gccaacacaa tgccactca cctcagcaac ggacagatgt ccacccctga 1201
gaccccacag ccctcaccgc caggtggctc agggtctgag ccctataaagc ttctgcccgg 1261
agecgctgcc acaatcgta agcgccttc tgccatcccc cagccgacca tcaccaagca 1321
ggaagttatc tagcaagccg ctggggcttg ggggctccac tggctcccc cagcccccta 1381
agagagcacc tggtgatcac gtggtcacgg caaaggaaaga cgigatgcga ggaccagtc 1441
cagagcagga atgggaagga tgaaggggccc gagaacatgg cctaaggggc acatcccact 1501
gcccacccgt acgcgcgtt ctggataaca agactttgac ttggggagac ctctactgccc 1561
ttggacaact ttctcatgt tgaagccact gccttcaccc tcacccatcat ccatgtccaa 1621
cccccgactt catcccaaag gacagccgcc tggagatgac ttgaggcctt acttaaacc 1681
agctcccttc ttccctagcc tggtgcttct cctctccat cccctgtcat ggtgtccaga 1741
cagagccctg tgaggctggg tccaattgtg gcacttgggg caccttgctc ctccctctgc 1801
tgctgcccccc acctctgtcg cctccctctg ctgtcacctt gtcagccat cccgtcttct 1861
ccaacaccac ctctccagag gccaaggagg ctgtggaaac gattccccca gtcattctgg 1921
gaacatgtt gaaacatgtt ctgggaccag gcaccaggca gggcttagaa ggctgtgggtg 1981
agggaaagacg ctttctctt ccaacccaaac ctcatctcc ttcttcaggg acttgggtgg 2041
gtacttgggt gaggatccct gaaggccttc aacccggaaa aacaaacca ggttggcgcac 2101
tgcacacagga acttggatgt gaggaaaaaa gcatcagaaa gaggcagacc atccaccagg 2161
cctttgagaa agggatggat tctgctggt agagcaggat agatgggaca ttccaaagaa 2221
cagcctgagc caaggcctag tggtagtaag atcttagcaa gaatttggaa agaatgggtt 2281
gggagaggga tggatggatgg agagaggggcc tgctggagag cataggctt ggaacaccag 2341
gctgagggtcc tggatggatcc caaggatgtt gcaaggatgtt gggcttccag aaaatgaaca 2401
cagcgttctt gcaaggatgtt ggaggctggg agctgggggg tcagggtggg tggatgtat 2461
aatgcgggtg agatgtatgtt ggcttggggc tggagaggac aagatgggtt aaccctcaca 2521
tcagagtgtt atccaggagg aataagctcc caggccctgtt ctcaagctt ctctactcc 2581
cagcactgt cttaaggcat ctgacatgca tcatttcattt taatcccttccat 2641

FIG. 7A7

ttaacctaga gattttttt gttttttatt ctcccttcc ctccccgcc 2701
 cactccctcc taacctagag attgttacag aagctgaat tgcgttctaa gaggtgaagt 2761
 gattttttt ctgaaaactca cacaacttagg aagtggctga gtccaggactt gaaccaggat 2821
 ctccctggat cagaacagga gctttaact acagtggctg aatagcttc ccaaaggatc 2881
 cctgtgttct caccgtgatc aagttgaggg gcttccggct cccttctaca gcctcagaaaa 2941
 ccagactcggt tcttctggaa accctgccc ctcccaggac caagattggc ctgaggctgc 3001
 actaaaattc acttagggtc ggcatacttg ttgtctgata aatattaagg agaattcatg 3061
 actcttgaca gttttctct cttcaactccc caagtcaagg ggaggggttgg caggggtctg 3121
 tttcctggaa gtcaggctca tctggctgt tggcatgggg gtgggacagt gtgcacagt 3181
 tgggggcagg ggaggctaa gcaggctgg gttttagggc tgctccggag accgtcaactc 3241
 cagggtcatt ctggaagcat tagaccccaag gatggagcga ccagcatgtc atccatgtgg 3301
 aatcttggtg gctttgagga catctggaa aatgccactg accagtgtga aaaaaaggaa 3361
 tgtgttatgg ggctggaggt gtgatttagt aggaggaaaa ctgttggacc gactcctgcc 3421
 cccgtctcaa cactgacccc tctgagtgg tggaggcagt gccccagtgc ccagaaatcc 3481
 caccattagt gattttttt tatgagaaaaq aggctgtggag aagtattggg gcaatgtgtc 3541
 agggaggaat caccacatcc ctacggcagt ccacggcaag cccccaatcc cagcggagac 3601
 tggccctgc tcagagctcc caagccttcc cccaccaccc cactcaagtg cccctgaaat 3661
 cccgtccaga cggctcagcc tggctgtggg taaggcaggg aggttggaaac catttctggg 3721
 cattgtggtc attcccactg ttttcttcca cttccctccct ccagcgttgc tcagacctct 3781
 gtcttggag aaggttgag ataagaatgt cccatggagt gccgtggca acagtggccc 3841
 ttcatggaa caatctttt ggcgggggg tcaatgttct gctggaaatc taccctttc 3901
 tggaggagaa acccatcca ccttaataaac ttattgtaa tgtgagaaac aaaaaacaaaa 3961
 gtttactttt ttgactctaa gctgacatga tatttagaaaa tctctcgctc tttttttttt 4021
 tttttttttt ttttttggct acttgatgtt tggtccctaa acataaaatc tcatggacaa 4081
 acagagggtt gctgggggg caagcgtggg cacaatttcc ccaccaagac accctgatct 4141
 tcaggcgggt ctctggagct tctaaaaatc cgcatggctc tcctgagagt ggacagagga 4201
 gaggagaggg tcagaatgt acgtcttctt atttcttgc attaccaage caattacttt 4261
 tgccaaattt ttctgtatc tgccctgtttt aagatgttta gtggaaatttt catcaagcaa 4321
 ttatcaaaggc gggctgggtc ccatcagaac gacccacatc ttctgtggg ttttggatgtc 4381
 attaggtctt gctgtaccc ctgagcccccc atcaactgccc cctgtatgggg caaagaaaca 4441
 aaaaacattt ctacttcc ttgttttaa caaaatgttta taaaacaaaaa taatggcgc 4501
 atatgttttcaaaaaaaaaaaaaaaa

GI: 385298687 (SEQ ID NO: 6)

ggccatggtc agcgtgaacg cgccccctcg ggctccagtg gagagtctt acgacacgtc 61
 cccatcagaa ggcaccaacc tcaacgcgcc caacagccctg ggtgtcagcg ccctgtgtgc 121
 catctgcggg gacggggcca cggccaaaca ctacggtgc tcgagctgtg acggctgcac 181
 gggcttcttc cggaggagcg tgccggaaagaa ccacatgtac tcctgcagat ttggccggca 241
 gtgcgtggtg gacaaagaca agaggaacca gtgcgcgtac tgccggatca agaaatgttt 301
 cccggctggc atgaagaagg aagccgttca gaatgagccg gacccggatca gcactcgaag 361
 gtcacatgat gaggacagca gcctgccttc catcaatgc ctccctcgagg cggaggcttc 421
 gtcccgacag atcacctccc ccgtctccgg gatcaacggc gacattcggg cgaagaagat 481
 tgccagcata gcaatgtgt gtggatccat gaaggagccg ctgttggatc tggttggatg 541
 ggccaaatgtac atcccaatgtt tctgcgatc cccctggac gaccaggatgg ccctgtctcag 601
 agccatgtct ggcggacacc tgctgctcg ggccaccaag agatccatgg ttttcaaggaa 661

FIG. 7A8

cgtgctgctc ctaggcaatg actacattgt ccctcgac tggcggagat 721
gagccgggtg tcatacgca tccttgcga gctggigctg ccctccagg agctgcagat 781
cgatgacaat gagtatgcct acctaagaac catcatctt tttgaccagg atgccaagg 841
gctgagcgat ccaggaaaga tcaagcgct gcttcccag gtgcaggta gcttggagg 901
ctacatcaac gaccgcaagt atgactcgq tggccgctt ggagagctgc tgctgctgct 961
gcccaccttg cagagcatca cctggcagat gatcgagcag atccagttca tcaagcttt 1021
cgccatggcc aagattgaca acctgttgcg ggagatgtg ctggggggc cgtgccaagc 1081
ccaggagggg cgggggttgg a gtggggactc cccaggagac aggcctcaca cagtgagctc 1141
acccttcagc tccttggct cccactgtg ccgtttggg caagttgtt aacctgtctg 1201
tgcttcagg ttcctcacca aaaaatggg acaaggcaat ggtctatgg ttcaaggcacc 1261
gagaacctag cacgtgccag tcactgttct aagtgcgtgc aattcagcaa agaacaagat 1321
cttgccttc ggggaggctg tgttgtgtg agtatgtatg gatgcgtgg tatctgtgt 1381
tatgcccgtt ttttgtgtca tgtgtatata aagcctcaca ttttatgatt ttgaaataaa 1441
caggtaata

FIG. 7A9

GI: 31077207 (SEQ ID NO: 7)

mrlsktlvdm dmadysaald payttafen vqvltmgndt spsegtnlna pnslgvsalc 61
aicgdratgk hygasscdgc kgffrrsvrk nhmyscrfsr qcvvdkdkrn qcrycrlkkc 121
fragmkkeav qnerdristr rssyedsslp sinallqaev lsrqitspvs gingdirakk 181
iasiaadvces mkeqlvvle wakyipafce lplddqvall rahagehlll gatkrsrmvf 241
dvlllgndyi vprhcpelae msrvsirild elvlpfqelq iddneyaylk aiiffdpdak 301
glsgpgkikr lrsqvqvsle dyindrqyds rgrfgeilll lptlqositwq mieqiqfikl 361
fgmakidnll qemllggsp s daphahhplh phlmqehmgt nvivantmpt hlsngqmstp 421
etpqpsppgg sgsepykllp gavativkpl saipaptitk qevi

GI: 31077205 (SEQ ID NO: 8)

mrlsktlvdm dmadysaald payttafen vqvltmgndt spsegtnlna pnslgvsalc 61
aicgdratgk hygasscdgc kgffrrsvrk nhmyscrfsr qcvvdkdkrn qcrycrlkkc 121
fragmkkeav qnerdristr rssyedsslp sinallqaev lsrqitspvs gingdirakk 181
iasiaadvces mkeqlvvle wakyipafce lplddqvall rahagehlll gatkrsrmvf 241
dvlllgndyi vprhcpelae msrvsirild elvlpfqelq iddneyaylk aiiffdpdak 301
glsgpgkikr lrsqvqvsle dyindrqyds rgrfgeilll lptlqositwq mieqiqfikl 361
fgmakidnll qemllggsp s daphahhplh phlmqehmgt nvivantmpt hlsngqmcew 421
prprgqaatp etpqpsppgg sgsepykllp gavativkpl saipaptitk qevi

GI: 31077209 (SEQ ID NO: 9)

mrlsktlvdm dmadysaald payttafen vqvltmgndt spsegtnlna pnslgvsalc 61
aicgdratgk hygasscdgc kgffrrsvrk nhmyscrfsr qcvvdkdkrn qcrycrlkkc 121
fragmkkeav qnerdristr rssyedsslp sinallqaev lsrqitspvs gingdirakk 181
iasiaadvces mkeqlvvle wakyipafce lplddqvall rahagehlll gatkrsrmvf 241
dvlllgndyi vprhcpelae msrvsirild elvlpfqelq iddneyaylk aiiffdpdak 301
glsgpgkikr lrsqvqvsle dyindrqyds rgrfgeilll lptlqositwq mieqiqfikl 361
fgmakidnll qemllggpcq aqegrqwsqd spgdrphtvs splsslasp crfgqva

GI: 71725339 (SEQ ID NO: 10)

mvsvnaplga p v e s s y d t s p s e g t n l a p n s l g v s a l c a i c g d r a t g k h y g a s s c d g c k g f f r s v r k n h m y s c r f s r q v v d k d k r n q c r y c r l k k c 61
f f r r s v r k n h m y s c r f s r q c v v d k d k r n q c r y c r l k k c f r a g m k k e a v q n e r d r i s t r r s 121
s y e d s s l p s i n a l l q a e v l s r q i t s p v s g i n g d i r a k k i a s i a d v c e s m k e q l l v l v e w a 181
k y i p a f c e l p l d d q v a l l r a h a g e h l l l g a t k r s r m v f k d v l l l g n d y i v p r h c p e l a e m s 241
r v s i r i l d e l v l p f q e l q i d d n e y a y l k a i i f f d p d a k g l s d p g k i k r l r s q v q v s l e d y 301
i n d r q y d s r g r f g e l l l l p t l q s i t w q m i e q i q f i k l f g m a k i d n l l q e m l l g g s p s d a 361
p h a h h p l h p h l m q e h m g t n v i v a n t m p t h l s n g q m c e w p r p r g q a a t p e t p q p s p p g g s g 421
s e p y k l l p g a v a t i v k p l s a i p q p t i t k q e v i

FIG. 7B1

GI: 71725341 (SEQ ID NO: 11)

mvsvnaplga p v e s s y d t s p s e g t n l n a p n s l g v s a l c a i c g d r a t g k h y g a s s c d g c k g 61
f f r r s v r k n h m y s c r f s r q c v v d k d k r n q c r y c r l k k c f r a g m k k e a v q n e r d r i s t r r s 121
s y e d s s l p s i n a l l q a e v l s r q i t s p v s g i n g d i r a k k i a s i a d v c e s m k e q l l v l v e w a 181
k y i p a f c e l p l d d q v a l l r a h a g e h l l l g a t k r s m v f k d v l l l g n d y i v p r h c p e l a e m s 241
r v s i r i l d e l v l p f q e l q i d d n e y a y l k a i i f f d p d a k g l s d p g k i k r l r s q v q v s l e d y 301
i n d r q y d s r g r f g e l l l l l p t l q s i t w q m i e q i q f i k l f g m a k i d n l l q e m l l g g s p s d a 361
p h a h h p l h p h l m q e h m g t n v i v a n t m p t h l s n g q m s t p e t p q p s p p g g s g s e p y k l l p g a 421
v a t i v k p l s a i p q p t i t k q e v i

GI: 71725336 (SEQ ID NO: 12)

mvsvnaplga p v e s s y d t s p s e g t n l n a p n s l g v s a l c a i c g d r a t g k h y g a s s c d g c k g 61
f f r r s v r k n h m y s c r f s r q c v v d k d k r n q c r y c r l k k c f r a g m k k e a v q n e r d r i s t r r s 121
s y e d s s l p s i n a l l q a e v l s r q i t s p v s g i n g d i r a k k i a s i a d v c e s m k e q l l v l v e w a 181
k y i p a f c e l p l d d q v a l l r a h a g e h l l l g a t k r s m v f k d v l l l g n d y i v p r h c p e l a e m s 241
r v s i r i l d e l v l p f q e l q i d d n e y a y l k a i i f f d p d a k g l s d p g k i k r l r s q v q v s l e d y 301
i n d r q y d s r g r f g e l l l l l p t l q s i t w q m i e q i q f i k l f g m a k i d n l l q e m l l g g p c q a q 361
e g r g w s g d s p g d r p h t v s s p l s s l a s p l c r f g q v a

FIG. 7B2

1

METHODS FOR THE TREATMENT AND PREVENTION OF LIVER DISEASE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Ser. No. 61/763,744 filed Feb. 12, 2013, the contents of which are incorporated by reference in its entirety.

GRANT INFORMATION

This invention was made with government support under DK048794 awarded by the National Institutes of Health. The government has certain rights in the invention.

SEQUENCE LISTING

The specification further incorporates by reference the Sequence Listing submitted herewith via EFS on May 19, 2014. Pursuant to 37 C.F.R. § 1.52(e)(5), the Sequence Listing text file, identified as 0723960546Seqlist.txt, is 65,477 bytes and was created on May 16, 2014. The Sequence Listing, electronically filed herewith, does not extend beyond the scope of the specification and thus does not contain new matter.

BACKGROUND

Cirrhosis of the liver, a disease that is difficult to manage, is responsible for 1.2% of all U.S. deaths (1). Cirrhosis is most commonly caused by alcoholism, hepatitis B and hepatitis C, and fatty liver disease, but has many other possible causes such as non-alcoholic steatohepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hereditary hemochromatosis, Wilson's disease, or alpha 1-antitrypsin deficiency.

Late stages of cirrhosis are characterized by portal hypertension and hepatic encephalopathy, terminal extrahepatic processes that result from fibrosis and vascular remodeling of the cirrhotic liver (2,3). These pathologies are superimposed on liver failure, which results from the inability of hepatocytes to adequately synthesize coagulation factors, conjugate and secrete bilirubin, and regulate metabolism (4-7). Generally, liver damage from cirrhosis cannot be reversed. Therefore, aggressive management can extend life, but the only definitive therapy for end-stage cirrhosis is orthotopic liver transplantation (8).

The cause of organ failure in cirrhosis is poorly understood, but impaired hepatocytes have both intrinsic damage and reside in an abnormal microenvironment (2-8). Studies have shown that somatic cells can be reprogrammed into pluripotent stem cells and fibroblasts or hepatocytes can be reprogrammed into other mature cell lineages following forced expression of selected transcription factors (9,10), although these methods have not been proven *in vivo* for the treatment of cirrhosis. Accordingly, there is a need for new methods to treat and/or manage cirrhosis and chronic liver disease.

SUMMARY

The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (HNF4 α ; also known as NR2A1), a transcription factor, reverses hepat-

2

cyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.

Accordingly, in one aspect, the present invention provides 5 a method of treating or reducing or preventing hepatic failure or cirrhosis in a subject, e.g., a human subject, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an HNF4 α agonist to the subject. In one embodiment, the agonist is a small molecule. In another embodiment, the agonist is an HNF4 α nucleic acid molecule. For example, the HNF4 α nucleic acid molecule can be a therapeutic vector comprising a nucleic acid molecule encoding HNF4 α . In one embodiment, a hepatocyte from the subject can be transduced with the therapeutic vector *in vitro* and reintroduced into the subject, or transduced *in vivo*. In another embodiment, the agonist is an HNF4 α protein or functional fragment thereof or a peptidomimetic thereof.

In another embodiment, the present invention provides 20 a method of treating or preventing hepatic failure or cirrhosis in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agonist to a hepatic network factor regulated by HNF4 α , such as, for example, HNF1 α , FOXA2, or CEBP α , alone or in combination with an HNF4 α agonist.

In some embodiments, the agonist is administered alone or in combination with one or more other agent or procedure used for the treatment or prevention of hepatic failure or cirrhosis or symptoms thereof, e.g., interferon therapy, 30 diuretic drugs, transjugular intrahepatic portosystemic shunt (TIPS), paracentesis, antibiotics, drugs for the prevention of variceal bleeding, lactulose, changes to diet, and/or abstinence from alcohol. In one embodiment, the HNF4 α agonist is administered in a subject as a bridge to liver transplantation.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-E. Characterization of the hepatocyte transcription factor network in decompensated cirrhosis. (A) Expression changes in the hepatocyte transcription factor network in decompensated cirrhosis (microarray data). (B) Immunohistochemistry; magnification, $\times 100$ and (cytospins) $\times 200$ (C) qPCR and (D) western blot for HNF4 α expression in liver tissue and isolated hepatocytes from compensated and decompensated cirrhotic livers. Normal age-matched livers or hepatocytes were used as controls. β -actin was used as the PCR control. (E) Expression of liver-specific genes and genes affected downstream of HNF4 α .

FIGS. 2A-B. Effect of HNF4 α re-expression in isolated hepatocytes from decompensated cirrhotic livers. (A) qRT-PCR analysis of hepatocyte transcription factor network and hepatocyte-specific genes. (B) Albumin synthesis and cytochrome P450 (CYP3A4) activity. Studies were carried 55 out on culture day 2 and compare hepatocytes from normal liver and decompensated cirrhotic livers, the latter also treated with AAV-HNF4 α -GFP or AAV-GFP.

FIGS. 3A-C. Effect of HNF4 α re-expression in rats with decompensated cirrhosis and liver failure. (A) Gross and microscopic (hematoxylin & eosin and fluorescence staining) assessment of decompensated cirrhotic livers two and fourteen weeks after intervention. Cirrhotic rats with continued severe liver failure, four weeks after their last dose of CCL4, were given a recombinant AAV expressing either HNF4 α and GFP or GFP only; microscopic magnification $\times 100$. (B) Fluorescence staining for GFP and co-staining for hepatocyte (albumin) or non-parenchymal liver

cell (α -SMA and EpCAM) markers; magnification $\times 200$. (C) Survival and clinical parameters of liver failure in control, AAV-GFP and AAV-HNF4 α -GFP-treated animals with decompensated cirrhosis.

FIGS. 4A-D. Characterization of hepatocytes recovered from treated decompensated cirrhotic rats after HNF4 α re-expression. (A) Albumin synthesis and Cytochrome P450 (CYP3A4) activity in decompensated cirrhotic hepatocytes recovered 14 weeks after AAV-HNF4 α /GFP treatment. Hepatocytes recovered from normal livers and compensated cirrhotic livers were used as controls. (B) qRT-PCR analysis of hepatocyte transcription factor network and hepatocyte-specific gene expression in hepatocytes recovered from decompensated cirrhotic livers and decompensated cirrhotic livers 14 weeks after AAV-HNF4 α /GFP treatment. (C) Fluorescence staining for Ki67, a proliferation marker, and its quantification in AAV-HNF4 α -GFP-treated decompensated cirrhotic hepatocytes; magnification $\times 200$ (D) qRT-PCR analysis for TERT expression and telomere length by genomic DNA analysis.

FIG. 5. Effect of HNF4 α re-expression on expression of hepatic progenitor and liver-specific genes in hepatocytes from decompensated cirrhotic livers. qPCR analyses of hepatic progenitor markers (AFP, CD44 and EpCAM), mature hepatic specific genes (Albumin, ASGPRI1, CK18), epithelial cell related genes (Cdh1 and Ctnnb1) and the protein TGF β 1. Each value represents the mean \pm SD. Statistical analysis was performed among three groups (normal, compensated and decompensated cirrhotic hepatocytes) and between un-treated decompensated cirrhotic hepatocytes and decompensated cirrhotic hepatocytes 14 weeks after in vivo HNF4 α re-expression (*p<0.05, **P<0.001).

FIGS. 6A-B. Effect of HNF4 α re-expression on histology and fibrosis-related genes in rats with decompensated cirrhosis and liver failure. (A) Masson and oil red stained photomicrographs with quantification of fibrosis and fat deposition in decompensated cirrhotic rat livers two and fourteen weeks after AAV-HNF4 α /GFP therapy. Normal control, compensated cirrhotic and un-treated or AAV-GFP treated decompensated cirrhotic livers were used as controls. Fibrosis and fat deposition decreased significantly two and fourteen weeks after HNF4 α re-expression. Magnification $\times 100$ (B) qPCR analysis of fibrosis-related genes (TIMP1, TIMP2, TIMP3, ACTA2, COL1a1, and TGF β 1) from isolated hepatocytes and tissue recovered from decompensated cirrhotic livers. HNF4 α re-expression induced down regulation of TIMP2 and TIMP3. Each value represents the mean \pm SD. Statistical analysis was performed among four groups (control decompensated cirrhotic hepatocytes, and decompensated cirrhotic hepatocytes 2 after AAV-GFP treatment, or 2 and 14 weeks after AAV-HNF4 α /GFP treatment (*p<0.05, **P<0.001).

FIGS. 7A1-7A9 and 7B1-7B2. (A) Exemplary human HNF4 α nucleic acid sequences, as set forth in SEQ ID NOS:1-6, include HNF4 α transcript variants 1-6, respectively, set forth as Genbank accession numbers GI:385298690, GI:385298689, GI:385298691, GI:385298688, GI:385298686, and GI:385298687, respectively. (B) Exemplary human HNF4 α amino acid sequences, as set forth in SEQ ID NOS:7-12, include HNF4 α transcript variants a-f, respectively, set forth as Genbank accession numbers GI:31077207, GI:31077205, GI:31077209, GI:71725339, GI:71725341, and GI:71725336, respectively.

DETAILED DESCRIPTION

The present disclosure describes the discovery that the forced expression of hepatocyte nuclear factor 4 alpha

(HNF4 α ; also known as NR2A1), a transcription factor, reverses hepatocyte dysfunction in cirrhosis in vivo. In particular, the present inventors have found that transduction of hepatocytes in cirrhotic animals with irreversible decompensated function produced a profound and immediate improvement in hepatic function and prolonged survival.

Furthermore, the present inventors confirm the role of HNF4 α as an important regulator of the hepatocyte transcription factor network and a master gene for liver function that is down-regulated in advanced cirrhosis. Down-regulation of HNF4 α has a profound effect on the end-stage cirrhotic hepatocyte in vitro, as replenishment of this single factor revitalizes hepatocyte function.

As described herein, using an animal model of cirrhosis and progressive liver failure (11), the inventors have shown that end-stage cirrhotic hepatocytes, previously considered to be senescent and irreversibly dysfunctional, can quickly revert to normal function following transduction with the transcription factor HNF4 α , even though surrounded by an abnormal extracellular matrix. HNF4 α reexpression immediately corrected the phenotype of cultured cirrhotic hepatocytes and reversed terminal end-stage cirrhosis and liver failure in vivo in this animal model. Normalization of function took place in two weeks while portal hypertension, evidenced by the presence of ascites, regressed when histological reversal of cirrhosis was more complete. It was found that HNF4 α acted by phenotypically correcting diseased hepatocytes, not by stimulating their replacement.

Accordingly, the invention provides methods for treating liver failure and cirrhosis (and/or improving liver function in a subject having a cirrhotic liver), comprising administering a therapeutically effective amount of an HNF4 α agonist, e.g., a HNF4 α nucleic acid, protein or functional fragment thereof, peptidomimetic, small molecule, or other drug candidate, to a subject, e.g., a mammal. In one embodiment, the HNF4 α agonist is a therapeutic vector comprising a nucleic acid molecule encoding HNF4 α protein or a functional fragment thereof. In another embodiment, the HNF4 α agonist is a small molecule agonist.

In another embodiment, the present invention provides a method of treating or preventing hepatic failure or cirrhosis in a subject comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agonist to a hepatic network factor regulated by HNF4 α , such as, for example, HNF1 α , FOXA2, or CEBP α (Locker J., Transcriptional Control of Hepatocyte Differentiation. In: Monda S P, editor, Molecular Pathology of Liver Disease. London, Academic Press; 2001; Kyrmizi, et al. 2006, *Genes Dev.* 20(16):2293-305; Odom et al. 2006 *Mol. Sys. Biol.* 2:2006), alone or in combination with an HNF4 α agonist.

An “individual” or “subject” herein is a vertebrate, such as a human. Mammals include, but are not limited to, humans, primates, farm animals, sport animals, rodents and pets.

An “effective amount” of a substance as that term is used herein is that amount sufficient to effect beneficial or desired results, including clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied. In the context of administering a composition that improves liver function, improves liver histology (e.g., fibrosis), or treats liver failure or cirrhosis, an effective amount of an HNF4 α agonist is an amount sufficient to achieve such a modulation as compared to the liver function, histology, or level of cirrhosis when there is no an HNF4 α agonist administered. An effective amount can be administered in one or more administrations.

As used herein, and as well-understood in the art, “treatment” is an approach for obtaining beneficial or desired results, including clinical results. For purposes of this subject matter, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, prevention of disease, delay or slowing of disease progression, and/or amelioration or palliation of the disease state. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.

Agonists

The term “HNF4 α therapeutic” refers to various forms of HNF4 α nucleic acids, polypeptides, peptidomimetics, or small molecules, which can increase expression of liver-specific genes, increase CYP activity, increase liver function, improves liver histology (e.g., fibrosis), treat or prevent cirrhosis, or prolong survival in a subject suffering from liver failure. An HNF4 α therapeutic that mimics, potentiates, or increases the activity of a wild-type HNF4 α polypeptide is a “HNF4 α agonist.” An HNF4 α therapeutic includes a gene therapy vector comprising an HNF4 α nucleic acid sequence.

The term “agonist,” as used herein, is meant to refer to an agent that mimics or upregulates (e.g., increases, potentiates or supplements) HNF4 α expression or bioactivity, or expression or bioactivity of a hepatic network factor regulated by HNF4 α , such as, for example, HNF1 α , FOXA2, or CEBP α .

An HNF4 α agonist can be a small molecule, a wild-type HNF4 α nucleic acid, protein, derivative, or functional fragment thereof having at least one bioactivity of the wild-type HNF4 α and the ability to increase expression of liver-specific genes, increase CYP activity, increase liver function, improve liver histology (e.g., fibrosis), treat or prevent cirrhosis, or prolong survival in a subject suffering from liver failure. In one embodiment, an HNF4 α agonist is an agent that upregulates expression (which includes forced reexpression) of an HNF4 α gene. An agonist can also be a compound which increases the interaction of a HNF4 α polypeptide with another molecule. Accordingly, a HNF4 α agonist includes a nucleic acid (e.g., using adenoviral expression), micro RNA, e.g., miR-122, which has been shown to be regulated by HNF4 α , (Li, et al, 2011 *J. Hepatol.* 55(3):602-11), a peptidomimetic, protein, or functional fragment thereof, peptide, or small molecule (or other drug candidate) that increases the expression or activity of HNF4 α .


Accordingly, an agonist against a hepatic network factor regulated by HNF4 α , such as, for example, HNF1 α , FOXA2, or CEBP α includes a nucleic acid (e.g., using adenoviral expression), micro RNA, a peptidomimetic, protein, or functional fragment thereof, peptide, or small molecule (or other drug candidate) that increases the expression or activity of a hepatic network factor regulated by HNF4 α .

Small Molecule Agonists

Small molecule agonists can be used in the methods of the invention to increase expression or activity of HNF4 α or a hepatic network factor regulated by HNF4 α , such as, for example, HNF1 α , FOXA2, or CEBP α . In one embodiment, exemplary small molecules that can be used in the methods of the invention are described in Le Guével R et al. *Bioorg. Med Chem.*, 2009 Oct. 1; 17(19):7021-30. The small molecules identified therein are synthetic compounds bearing a methoxy group branched on a nitronaphthofuran backbone. The nitro group and a complete naphthofuran backbone were required for full activity of the small molecules tested.

Furthermore, adding a hydroxy group at position 7 of the minimal backbone led to an active compound. These compounds were found to be highly toxic in a human HepG2C3A hepatoma cell assay, except when methylated on the furan ring. One such compound was able to modulate HNF4 α -driven transcription in transfected HepG2C3A cell. Therefore, HNF4 α activity can be modulated (e.g., increased) by small molecules.

In certain non-limiting embodiments, the small molecule comprises the structure of Formula I:




wherein R₁ is selected from the group consisting of NO₂, COOEt, COOH, CONH₂, and H; and wherein R₂ is selected from the group consisting of OCH₃, H, OH, OCH₂COOEt, OCH₂COOH, and OMe; wherein Me is methyl and Et is ethyl.


In certain non-limiting embodiments, the small molecule comprises the structure of Formula I wherein R₁ is NO₂ and R₂ is OH.

In certain non-limiting embodiments, the small molecule comprises the structure of Formula I wherein R₁ is CONH₂ and R₂ is H.


In certain non-limiting embodiments, the small molecule comprises the structure of Formula II:




wherein R is selected from the group consisting of:




7
-continued




In certain non-limiting embodiments, the small molecule comprises the structure of Formula III:




In certain non-limiting embodiments, the small molecule comprises the structure of Formula IV:




In certain non-limiting embodiments, the small molecule comprises the structure of Formula VIII:




In certain non-limiting embodiments, the small molecule comprises the structure of Formula IX:




In certain non-limiting embodiments, the small molecule comprises the structure of Formula X:





In certain non-limiting embodiments, the small molecule comprises the structure of Formula V:



In certain non-limiting embodiments, the small molecule comprises the structure of Formula VI:




In certain non-limiting embodiments, the small molecule comprises the structure of Formula XI:




In certain non-limiting embodiments, the small molecule comprises the structure of Formula VII:


In certain non-limiting embodiments, the small molecule comprises the structure of Formula XII:



In certain non-limiting embodiments, the small molecule comprises the structure of Formula XIII:



In certain non-limiting embodiments, the small molecule comprises the structure of Formula XIV:



HNF4 α Nucleic Acid Agonists

The term "HNF4 α nucleic acid" or "HNF4 α " refers to a nucleic acid encoding an HNF4 α protein, such as, but not limited to, nucleic acids having SEQ ID NOS:1-6 (Genbank accession numbers GI:385298690, GI:385298689, GI:385298691, GI:385298688, GI:385298686, and GI:385298687, respectively; FIG. 7A), fragments thereof, complement thereof, and derivatives thereof.

The invention further provides for the use of variant HNF4 α polynucleotides, and fragments thereof, that differ from the nucleotide sequence shown in SEQ ID NOS: 1-6 due to degeneracy of the genetic code and thus encode the same protein as that encoded by the nucleotide sequences shown in SEQ ID NOS: 1-6.

The invention also provides for the use of HNF4 α nucleic acid molecules encoding the variant polypeptides described above. Such polynucleotides may be naturally occurring, such as allelic variants (same locus), homologs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. Accordingly, as discussed herein, the variants can contain nucleotide substitutions, deletions, inversions and insertions.

Typically, variants have a substantial identity with a nucleic acid molecules of SEQ ID NOS:1-6 and the complements thereof. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. These variants comprise a nucleotide sequence encoding a polypeptide that is typically at least about 60-65%, 65-70%, 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more homologous to the nucleotide

sequence shown in SEQ ID NOS:1-6 or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under stringent conditions, to the nucleotide sequence shown in SEQ ID NOS:1-6 or a fragment of the sequence.

In one embodiment, nucleic acids comprising sequences encoding HNF4 α protein are administered to treat or prevent liver failure or cirrhosis, by way of gene therapy. Gene therapy refers to therapy performed by the administration to 10 a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary 15 methods are described below. For a review of gene therapy in the liver, see Domvri, et al., Current Gene Therapy 12(6): 463-483(21) (2012) and Atta, World J Gastroenterol. 2010 Aug. 28; 16(32): 4019-4030. For general reviews of the methods of gene therapy, see Kron and Kreppel, Curr Gene Ther 12(5):362-73 (2012); Yi et al. Curr Gene Ther 11(3): 218-28 (2011); Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and 20 Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly 25 known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY 30 (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an HNF4 α polypeptide or functional fragment thereof, said nucleic acid sequences being 35 part of expression vectors that express the HNF4 α polypeptide or functional fragments thereof in a suitable host. In particular, such nucleic acid sequences have promoters operably linked to the HNF4 α coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. Because of their universal activity, viral promoters 40 were components of many first-generation vectors. However, many of the viral promoters, such as the cytomegalovirus (CMV) promoter, are attenuated or completely shut-off in organs such as the liver. In comparison to viral or housekeeping promoters, tissue- or liver-specific promoters direct higher levels of expression in vivo. (Atta, World J Gastroenterol. 2010 Aug. 28; 16(32): 4019-4030).

Delivery of nucleic acid into a subject or hepatocyte may be either direct, in which case the subject or hepatocyte is 45 directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, hepatocytes are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

The nucleic acid may be directly administered in vivo, where it is expressed to produce the encoded product. This 50 can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Pat. No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors 55 or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus,

by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu and Wu, *J Biol. Chem.* (1987); 262:4429-4432). The nucleic acid-ligand complexes can also be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In addition, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* (1989); 86:8932-8935; Zijlstra et al., *Nature* (1989); 342:435-438).

The liver is an attractive target for gene therapy because hepatocytes are readily accessible via the blood stream. The endothelium of hepatic sinusoids displays fenestrations that are 100 nm wide and that allow macromolecules such as viral particles to cross the endothelium and reach hepatocytes. Moreover, the hepatic blood flow represents one-fifth of the cardiac output. Thus, any particle injected into the blood circulation can quickly reach the liver. For this reason, the vascular route is commonly used. (Atta, *World J Gastroenterol.* 2010 Aug. 28; 16(32): 4019-4030).

A method for intravascular regional hydrodynamic delivery of vectors has been developed. The method entails the use of an occlusion balloon catheter into the inferior vena cava and retro dynamically injecting the plasmid in saline solution towards the liver and through the hepatic vein. This retrodynamic hepatic vein gene delivery method has been performed in pigs, and led to liver transgene expression. (Crespo A, *Gene Ther.* 2005; 12:927-935; Eastman S J, *Hum Gene Ther.* 2002; 13:2065-2077; Brunetti-Pierri N, *Mol Ther.* 2007; 15:732-740; Dariel A, *J Pediatr Surg.* 2009; 44:517-522).

Retrograde administration of adenoviruses into the common bile duct has been shown to induce efficient transgene expression in the liver without causing severe adverse effects, thus supporting the feasibility of adenovirus-mediated gene transfer into the liver in clinical settings by means of endoscopic retrograde cholangiography. (Kuriyama S, *Int J Mol Med.* 2005; 16:503-508; Kuriyama S, *Oncol Rep.* 2005; 13:825-830; Peeters M J, *Hum Gene Ther.* 1996; 7:1693-1699). Repeat administration of adenoviruses into the common bile duct is successful in re-expressing the transgene in the liver. (Tominaga K, *Gut.* 2004; 53:1167-1173; Tsujinoue H, *Int J Oncol.* 2001; 18:575-580).

Another method for delivery of gene products into liver cells is also described in U.S. Patent Application Publication No. 20100010068. This method involves limiting blood flow to the liver during infusion of the vector into the liver.

In a specific embodiment, a viral vector that contains nucleic acid encoding an HNF4 α polypeptide or a functional fragment thereof may be used. For example, a retroviral vector can be used (see Miller et al., *Meth. Enzymol.* (1993); 217:581-599). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* (1994); 6:291-302. Other references illustrating the use of retroviral vectors in gene therapy are: Anson, *Genet Vaccines Ther.* 13; 2(1):9 (2004); Clowes et al., *J. Clin. Invest.* (1994); 93:644-651; Kiem et al., *Blood* (1994); 83:1467-1473; Salmons and Gunzberg, *Human Gene Therapy* (1993); 4:129-141; and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* (1993); 3:110-114.

Adenoviruses are especially attractive vehicles for delivering genes. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems include the liver. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kron and Kreppel, *Curr Gene Ther* 12(5):362-73 (2012) and Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In one embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) may also be used (Zhong et al. *J Genet Syndr Gene Ther* January 10; S1. pii:008; High, K A, *Blood*, 120(23):4482-7 (2012); Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Pat. No. 5,436,146). In a preferred embodiment, AAV vectors are used. Vectors that can be used in gene therapy are discussed below in detail below.

Another approach to gene therapy involves transferring a gene to a hepatocyte in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the hepatocytes. The cells are then placed under selection to isolate those hepatocytes that have taken up and are expressing the transferred gene. Those hepatocytes are then delivered to a patient.

In one embodiment, a genetic construct expressing HNF4 α can be introduced into the subject's hepatocytes which can then be propagated ex vivo in, for example, a tolerized non-human animal with a chimeric liver as described in, for example, U.S. Pat. No. 6,525,242. Alternatively, the hepatocytes may be used to colonize the liver of a tolerized animal prior to or contemporaneous with the introduction of the desired transgene via a gene therapy vector. The cells can then be harvested from the chimeric animal and reintroduced into the subject. Hepatocytes used for colonization may be enriched for cells containing the desired construct, for example, by selection by culture conditions, antibody/FACS methods, etc. which eliminate cells lacking the construct.

The nucleic acid can be introduced into a hepatocyte prior to administration in vivo of the resulting recombinant hepatocyte. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

13

The resulting recombinant hepatocytes can be delivered to a patient by various methods known in the art. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Recombinant cells can also be used in gene therapy, where nucleic acid sequences encoding an HNF4 α protein or functional fragment thereof, are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. For example, stem or progenitor cells can be used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used (see e.g., PCT Publication WO 94/08598; Porada and Porada, J. Genet Syndr Gene Ther., May 25; S1. p 11:011 (2012); Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

HNF4 α Polypeptide Agonists

The terms "HNF4 α polypeptide," "HNF4 α protein" and "HNF4 α " are intended to encompass polypeptides comprising the amino acid sequence of SEQ ID NOS: 7-12 (Genbank accession numbers GI:31077207, GI:31077205, GI:31077209, GI:71725339, GI:71725341, and GI:71725336, respectively; FIG. 7B), fragments thereof (e.g., functional fragments thereof), and variants thereof, and include agonist polypeptides.

In one embodiment, the present invention provides for the use of an isolated or purified HNF4 α polypeptide and variants and fragments thereof. The invention also encompasses the use of sequence variants. Variants include a substantially homologous protein encoded by the same genetic locus in an organism, i.e., an allelic variant. Variants also encompass proteins derived from other genetic loci in an organism, but having substantial homology to the HNF4 α protein of SEQ ID NOS: 7-12. Variants also include proteins substantially homologous to the HNF4 α protein but derived from another organism, i.e., an ortholog. Variants also include proteins that are substantially homologous to the HNF4 α protein that are produced by chemical synthesis. Variants also include proteins that are substantially homologous to the HNF4 α protein that are produced by recombinant methods.

As used herein, two polypeptides (or regions thereof) are substantially homologous when the amino acid sequences are at least about 60-65%, 65-70%, 70-75%, typically at least about 80-85%, and most typically at least about 90-95%, or 95-99% or more homologous. A substantially homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence hybridizing to the nucleic acid sequence, or portion thereof, of the sequence shown in SEQ ID NOS:-7-12 under stringent conditions.

The HNF4 α proteins used in the methods of the invention also include HNF4 α polypeptides having additions, deletions or substitutions of amino acid residues (variants) which do not substantially alter the biological activity of the protein. Those individual sites or regions of HNF4 α which may be altered without affecting biological activity may be determined by examination of the structure of the HNF4 α binding domains, for example. Alternatively, one may empirically determine those regions which would tolerate amino acid substitutions by alanine scanning mutagenesis (Cunningham et al. Science 244, 1081-1085 (1989)). In this method, selected amino acid residues are individually substituted with a neutral amino acid (e.g., alanine) in order to determine the effects on biological activity.

14

It is generally recognized that conservative amino acid changes are least likely to perturb the structure and/or function of a polypeptide. Accordingly, the invention encompasses one or more conservative amino acid changes within a HNF4 α protein. Conservative amino acid changes generally involve substitution of one amino acid with another that is similar in structure and/or function (e.g., amino acids with side chains similar in size, charge and shape). Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residue within a HNF4 α protein can be replaced with other amino acid residues from the same side chain family and the altered protein can be tested for retained function using the functional assays described herein. Modifications can be introduced into an antibody of this disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. If such substitutions result in a retention in biological activity, then more substantial changes may be introduced and/or other additions/deletions may be made and the resulting products screened. In one embodiment, deletions or additions can be from 5-10 residues, alternatively from 2-5 amino acid residues, or from 1-2 residues.

Vectors

The terms "vector" and "expression vector" mean the vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a host cell, so as to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, etc.; they are discussed in greater detail below. A "therapeutic vector" as used herein refers to a vector which is acceptable for administration to an animal, and particularly to a human.

Vectors typically comprise the DNA of a transmissible agent, into which foreign DNA is inserted. A common way to insert one segment of DNA into another segment of DNA involves the use of enzymes called restriction enzymes that cleave DNA at specific sites (specific groups of nucleotides) called restriction sites. Generally, foreign DNA is inserted at one or more restriction sites of the vector DNA, and then is carried by the vector into a host cell along with the transmissible vector DNA. A segment or sequence of DNA having inserted or added DNA, such as an expression vector, can also be called a "DNA construct." A common type of vector is a "plasmid", which generally is a self-contained molecule of double-stranded DNA, usually of bacterial origin, that can readily accept additional (foreign) DNA and which can readily be introduced into a suitable host cell. A plasmid vector often contains coding DNA and promoter DNA and has one or more restriction sites suitable for inserting foreign DNA. Coding DNA is a DNA sequence that encodes a particular amino acid sequence for a particular protein or enzyme. Promoter DNA is a DNA sequence which initiates, regulates, or otherwise mediates or controls the expression of the coding DNA. Promoter DNA and coding DNA may be from the same gene or from different genes, and may be from the same or different organisms. A large number of vectors, including plasmid and fungal

vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts. Non-limiting examples include pKK plasmids (Clonetech), pUC plasmids, pET plasmids (Novagen, Inc., Madison, Wis.), pRSET plasmids (Invitrogen, San Diego, Calif.), pCDNA3 plasmids (Invitrogen), pREP plasmids (Invitrogen), or pMAL plasmids (New England Biolabs, Beverly, Mass.), and many appropriate host cells, using methods disclosed or cited herein or otherwise known to those skilled in the relevant art. Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g., antibiotic resistance, and one or more expression cassettes.

Suitable vectors include viruses, such as adenoviruses, adeno-associated virus (AAV), vaccinia, herpesviruses, baculoviruses and retroviruses, parvovirus, lentivirus, bacteriophages, cosmids, plasmids, fungal vectors, naked DNA, DNA lipid complexes, and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.

Lentiviral vectors have been reported to deliver genes to primary liver cells efficiently and permanently, integrating into the genome of non-dividing cells such as primary liver cells (Lewis and Emerman "Passage through mitosis is required for oncoretroviruses but not the immunodeficiency virus" *J. Virol.* 1994, 68:510-6). Lentiviral vectors are described in, for example, Choi et al (2001, *Stem Cells* 2001; 19(3):236-46) or in U.S. Pat. No. 6,218,186.

Viral vectors, especially adenoviral vectors can be complexed with a cationic amphiphile, such as a cationic lipid, polyL-lysine (PLL), and diethylaminoethyldextran (DE-LAE-dextran), which provide increased efficiency of viral infection of target cells (See, e.g., PCT/US97/21496 filed Nov. 20, 1997, incorporated herein by reference). AAV vectors, such as those disclosed in Zhong et al., *J. Genet Syndr Gene Therapy* 2012 Jan. 10; S1, pii: 008, U.S. Pat. Nos. 5,139,941, 5,252,479 and 5,753,500 and PCT publication WO 97/09441, the disclosures of which are incorporated herein, are also useful since these vectors integrate into host chromosomes, with a minimal need for repeat administration of vector. For a review of viral vectors in gene therapy, see McConnell et al., 2004, *Hum Gene Ther.* 15(11):1022-33; McCarty et al., 2004, *Annu Rev Genet.* 38:819-45; Mah et al., 2002, *Clin. Pharmacokinet.* 41(12): 901-11; Scott et al., 2002, *Neuromuscul. Disord.* 12(Suppl 1):S23-9.

Pharmaceutical Compositions

The present invention further provides pharmaceutical compositions which comprise an HNF4 α agonist, e.g., all or portions of HNF4 α polynucleotide sequences, HNF4 α polypeptides or functional fragments thereof, small molecule, or other HNF4 α agonists, alone or in combination with at least one other agent, such as a stabilizing compound, and may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The composition may be in a liquid or lyophilized form and comprises a diluent (Tris, citrate, acetate or phosphate buffers) having various pH values and ionic strengths, solubilizer such as Tween or Polysorbate, carriers such as human serum albumin or gelatin, preservatives such as thimerosal, parabens, benzylalconium chloride or benzyl alcohol, antioxidants such as ascorbic acid or sodium metabisulfite, and other components such as lysine or glycine. Selection of a particular composition will depend upon a number of factors, including the condition being

treated, the route of administration and the pharmacokinetic parameters desired. A more extensive survey of components suitable for pharmaceutical compositions is found in Remington's Pharmaceutical Sciences, 18th ed. A. R. Gennaro, ed. Mack, Easton, Pa. (1980).

The methods of the present invention find use in treating hepatic failure or cirrhosis. Peptides can be administered to the patient intravenously in a pharmaceutically acceptable carrier such as physiological saline. Standard methods for intracellular delivery of peptides can be used (e.g., delivery via liposome). Such methods are well known to those of ordinary skill in the art. The formulations of this invention are useful for parenteral administration, such as intravenous, subcutaneous, intramuscular, and intraperitoneal. Therapeutic administration of a polypeptide intracellularly can also be accomplished using gene therapy. The route of administration eventually chosen will depend upon a number of factors and may be ascertained by one skilled in the art.

In other embodiments, the pharmaceutical compositions 20 of the present invention can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral or nasal ingestion by a patient to be treated.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the 30 intended purpose. For example, a therapeutically effective amount of an HNF4 α agonist is that amount that increases expression of liver-specific genes, increases CYP activity, increases liver function, improves liver histology (e.g., fibrosis), treats or prevents cirrhosis, or prolongs survival in 35 a subject suffering from liver failure. The amount will vary from one individual to another and will depend upon a number of factors, including the overall physical condition of the patient, severity and the underlying cause of liver failure and/or cirrhosis.

A target liver function can be determined by a liver 40 function test, which typically measures, for example, albumin, total bilirubin, direct bilirubin, and/or INR Prothrombin Time. The clinical signs of protein dysfunction, manifested by hepatic encephalopathy (which can be measured by an elevated arterial ammonia level), and muscle wasting are manifestations of hepatocyte failure, which can be made worse by portal hypertension. Therefore, improvement in liver function can also be assessed by the presence or absence of fibrosis in the liver, ascites, muscle wasting, 45 ammonia levels, neurologic function (hepatic encephalopathy), etc. in the subject. Liver biopsy, such as a needle biopsy, can be used to assess the degree of fibrosis and cirrhosis of the liver. It is understood that such targets will vary from one individual to another such that physician discretion may be appropriate in determining an actual target liver function for any given patient. Nonetheless, determining a target liver function is well within the level of skill in the art.

The formulations of the invention can be administered for 50 prophylactic and/or therapeutic treatments. For example, in alternative embodiments, pharmaceutical compositions of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate liver failure and/or cirrhosis. As is well known in the medical arts, dosages for any one 55 patient depends upon many factors, including stage of the disease or condition, the severity of the disease or condition, the patient's size, body surface area, age, the particular

17

compound to be administered, sex, time and route of administration, general health, and interaction with other drugs being concurrently administered.

Accordingly, in some embodiments of the present invention, HNF4 α nucleotide and HNF4 α amino acid sequences or other HNF4 α agonists can be administered to a patient alone, or in combination with one or more other nucleotide sequences, drugs, lifestyle changes, etc. used in the treatment or prevention of liver failure and/or cirrhosis or symptoms thereof (for example, interferon therapy, diuretic drugs, transjugular intrahepatic portosystemic shunt (TIPS), paracentesis, antibiotics, drugs for the prevention of variceal bleeding, lactulose, changes to diet, and/or abstinence from alcohol) or in pharmaceutical compositions where it is mixed with excipient(s) or other pharmaceutically acceptable carriers. In one embodiment, the HNF4 α agonist is administered in a subject as a bridge to liver transplantation.

In one embodiment of the present invention, the pharmaceutically acceptable carrier is pharmaceutically inert. In another embodiment of the present invention, HNF4 α poly-nucleotide sequences or HNF4 α amino acid sequences or other HNF4 α agonists may be administered alone to individuals subject to or suffering from liver failure and/or cirrhosis. The dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the active agents' rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996) Pharmazie 51:337-341; Fotherby (1996) Contraception 54:59-69; Johnson (1995) J. Pharm. Sci. 84:1144-1146; Rohatagi (1995) Pharmazie 50:610-613; Brophy (1983) Eur. J. Clin. Pharmacol. 24:103-108; the latest Remington's, supra). The state of the art allows the clinician to determine the dosage regimen for each individual patient, active agent and disease or condition treated. Guidelines provided for similar compositions used as pharmaceuticals can be used as guidance to determine the dosage regimen, i.e., dose schedule and dosage levels, administered practicing the methods of the invention are correct and appropriate.

Single or multiple administrations of formulations can be given depending on the dosage and frequency as required and tolerated by the patient. The formulations should provide a sufficient quantity of active agent to effectively treat, prevent or ameliorate or liver failure and/or cirrhosis or symptoms thereof as described herein. For example, an exemplary pharmaceutical formulation for oral administration can be in a daily amount of between about 0.1 to 0.5 to about 20, 50, 100 or 1000 or more μ g per kilogram of body weight per day of protein. In an alternative embodiment, dosages are from about 1 mg to about 4 mg per kg of body weight per patient per day of protein are used. For example, in one embodiment a therapeutically effective amount of a polypeptide of this invention is a dosage of between about 0.025 to 0.5 milligram per 1 kilogram of body weight of the patient; or, a therapeutically effective amount is a dosage of between about 0.025 to 0.2 milligram, or 0.05 to 0.1 milligram, or 0.075 to 0.5 milligram, or 0.2 to 0.4 milligram, of the compound per 1 kilogram of body weight of the patient. In another embodiment, a single dose is sufficient to achieve the desired results.

In one embodiment, the HNF4 α agonists of the invention are administered once, twice, or three times per week for all indications except the surgery indication, by intravenous (IV) or subcutaneous (SC) injection to reach a suggested target liver function range. Once the target liver function has been achieved, a maintenance dosing schedule is established which will vary depending upon the patient.

18

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals (LD50, the dose lethal to 50% of the population; and ED50, the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio LD50/ED50. Compounds that exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and additional animal studies can be used in formulating a range of dosage for human use. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The following Example is offered to more fully illustrate the invention, but is not to be construed as limiting the scope thereof.

Example 1: Upregulation of HNF4 α to Treat Hepatic Failure

This Example illustrates that end-stage cirrhotic hepatocytes, previously considered to be senescent and irreversibly dysfunctional, can revert to normal function following transduction with nucleic acid encoding the transcription factor HNF4 α , even though surrounded by an abnormal extracellular matrix. As described herein, HNF4 α reexpression immediately corrected the phenotype of cultured cirrhotic hepatocytes and reversed terminal end-stage cirrhosis and liver failure *in vivo*.

More than a decade ago, the inventors developed a unique model in rats, using chronic administration of CCl₄, to produce a syndrome of cirrhosis and progressive liver failure that greatly resembles human disease (11). While the latter has different etiologies that include HBV, HCV, alcohol, or NASH/metabolic syndrome, the CCl₄-injured rat reproduces the most important feature of advanced cirrhosis, the irreversibly decompensated hepatocyte.

Previously, the inventors analyzed the transcriptome of hepatocytes recovered from advanced cirrhotic livers (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22977>; Liu L, Yannam G R, Nishikawa T, Yamamoto T et al. Hepatology 2012 May; 55(5):1529-39, the contents of which are expressly incorporated herein by reference) and also transplanted them. Microarrays showed marked decreases in the expression of HNF4 α , Foxa2, C/EBP α , and HNF1 α , molecules that are part of the network of hepatocyte-enriched transcription factors, sequentially established during development, that regulate the mature hepatocyte phenotype, controlling expression of proteins of coagulation, biliary metabolism, and lipid metabolism (12, 13). Transplantation of hepatocytes from end-stage cirrhotic rats into non-cirrhotic host livers eventually restored their regenerative capacity (14), but the delay in restoration suggested that the process was not the simple expansion of engrafted cells that occurs with normal regeneration.

Since deficient transcription factors could explain hepatocyte impairment, the inventors investigated the therapeutic effects of forced re-expression. HNF4 α was chosen for this therapy because it is the central regulator of the hepatocyte transcription factor network, has no other hepatocyte homolog, and showed the greatest reduction in the decompensated hepatocyte (FIG. 1A).

As described herein, cirrhosis was induced in Lewis rats by treatment with phenobarbital and carbon tetrachloride (CCl₄). Animals treated for 14 weeks had normal liver

function (compensated cirrhosis), whereas 26-28 weeks of CCl₄ produced decompensated liver function with elevated bilirubin, decreased albumin, prolonged prothrombin time, and hepatic encephalopathy scores of 8±0.7 vs. a normal score of 15 (11). All animals were assessed for liver function 4 weeks after receiving their last dose of CCl₄ to guarantee that alterations in liver function were not the consequence of the acute effects of CCl₄ administration.

To confirm the inventors' previous microarray studies (Liu L, Yannam G R, Nishikawa T, Yamamoto T et al. Hepatology 2012 May; 55(5):1529-39), a detailed analysis of the expression of HNF4α and its target genes in isolated hepatocytes and liver tissue was performed. qRT-PCR analysis confirmed severe downregulation of HNF4α expression, and quantification of HNF4α in hepatocytes by Western blot and by immunofluorescent staining of cytospin samples gave similar results (FIG. 1B-D). Immunohistochemical localization of HNF4α showed expression in nuclei of hepatocytes but not in bile duct or other non-parenchymal cells. Nuclear HNF4α was present in the majority of hepatocytes from animals with compensated cirrhosis but was severely diminished in hepatocytes in the nodular livers of decompensated cirrhosis, where it selectively localized to the periportal region. Down-regulation of HNF4α expression has also been reported in human cirrhosis (15, 16). Thus, a significant decrease of HNF4α in hepatocytes correlates with decompensation in cirrhosis. As HNF4α affects the expression of many liver-specific target genes involved in glucose, lipid, amino acid, xenobiotic, and drug metabolism (17), the expression of α1-antitrypsin; apolipoproteins A2, C3, and E; cytochrome P450 3a23, coagulation factor VII, hepatocyte nuclear factor 1α, ornithine transcarbamylase, tyrosine aminotransferase, tryptophan 2,3-dioxygenase, transferrin, and transthyretin was evaluated (FIG. 1E). All of these genes were severely down-regulated in advanced cirrhosis in parallel to HNF4α.

To assess whether forced reexpression of HNF4α could affect the function of cirrhotic hepatocytes, *in vitro* culture system was first used. Hepatocytes, isolated from animals with cirrhosis and decompensated liver function, were transduced with adeno-associated virus (AAV) vectors to express HNF4α and GFP or GFP alone. At 48 hours, qRT-PCR analysis showed HNF4α reexpression restored to nearly normal levels the hepatic transcription factors C/EBPα, HNF1α, and PPARα, and the phenotypic targets genes important for liver-specific activity (FIG. 2A). HNF4α expression also improved secretion of albumin into the culture supernatant—severely impaired in hepatocytes isolated from decompensated cirrhosis (14)—and activity of Cytochrome P450 3A4, a major enzyme of xenobiotic metabolism (FIG. 2B).

In previous studies using this model of decompensated liver failure from cirrhosis, it was shown by the inventors that after withdrawal of CCl₄ and a four-week observation period, 100% of untreated animals die of progressive hepatic failure in 2 to 3 weeks. Intrasplenic hepatocyte transplantation dramatically improved function and survival, but was only effective for a period of weeks to months (11,18) despite transplantation with syngeneic hepatocytes. The therapeutic benefit was moderate, since the end-stage cirrhotic rats still died of progressive hepatic failure and persistent severe cirrhosis. With this background, animals with liver failure and cirrhosis were transduced to re-express HNF4α in their hepatocytes by intravenous infusion of 3×10¹¹ AAV-HNF4α-GFP genomes. Animals sacrificed 2 weeks after infusion demonstrated high transduction efficiency uniformly distributed in most hepatocytes. Moreover,

the impaired albumin expression of decompensated cirrhosis was dramatically improved and its expression increased until the time of sacrifice at 100 days following the observation period (FIG. 3A). Administration of the AAV-GFP control vector did not affect liver function. Co-staining for GFP, albumin, α-smooth muscle, and EpCam indicated transduction of approximately 60-80% of hepatocytes, but not non-parenchymal cells (FIG. 3B). Pathophysiologic testing showed striking and persistent improvement in liver function, ascites, activity, and neurologic function, and survival was prolonged to the end-point of the study at 100 days post observation after CCl₄ withdrawal (FIG. 3C).

Functional analysis of cells isolated from treated animals showed significant improvement of albumin secretion and CYP3A4 activity (FIG. 4A). In addition, there was improvement in expression levels of HNF4α target genes (FIG. 4B) and decreased expression of the hepatic progenitor cell markers AFP, CD44, and EpCAM (FIG. 5). The healing effects of HNF4α reexpression did not depend on proliferation, since there was no increase apparent in Ki67 staining (FIG. 4C). HNF4α did not significantly augment TERT expression and telomere length in the cirrhotic hepatocytes remained critically short (FIG. 4D). Thus, HNF4α acted by phenotypically correcting diseased hepatocytes, not by stimulating their replacement.

The corrected hepatocytes had a striking extrinsic effect on the extracellular matrix, because the fibrotic remodeling of the liver, the hallmark of cirrhosis, was also corrected. Histologic studies showed improvement in fat deposition and fibrosis as early as 2 weeks following treatment with AAV-HNF4α-GFP and significant further improvement at 100 days (FIG. 3, FIG. 6A), results that are in sharp contrast to the inventors' previous experience with hepatocyte transplantation (11, 18). Expression of TIMP1-3, natural inhibitors of metalloproteinases that degrade the extracellular matrix, and TGFβ, a hepatocyte-secreted cytokine that stimulates fibrogenesis was also investigated. TIMP2 and TIMP3 expression was immediately down-regulated *in vitro* following HNF4α re-expression, while TGFβ and TIMPs 1, 2, and 3 were down-regulated within 2 weeks of HNF4α transduction in cirrhotic rats (FIG. 6B).

These studies show that down-regulation of HNF4α has a profound effect on the end-stage cirrhotic hepatocyte *in vitro*, since replenishment of this single factor immediately revitalizes function. Moreover, transduction of hepatocytes in cirrhotic animals with apparently irreversible decompensated function produced a profound and immediate improvement in hepatic function. Normalization of function took place in two weeks while portal hypertension, evidenced by the presence of ascites, regressed when histological reversal of cirrhosis was more complete. This outcome is consistent with the central role of HNF4α within the hepatocyte transcription factor network (12, 20, 21). Impaired expression of HNF4α could reflect direct regulation or inhibition of another network factor that activates HNF4α transcription (22-24) and could result from either cell-extrinsic or cell-intrinsic mechanisms. Toxins, chemical injury, and cytokines generated from inflammation or injured cells can all induce inhibition of critical transcription factors (25). Such extrinsic mechanisms should be corrected immediately by removing the injury *in vivo*, or by culturing the hepatocytes *in vitro*. However, neither withdrawing CCl₄ nor primary cell culture effectively reversed the hepatocyte dysfunction. Since down regulation of network factors HNF1α, FOXA2, CEBPα, and PPARα was also clear in these studies, it is likely that HNF4α, or another network gene, is the critical target of an inhibitory pathway. These

data indicate the target is HNF4 α , since its reexpression restores the other three factors. Research on hepatocyte injury has highlighted three candidate pathways that could mediate this inhibition—TNF α -NF κ B, IL6-Stat3, and TGF β -SMAD—and the inventors' preliminary research showed NF κ B and TGF β signatures by microarray and direct transcript analysis (26). Thus, it is likely that cytokine/injury effects alter expression of the hepatocyte transcription factor network by extrinsic mechanisms, with the result that network factors establish a new steady-state equilibrium in the dysfunctional hepatocyte that can no longer compensate to restore normal gene expression. This has important therapeutic implications, because it may require only transient therapy with HNF4 α to restore the transcription factor network once the injury has been moderated.

Further studies (see Example 3 below) will determine the efficacy of this intervention when there may be ongoing hepatocellular insults, as is the case with clinical cirrhosis, typically associated with hepatitis or alcohol abuse.

These studies indicate that in addition to regeneration mediated by expansion of mature hepatocytes or differentiation and expansion of induced progenitors, normalized function can be accomplished by transcriptional reprogramming with reversal of de-differentiation but not senescence. The results also indicate that HNF4 α therapy could be effective in treating advanced liver cirrhosis with impaired hepatic function as a bridge to organ transplantation or possibly even as destination therapy.

Material and Methods

Animals: Lewis rats were obtained from Charles River Laboratory (Cambridge, Mass.) and were maintained in isolation cages in the Department of Laboratory and Animal Resources at the University of Pittsburgh. Animals were housed in temperature- and light-dark cycle-controlled rooms. All procedures performed on animals were approved by the University of Pittsburgh Animal Care and Use Committees, and thus within the guidelines for humane care of laboratory animals.

Induction of liver cirrhosis: Liver cirrhosis was induced as described beginning in four-week-old inbred male Lewis rats, weighing 100 to 130 g, using Phenobarbital (Sigma Chem. Co. St. Louis, Mo.) and carbon tetrachloride (CCl₄, Sigma) (27). Rats were given Phenobarbital (0.5 g/L) added to the drinking water. Starting two weeks later, CCl₄ (diluted 1:9 in the olive oil) was administered by gavage on a full stomach twice a week. Following an initial dose of 0.2 ml/kg each subsequent dose was adjusted weekly on the basis of changes in body weight. If the body weight increased or remained unchanged CCl₄ was continued at 0.2 ml/kg twice weekly. When body weight decreased by 1-5 g the dose of CCl₄ was reduced to 0.15 ml/kg, and if body weight decreased by 6-10 g the CCl₄ was reduced to 0.1 ml/kg. In rats that lost more than 10 g of body weight, CCl₄ was withheld until reassessment one week later. All animals were monitored by body weight, activity, amount of ascites, and by hepatic encephalopathy (HE) score, which constituted a coma scale based on spontaneous levels of flexion, grasping, righting, placement, corneal, and head-shaking reflexes. Normal activity score was 5; maximum ascites score was 3; and a HE score of 15 indicated normal behavior (28). Whole blood was obtained at different time points and analyzed for bilirubin and albumin using a microfluidic metabolic assay system (Picollo-Abaxis, Union City, Calif.). Ammonia (NH₃) and INR in serum were measured in the clinical laboratory at the Children's Hospital of Pittsburgh.

When rats received a minimum of 2.6 ml CCl₄ and developed persistent ascites, an activity score of <4 and an

HE score of <10, laboratory tests were performed weekly to estimate liver function. Phenobarbital and CCl₄ were discontinued when (1) plasma total bilirubin levels exceeded 0.5 mg/dL (normal <0.2 mg/dL); (2) the INR exceeded 1.7; (3) plasma ammonia concentrations were above 90 mmol/L (normal <70 mmol/L); (4) ascites was found to be persistent by clinical examination, and (5) the hepatic encephalopathy (HE) score was persistently <10. If four weeks after complete cessation of phenobarbital and carbon tetrachloride treatment, the laboratory measures, encephalopathy score and ascites did not improve, rats were considered to have chronic liver failure from decompensated cirrhosis. All animals receiving CCl₄ were observed for four weeks after receiving their last dose of CCl₄ to eliminate the acute effects of toxin exposure before hepatocytes were recovered for analysis and transplantation.

Animals required 2.8±0.2 mL CCl₄ over 26 to 28 weeks to generate cirrhosis that produced irreversible liver failure, and these animals died approximately 2-4 weeks after the four-week observation period with progressive worsening of liver function if they received no treatment. Animals with cirrhosis without liver failure received 13 to 14 weeks of CCl₄, and a total dose of 1.3±0.1 mL of CCl₄. Laboratory tests and ascites resolved quickly in all of these animals after the four week observation period after discontinuing carbon tetrachloride.

Isolation of hepatocytes: Hepatocytes were isolated from donor rats by in situ collagenase perfusion as originally described by Berry and Friend and later modified by Seglen (29, 30). Briefly, a 20 G cannula (Becton, Dickinson Infusion Therapy Systems Inc., Sandy, Utah) was inserted into the portal vein. Perfusion using 0.5 mM EGTA in Leffert's buffer was started via the portal vein for 10 minutes, and the inferior vena cava (IVC) was cut for drainage. The liver was then perfused with collagenase (Liberase, Roche, Germany) at 21 units/200 mL in Leffert's solution for 10 minutes. The perfusion time varied from 10 to 20 minutes based on the consistency of liver tissue in response to collagenase digestion. After perfusion, the liver was excised and chopped into small millimeter sized pieces using a scalpel in a 10 cm sterile tissue culture dish. Cells were then collected in Leffert's solution containing 2.5 mM CaCl₂ and filtered through a 200 micron nylon mesh to remove aggregated cells and residual tissue, centrifuged at 50 g for 3 minutes, and washed three times with chilled Dulbecco's Modified Eagle's Medium (DMEM). Viability was assessed by Trypan blue exclusion and by plating efficiency at 24 hours. Cell viability, as determined by trypan blue exclusion and plating efficiency, was required to be 80% or greater to be acceptable for in vitro analysis. For cytopsin samples, 5×10⁴ hepatocytes were centrifuged at 50 g for 5 minutes for attachment to slides. After air-drying, the cells were fixed with 4% paraformaldehyde for 15 minutes and preserved at -80° C.

Hepatocyte culture: Five hundred thousand hepatocytes isolated from control and cirrhotic livers were seeded into individual wells of collagen-coated 6-well plates (Becton Dickinson Labware, NJ) and cultured at 37° in 5% CO₂ in F-12 medium (DMEM supplemented with 5% FBS, 2 mM Glutamine, 100 U/mL Penicillin, 100 ug/mL Streptomycin, 100 nM dexamethasone, 0.872 uM insulin and 5 ng/mL epithelial growth factor). Tissue culture medium was changed after overnight culture following the isolation and freshly exchanged everyday. The supernatant was collected 24 hours later to determine albumin secretion.

Total RNA extraction and quantitative real-time PCR (QPCR): RNA was extracted from isolated rat hepatocytes

or liver tissue using the RNeasy Mini Kit (QIAGEN, Valencia Calif.) according to the manufacturer's instructions. RNA quantity and integrity were evaluated using a NANO DROP 1000 spectrometer (Thermo Fisher Scientific Inc). cDNA was reverse transcribed from 1 ug total RNA using

SuperScript III reverse transcriptase (Invitrogen). Each gene expression was measured using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster, Calif., USA), using a ABI 7500 real time PCR System. The sequences of the primers used for this Example are listed in Table 1.

TABLE 1

Primer Name	Primer sequence	Length of PCR product
HNF4a-F	5'-ATGGACATGGCTGACTACAGTGCT-3' (SEQ ID NO: 13)	204 bp
HNF4a-R	5'-ACAGCTTGAGGCTCCGTAGTGT-3' (SEQ ID NO: 14)	
A1AT-F	5'-TCTAGAGGGCTGGAGTTCA-3' (SEQ ID NO: 15)	99 bp
A1AT-R	5'-TCACGTCTGGCCTTGTAG-3' (SEQ ID NO: 16)	
ACTA2-F	5'-TTCAATGTCCCTGCCATGTA-3' (SEQ ID NO: 17)	94 bp
ACTA2-R	5'-CATCTCCAGAGTCCACCACA-3' (SEQ ID NO: 18)	
ACTB-F	5'-TTGCTGACAGGATGCGAGAAG-3' (SEQ ID NO: 19)	122 bp
ACTB-R	5'-CAGTGAGGCCAGGATAGAGC-3' (SEQ ID NO: 20)	
AFP-F	5'-GCCCAGCATACGAAGAAAACA-3' (SEQ ID NO: 21)	176 bp
AFP-R	5'-TCTCTTGTCTGGAAGCATTCC-3' (SEQ ID NO: 22)	
ALB-F	5'-TCTGCACACTCCCAGACAAG-3' (SEQ ID NO: 23)	114 bp
ALB-R	5'-AGTCACCCATACCGCTTC-3' (SEQ ID NO: 24)	
ApoA2-F	5'-GGCAAGGATTGATGGAGAA-3' (SEQ ID NO: 25)	108 bp
ApoA2-R	5'-CCCAGTTCTGGACAAAGG-3' (SEQ ID NO: 26)	
ApoC3-F	5'-ACATGGAACAAGCCTCCAAG-3' (SEQ ID NO: 27)	75 bp
ApoC3-R	5'-TGGCCACCACAGCTATATCA-3' (SEQ ID NO: 28)	
ApoE-F	5'-TGAACCGTTCTGGGATTAC-3' (SEQ ID NO: 29)	85 bp
ApoE-R	5'-TGTGTGACTTGGGAGCTCTG-3' (SEQ ID NO: 30)	
ASGR1-F	5'-GGAGGATCTGAGGGAAAGACC-3' (SEQ ID NO: 31)	125 bp
ASGR1-R	5'-GGCAGCAGATCCTTCAGAG-3' (SEQ ID NO: 32)	
CD44-F	5'-TTTGGTGGCACACAGCTTG-3' (SEQ ID NO: 33)	104 bp
CD44-R	5'-ATGGAATACACCTGCGTAACGG-3' (SEQ ID NO: 34)	
Cdh1-F	5'-GAAGGCCTAACGACAACAGC-3' (SEQ ID NO: 35)	99 bp
Cdh1-R	5'-AAGCAGTGGCACACAGCTTG-3' (SEQ ID NO: 36)	
C/EPBa-F	5'-GCCAAGAAGTCGGTGGATAA-3' (SEQ ID NO: 37)	125 bp
C/EPBa-R	5'-AACACCTTCTGCTGCGTCTC-3' (SEQ ID NO: 38)	
CK18-F	5'-GCTCAGATCTTGCAGATTTC-3' (SEQ ID NO: 39)	204 bp
CK18-R	5'-CGCTTCGATTCTGTCTCC-3' (SEQ ID NO: 40)	
COL1a1-F	5'-TGGCCTCAAGGTTCCAAG-3' (SEQ ID NO: 41)	123 bp
COL1a1-R	5'-TTACCAGCTTCCCCATCATC-3' (SEQ ID NO: 42)	
Ctnnb1-F	5'-TGCAGAAAATGGTTGCTTG-3' (SEQ ID NO: 43)	98 bp
Ctnnb1-R	5'-GCTTCCTGATTGCCGTAAG-3' (SEQ ID NO: 44)	
CYP3a23/3a1-F	5'-ATGGAGATCACAGCCCAGTC-3' (SEQ ID NO: 45)	130 bp
CYP3a23/3a1-R	5'-CGATCTCCTCCTGCAGTTTC-3' (SEQ ID NO: 46)	

TABLE 1-continued

Primer sequences			Length of PCR product
Primer Name	Primer sequence		
EpCAM-F	5'-TGAGAATGGTGAATGCCAGT-3'	(SEQ ID NO: 47)	101 bp
EpCAM-R	5'-GAGTCATCTCCGCCTTCATC-3'	(SEQ ID NO: 48)	
F7-F	5'-TAACCCAGGAGGAAGCACAC-3'	(SEQ ID NO: 49)	102 bp
F7-R	5'-CTTCATTGCACTCCCTCTCC-3'	(SEQ ID NO: 50)	
Foxa2-F	5'-CCATCCGTCAATTCTCTCC-3'	(SEQ ID NO: 51)	112 bp
Foxa2-R	5'-TCGAACATGTTGCCAGAGTC-3'	(SEQ ID NO: 52)	
HNFla-F	5'-GACGTCTCCAGGTCTCAACC-3'	(SEQ ID NO: 53)	119 bp
HNFla-R	5'-CACCCGTGTTAGTGAACGTG-3'	(SEQ ID NO: 54)	
OTC-F	5'-CTCACCCTCAGCTGGATAGG-3'	(SEQ ID NO: 55)	101 bp
OTC-R	5'-CCCTTGGAGTAGCTGCTTG-3'	(SEQ ID NO: 56)	
Ppara-F	5'-AATGCAATCGTTGAGGCTGC-3'	(SEQ ID NO: 57)	116 bp
Ppara-R	5'-GCCAGAGATTTGAGGTCTGC-3'	(SEQ ID NO: 58)	
TAT-F	5'-CATCGTGGACAACATGAAGG-3'	(SEQ ID NO: 59)	101 bp
TAT-R	5'-CAGGGTCTGTAGGCAGGTTC-3'	(SEQ ID NO: 60)	
TDO2-F	5'-TTGAAGGGTCTGGAAGAGGA-3'	(SEQ ID NO: 61)	119 bp
TDO2-R	5'-TCATCGAACAAAGCAGAGCAG-3'	(SEQ ID NO: 62)	
TERT-F	5'-GCATCTGACCCGAGTCTCTC-3'	(SEQ ID NO: 63)	105 bp
TERT-R	5'-GAATGGCCTGAGCTTTCAG-3'	(SEQ ID NO: 64)	
TF-F	5'-AATGGAGATGGCAAAGAGGA-3'	(SEQ ID NO: 65)	100 bp
TF-R	5'-GAGAGCCGAACAGTTGGAAG-3'	(SEQ ID NO: 66)	
TGFb1-F	5'-GGACTCTCCACCTGCAAGAC-3'	(SEQ ID NO: 67)	100 bp
TGFb1-R	5'-GACTGGCGAGCCTTAGTTG-3'	(SEQ ID NO: 68)	
TIMP1-F	5'-GGTCCCTGGCATAATCTGA-3'	(SEQ ID NO: 69)	99 bp
TIMP1-R	5'-ATGGCTGAAACAGGGAAACAC-3'	(SEQ ID NO: 70)	
TIMP2-F	5'-TGGACGTTGGAGGAAAGAAG-3'	(SEQ ID NO: 71)	97 bp
TIMP2-R	5'-TCCCAGGGCACAATAAGTC-3'	(SEQ ID NO: 72)	
TIMP3-F	5'-TGTGCAACTTTGTGGAGAGG-3'	(SEQ ID NO: 73)	84 bp
TIMP3-R	5'-AATTGCAACCCAGGTGGTAG-3'	(SEQ ID NO: 74)	
TTR-F	5'-TCGTACTGGAAAGGCTTGG-3'	(SEQ ID NO: 75)	120 bp
TTR-R	5'-GTAGGAGTACGGGCTGAGCA-3'	(SEQ ID NO: 76)	

* These primers were used for quantitative RT-PCR

The PCR reaction was programmed as follows: initial denaturing at 95° C. for 10 min followed by 95° C. for 15 sec, 60° C. for 1 min, cycled 40 times. The median cycle threshold value and the relative cycle threshold method were used for analysis. All cycle threshold values were normalized to the expression of the housekeeping gene ACTB. All reactions were performed with four biological replicates and three technical replicates with reference dye normalization. All values were normalized to control normal hepatocytes.

A p value of less than 0.05 was used for the significance cutoff point for all genes tested. ANOVA (Tukey-Kramer multiple comparison test) was used for statistical comparison within experimental groups. Each value represents the mean±SD.

DNA extraction and telomere length measurement by 65 QPCR: Genomic DNA was extracted from isolated rat hepatocytes using the DNeasy Blood & Tissue Kit (QIA-GEN, Valencia Calif.) according to the manufacturer's

instructions. The samples were used for examination of telomere length in QPCR using the modified Cawthon's method (31). Briefly, telomere and single copy gene (β -globin) PCRs were performed in separate 96-well plates using the same DNA sample. The telomere/single copy gene (T/S) ratio was calculated as the index of telomere length in each sample. Triplicate PCR reactions for each sample were performed with Power SYBR Green PCR Master Mix, DNA and primer pairs using the ABI 7500 real time PCR System. Primers for telomeres and β -globin were added to a final concentrations of 250 nM. The primer sequences were tel-1, 5'-GGTTTTGAGGGTGAGGGTGAGGGTGAGGGT-GAGGGT-3' (SEQ ID NO:77); tel-2, 5'-TCCCGACTATC-CCTATCCCTATCCCTATCCCTATCCCTA-3' (SEQ ID NO:78); β -globin-F, 5'-CAGCAAGTGGGAAGGTG-TAATCC-3' (SEQ ID NO:79); β -globin-R, 5'-CCCATTC-TATCATCAACGGGTACAA-3' (SEQ ID NO:80). PCR was performed at 95° C. for 10 min, followed by 40 cycles at 95° C. for 15 sec, and 54° C. for 2 min for the telomere reaction or 40 cycles at 95° C. for 15 sec, 60° C. for 60 sec for the β -globin reaction. Standard curves for both telomere length and the single copy gene were generated from five concentrations (42, 25.2, 15.1, 9.1, 5.4 ng/aliquot) of a reference DNA sample serially diluted 1.68 fold with PCR grade water.

Western blot analysis: Isolated hepatocyte fractions were lysed in RIPA buffer (Sigma Aldrich) with 1% proteinase inhibitor cocktail (Calbiochem) on ice. The supernatant was collected as cellular protein after centrifugation at 8000 g for 15 min. and the supernatant was preserved at -80° C. Forty micrograms of the cellular protein was electrophoresed in a 4-12% bis-tris gel and then transferred to a nitrocellulose membrane (Invitrogen). The immunological detection of HNF4 α and beta-actin was performed as previously described. Antibodies for HNF4 α and beta-actin were purchased from Abeam Inc. (Cambridge, Mass.) and Cell Signaling Technology, Inc. (Beverly, Mass.) respectively. After incubation with a horseradish peroxidase-conjugated secondary antibody for 1 h, immune detection of each band was performed with SuperSignal West Pico Chemiluminescent Substrate (PIERCE, Rockford, Ill.). The density of each band was measured using Image J software.

Histology: Five-micrometer-thick sections were prepared from paraffin embedded liver tissue fixed in 4% paraformaldehyde (PFA) and two slides each were used for hematoxylin and eosin (H & E) and Masson trichrome staining according to the manufacturer's protocols from Sigma. Oil red O staining was performed to detect cellular deposition of triglycerides using 5 micron sections from OTC compound embedded frozen liver tissues fixed in 2% PFA. Briefly, after fixation in 10% formaldehyde for 15 minutes at room temperature, sections were washed twice with deionized water for 1 minute, and then rinsed in 60% isopropanol for 1 minute. Subsequently, the sections were immersed in the oil red O working solution for 30 min at 37° C. After washing three times with deionized water, sections were counterstained using Gill's haematoxylin for 60 seconds to visualize nuclei. Sections were then rinsed with water for 10 min and mounted using crystal mount (Biomedica corp., Foster city, CA). Images were taken at low magnification (100 \times) using an Olympus Provis light microscope. To quantify detection of fibrotic areas in the Masson trichrome stained sections or fat deposition on oil red O stained sections, the signal intensity was measured over five different fields using Image J software and the average value was used as the semi-quantitative measurement of fibrosis or fat deposition within the liver.

Immunohistochemistry: Sections, five-microns in thickness, were heated in a microwave oven in citrate sodium buffer, pH6.0 (DAKO, CA) for 5-10 minutes at 95° C., and cooled at room temperature for 20 minutes. After blocking with PBS and 2% FCS for 15 minutes, samples were incubated with one or a combination of diluted primary antibodies (1:100) for 1 hour at room temperature. After washing three times in PBS, samples were incubated with diluted secondary antibodies conjugated with fluorescein isothiocyanate (1:250) for 60 minutes at room temperature for immunofluorescence staining. Samples were then finally mounted in VECTASHIELD (Vector Laboratories, Inc., Burlingame, Calif.) containing DAPI solution. Immunohistochemistry was also performed using the same method described above, except for the blocking of endogenous peroxidase by incubation in methanol and 0.3% hydroxylperoxydase for 20 minutes. The VECTASTAIN ABC kit for mouse IgG (Vector Laboratories, Inc) was used to detect the immunocomplex signal and the samples were counterstained using Gill's haematoxylin for 60 seconds. The stained samples were examined using Olympus Provis light microscope. Mouse anti-HNF4 α monoclonal antibody, rabbit anti-GFP polyclonal antibody, rabbit anti-Epcam polyclonal antibody, rabbit Ki67 polyclonal antibody, mouse anti-alpha smooth muscle actin monoclonal antibody were purchased from Abeam Inc., mouse anti-GFP monoclonal antibody from Cell Signaling Technology, Inc. and sheep anti-rat albumin polyclonal antibody from Bethyl Laboratories, Inc. (Montgomery, Tex.) as primary antibodies in this study. Alexa Fluor 488-conjugated goat anti-rabbit IgG and anti-mouse IgG antibodies and Alexa Fluor 594-conjugated goat anti-rabbit IgG, anti-mouse IgG and donkey anti-sheep IgG antibody were purchased from Invitrogen as secondary antibodies. For calculation of percent positive cells at least four low power digital images (100 \times) per sample were analyzed using an Olympus Provis light microscope using ImageJ software.

AAV cloning and virus preparation: Two AAV vectors were used for these studies; one capable of expressing GFP from an IRES promoter, pAAV-GFP, and the other capable of expressing HNF4 α under control of a CMV promoter and GFP under control of the IRES promoter, pAAV-HNF4 α /GFP. Cells were transduced in vitro at an MOI of 2000, and the transduction efficiency in vitro was >90%.

A 1.5 kb EcoRI fragment of rat-HNF4 α 2 was cloned into the bicistronic plasmid pAAV-IRES-GFP (Cell Biolabs, Inc; San Diego, Calif.), which expresses HNF4 α under control of the CMV promoter and GFP under control of the IRES promoter. AAV vector preparation was performed using the helper-virus-free CaPO₄ triple transfection method. Briefly, HEK293 cells were grown in DMEM with 10% FCS to 75% confluence in 12 150 cm² flasks. For each flask, 15 μ g of each plasmid [pAAV-CMV-HNF4 α /IRES-GFP, pladeno5 (32), pAAV-DJ (33)] was added to 3 ml of 300 mM CaCl₂. This mixture was then added to 3 ml of 2 \times -HEPES-buffered saline (50 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], 280 mM NaCl, 1.5 mM NaH₂PO₄, pH 7.1), vortexed and let stand for 5 minutes, then added to the flask and incubated at 37° C. for 4-6 hrs. Media was changed to DMEM with 2% FCS and cultured for 48-72 hrs. For harvest, EDTA was added to the flask to a final concentration of 10 mM and incubated for 3-5 min. Cells were dislodged by gentle shaking and cells and media were harvested and centrifuged at 100 \times g. The cell pellet was suspended in DMEM and subjected to 3 freeze-thaw cycles in dry-ice/ethanol and 37° C. baths. Cell debris was removed by centrifugation at 10,000 \times g for 10 min. Supernatant was

collected and virus was purified and concentrated using the ViraBind™ AAV purification kit (Cell Biolabs, Inc; San Diego, Calif.) per manufacturer's instructions. Viral titer in genome copies (gc)/ml was determined by dot blot of serial dilutions of virus using linearized pAAV-CMV-HNF4α/IRES-GFP as a standard and a HNF4α cDNA fragment as probe.

Transduction to express HNF4α: For in vitro studies, freshly isolated hepatocytes were plated at a density of 0.5 million cells per well in collagen-coated 6-well plates. After incubation in DMEM/F12 for 2 hours at 37° C. and 5% CO₂, the culture medium was changed to one containing each AAV vector at an MOI of 2000. Cells were incubated for 24 hours at 37° C. and 5% CO₂, and then washed twice with PBS. Two ml of fresh culture medium was added into each well, starting 24 hours after AAV transduction (Day 0), and repeated daily up to day 7. Supernatant samples were collected and preserved at -80° C. After viral transduction, cell samples were also collected from each well on day 2 for extraction of genomic DNA, total RNA and whole cellular protein for analysis.

For AAV transduction in vivo, 3.0×10¹¹ viral genomes of AAV-DJ-HNF4α-IRES-GFP (n=5) and AAVDJ-IRES-GFP (n=4) were injected into the tail vein. Five animals with decompensated cirrhosis were also monitored that received no AAV infection as a control group. All animals were monitored and scored for clinical changes and by laboratory tests every week until expiration or until the end of the observation period at 14 weeks after viral infection. Untreated animals and animals treated with the control AAV-GFP vector developed progressively worsening liver function and died with a mean survival of 19 days. Treated rats showed improvement in clinical parameters, INR, total bilirubin, serum albumin level, and ammonia. All were nearly at normal levels within 2 weeks of treatment, and sustained those levels for at least 100 days. One animal treated with AAVDJ-HNF4α-IRES-GFP was sacrificed 2 weeks after viral injection to estimate early transduction efficiency. Survival assessment was statistically performed by log-rank test among three groups (*p<0.05). Value represent mean±SD. Specimens were collected following euthanasia and samples were preserved unfixed at -80° C., embedded in paraffin after 4% PFA fixation, and embedded in OTC compound after 2% PFA fixation. Vector transduction efficiency was estimated by immune detection for GFP.

Albumin measurement: Albumin levels from hepatocyte culture supernatants were measured by ELISA according to manufacturer's instructions (Bethyl Laboratories, TX). Five hundred thousand freshly isolated viable hepatocytes were seeded into each well of a collagen-coated 6 well plate containing 2 ml DMEM/F12 and incubated overnight at 37° C. in 5% CO₂. The culture medium was replaced with 2 ml of new every day. Collected samples were stored at -80° C. prior to analyses. For the ELISA, high binding 96 well plates (Corning, N.Y.) were coated with 100 uL of an anti-rat albumin affinity purified antibody (1:100) (Bethyl laboratories) in 0.05M carbonate-bicarbonate, pH 9.6 for 1 hr at 25° C. Plates were washed three times with 50 mM Tris, 0.14M NaCl, and 0.05% (v/v) Tween 20 pH 8.0. Nonspecific binding was blocked by adding 1% BSA for 1 h at 25° C. After washing three times, 200 uL of each sample (in duplicate) and standards were added and incubated for 1 h at 25° C. Samples were diluted as needed up to 1:150000 in 50 mM Tris, 0.14M NaCl, 1% BSA, and 0.05% (v/v) Tween 20 pH 8.0. Wells were then washed five times, and 100 uL of an anti-albumin HRP conjugate, diluted 1:10000 in the above buffer was added. Plates were incubated for 1 h at 25°

C. After washing, 100 uL of substrate ABTS (KPL, MD) was added in each well. After 30 min, the reaction was stopped by adding 1% SDS to each well. Absorbance was measured at 405 nm using a Benchmark microplate reader (Biorad, CA). The absence of cross reactivity with fetal bovine serum (present in F-12 medium) was verified using samples of culture medium used as blanks. Lewis rat serum was used as a positive control.

CYP3A4 activity assay: Isolated cells were cultured in 10 DMEM/F12 at density of 0.5 million cells per well in collagen-coated 6-well plates, as described above. CYP3A4 activity was measured on day 2 of culturing, when expression following HNF4α vector transduction had peaked, using the P450-Glo™ CYP3A4 assay kit (Promega Corporation, Madison, Wis.), according to manufacturer's instructions. Briefly, the culture medium was exchanged with one ml of fresh media (without Phenol red) containing 3 uM Luciferin-IPA. After incubation for 30 minutes at 37° C., 200 ul of culture supernatant was collected from each well 20 and transferred into luminometer tubes. Then 200 ul of Luciferin detection regent was added into each tube. The mixture was incubated for 20 minutes at room temperature, protected from light, and the luminescence was immediately detected using a TD-20/20 luminometer (Turner BioSystems, Inc., Sunnyvale, Calif.).

Statistical analysis: Differences among group results were deemed significant when the P-value was less than 0.05. Statistical analyses were performed using the Tukey-Kramer multiple comparisons procedure and Student's t-test using 30 SPSS v16.0 software (SPSS Inc., Chicago, Ill., USA). Survival in vivo was evaluated by log-rank test. Each value represents the mean±SD. Statistical analysis was performed 35 among three groups (normal, compensated and decompensated cirrhotic hepatocytes) and between un-treated decompensated cirrhotic hepatocytes and decompensated cirrhotic hepatocytes 14 weeks after in vivo HNF4α re-expression (*p<0.05, **P<0.001).

Example 2: Effect of Transient Expression of Exogenous HNF4α in Cirrhotic Rats

Short-term HNF4α re-expression may reactivate the hepatocyte transcription factor network. Alternatively, the therapeutic effects could require continuous expression of exogenous HNF4α. Determination of which scenario is accurate will profoundly affect clinical therapeutic strategies. Therefore, a recombinant AAV vector is constructed that expresses HNF4α from an inducible promoter controlled by Tet-ON/OFF system.

The bicistronic vector ("Tet-ON-AAV-CMV-rtTA/TRE-HNF4α", modeled after Zheng et al. (2012 *BMC Cancer*, 12:153) will express the rtTA (Tet repressor) under the control of a CMV promoter and the human HNF4α cDNA under the control of the TRE (tet regulated promoter). The 50 CMV-rtTA is 2200 bp and the TRE-HNF4α is 2100 bp, a total within the 5 kb capacity of AAV. Tet ON:AAV-CMV rtTA/TRE-GFP is generated as a control virus. Transduction efficiency and efficacy of the conditional constructs is confirmed by immunochemistry and in vitro studies.

An alternative approach will be to simultaneously administer separate viruses containing the rtTA and TREHNF4 or TRE-GFP. IV injection on 2-consecutive days can also be done to achieve maximal target cell transduction with no increased immune response. Tetracycline inducible systems have been widely used to administer regulated gene expression, but expression can be leaky. Therefore, a newer third generation Tetracycline-inducible system, the Tet-ON-3 G

31

(Clontech), will be utilized, which has been engineered to have reduced basal expression and enhanced sensitivity to doxycycline.

HNF4 α expression is induced by administration of doxycycline (1 mg/ml in drinking water) and animals will be assessed weekly for improved hepatic function (INR, total bilirubin, serum NH3, albumin, and encephalopathy score). Exogenous HNF4 α expression is halted by withdrawal of doxycycline at one, 2, 4, 6, and 8 weeks after correction of hepatic function and assessed for sustained normalization of hepatic function and survival. If liver function does not deteriorate 2 weeks after withdrawal of exogenous HNF4 α expression (i.e., animals are improving), liver specimens are collected and HNF4 α expression is determined by immunohistochemistry, Western blot, northern blot, and qPCR. Hepatocytes are also isolated from treated cirrhotic livers and examined following cytospin for gene expression by IHC (HNF4 α , albumin, etc.). In addition, RNA is collected from hepatocytes for qPCR analysis to assess HNF4 α expression and associated changes in liver specific gene expression. Exogenous and endogenous HNF4 α expression is distinguished by qRT-PCR, since the mRNAs differ in their 3'-untranslated regions.

Example 3: Effect of Ongoing CCl₄ Treatment on Liver Function and Gene Expression in Cirrhotic Rats with Liver Failure Treated with AAV-HNF4/GFP

Human cirrhosis patients have continuing injury, whether from alcohol, HCV, or other chronic insults. Therefore, how HNF4 α therapy modulates continuing injury with CCl₄ is studied. Rats with end-stage cirrhosis whose liver function has been corrected following administration with AAV-HNF4 α receive ongoing treatment with CCl₄, starting 2 weeks after AAV treatment. Animals are assessed weekly by blood tests for maintenance of improved hepatic function following AAV-HNF4 α treatment. CCl₄ treatment is discontinued if the hepatic encephalopathy score falls below 9 (Kobayashi, et al. 2000, *Hepatology* 31(4):851; Bures, et al. Innate and motivated behavior. Techniques and Basic Experiments for the Study of Brain and Behavior. New York: Elsevier; 1976, p. 37-45)). If hepatic function deteriorates but does not correct within 2 weeks of stopping treatment with CCl₄, animals are sacrificed and liver specimens and isolated hepatocytes are examined for HNF4 α and liver-specific gene expression.

Example 4: To Determine the Mechanism of HNF4 α Downregulation in Human End-Stage Cirrhosis and to Examine Whether Exogenous HNF4 α can Correct for Loss of Function

To extend the rat observations to human liver disease, control and cirrhotic livers are examined for function and changes in gene expression and chromatin. There are a wide variety of fibrotic liver diseases, with some differences from the rat CCl₄ model. Nevertheless, the focus on liver failure via transcriptionally regulated hepatocyte decompensation is distinctive, and there is a striking similarity between the rat and human diseases. It has been found that HNF4 α expression is a dramatically diminished in cirrhotic livers with decompensated hepatic function (Berasain, C. et al. 2003 *Hepatology* 38(1):148-57). Thus, the extent to which networks altered in rodent studies are similarly altered in human hepatocytes will be determined. Since diminished HNF4 α expression has been identified, further examination

32

focuses on the extent to which providing exogenous HNF4 α to human hepatocytes will correct hepatic function toward normal.

Characterization of Transplanted Hepatocytes Derived from Cirrhotic Livers.

In the animal studies described herein, the yield of hepatocytes recovered by collagenase digestion of cirrhotic livers was significantly lower than from age-matched controls, but hepatocyte viability and plating efficiency were not statistically different among groups. However, hepatocytes from the livers of rats with decompensated cirrhosis functioned less well in vitro than those from all other donor groups. Preliminary studies of human disease were performed, using explanted diseased livers recovered during liver transplantation at Children's Hospital of Pittsburgh. Cirrhotic livers were classified according to severity based on Child-Pugh Classification of severity of liver disease (determined based on the criteria set forth in Table 2, below). Cells were isolated from cirrhotic livers, from the livers of patients with liver-based metabolic disorders, and from pediatric age-matched controls. There was no difference in viability or plating efficiency within groups. However, albumin secretion and urea synthesis was significantly diminished in hepatocytes from Child-B livers. A decrease in inducible CYP 1A1/1A2 activity in hepatocytes from human Child-B but not Child-A cirrhotic hepatocytes was observed. As cirrhosis became more advanced, human hepatocytes showed an increase in mRNA expression for progenitor cell genes, most markedly for CD44 and EpCAM.

TABLE 2

Criteria for Child-Pugh Classification Scores for each of five clinical and biochemical measurements are combined for a Grade, Grade A = 5-6 Grade B = 7-9 Grade C = 10-15			
Clinical and Biochemical	Points Scored for Increasing Abnormality		
	1	2	3
Measurements			
Hepatic encephalopathy (grade)*	None	1 and 2	3 and 4
Ascites	Absent	Mild	Moderate
Total bilirubin (mg/dl)	<2.0	2.0-3.0	>3.0
Serum albumin (g/dl)	>3.5	2.8-3.5	<2.8
Prothrombin time (sec. prolonged) or Prothrombin time INR**	<4 or <1.7	4-6 or 1.7-2.3	>6 or >2.3

*According to grading of Trey, Burns, and Saunders (1996).

**Lucey MR, et al. Minimal Criteria for Placement of Adults on the Liver Transplant Waiting List *Liver Transplantation and Surgery*. Vol. 3, No 6 (November). 1997: pp 628-637.

HNF4 α Expression is Downregulated in Human Livers with Advanced Cirrhosis.

As in rat cirrhosis, HNF4 α downregulation occurs in human livers with advanced cirrhosis (Berasain, C. et al. 2003 *Hepatology* 38(0:148-57). This finding was confirmed by qPCR of cirrhotic and control hepatocytes recovered at Children's Hospital of Pittsburgh. By qRT-PCR, levels of HNF4 α were significantly lower than that found in control normal livers.

Research Design:

Characterization of Human Livers and Hepatocytes Derived from these Livers.

Normal livers from nonheart-beating donors, and livers representing different stages of fibrosis and cirrhosis are recovered for analysis. Serum bilirubin, albumin, INR level, extent of ascites, and encephalopathy are recorded for each

liver where hepatocytes are recovered. Tissue biopsies assess the extent of regenerative hyperplasia and cirrhosis. Extent of collagen deposition is determined by Masson-Trichrome and Sirius red-stained sections using ImageJ software. The yield of hepatocytes from cirrhotic and control livers recovered by collagenase digestion, including their viability and plating efficiency, is recorded. Four groups are established based on severity of donor liver disease. Group 1: normal control livers; Group 2: livers with significant liver injury but associated with no, or minimal, change in hepatic function (Child-Pugh A); Group 3: livers with modest loss of function (Child-Pugh B); Group 4: livers with severe loss of hepatic function (Child-Pugh C).

Baseline Functional Analysis and Gene Expression Profile of Hepatocytes Recovered from Human Livers.

As with hepatocytes derived from our rat model, measure human hepatocyte function is measured [albumin secretion, urea synthesis, qPCR for expression of liver-specific genes including HNF4 α , and baseline and induced cytochrome P450 activity; evidence of replicative senescence [qRT-PCR for NF- κ B, telomerase expression, functional telomerase activity, and telomere length (Southern blot analysis)].

Differences among groups are analyzed statistically using ANOVA. It has been calculated that at least 10 samples representing each experimental group is required for comparison.

Human-Rat Comparison of the Dynamic Genetic Changes Associated with Progressive Cirrhosis and Liver Failure.

RNA-Seq analysis is carried out and expression levels of selected liver specific genes are also examined by quantitative PCR. As in the rodent studies, transcriptome analysis provides a fundamental resource for elucidating the mechanisms by which cells derived from normal, compensated, and decompensated cirrhotic livers develop hepatic dysfunction. The cluster analysis of the rat studies revealed signatures of NF κ B stimulation and HNF4 α inhibition (see above) (Liu, L. et al. 2012 *Hepatology* 55(5):1529-39). It is hypothesized that similar patterns of expression will discriminate normal vs. compensated vs. decompensated cirrhosis in human livers. Hepatocytes, recovered as outlined above, and donor liver segments are processed for mRNA and subsequent analysis by RNA-Seq. transcriptomic dynamics of normal liver cells is defined, followed by a similar analysis of cells derived from compensated cirrhotic livers, culminating in an analysis of the transcriptomic dynamics of hepatocytes from decompensated cirrhotic livers.

Transduction of Hepatocytes from Cirrhotic Human Livers Associated with Decompensated Function to Express HNF-4 α .

Adult human hepatocytes derived from end-stage cirrhotic livers are transduced to express HNF4 α by AAV. MOI is optimized to attain >80% transduction of human hepatocytes without injury. An AAV vector has been generated containing the gene encoding human HNF4 α . However, a new vector expressing both HNF4 α and GFP is constructed to allow easy assessment of transduction efficiency. Controls receive a GFP-expressing vector. 5 \times 10⁵ human hepatocytes are cultured in each well of a 6-well plate. Following transduction, liver-specific gene expression is assessed in hepatocytes from normal and decompensated Child's A, B, and C livers. Following transduction, supernatants are collected daily from hepatocytes for measurement of albumin and urea secretion. Furthermore, mRNA is recovered from hepatocytes and qRT-PCR is performed to assess AAT, ApoA, ApoC, Cyp3A4, FVII, HNF1 α , TAT, Tdo2, TF, TTR,

and endogenous and exogenous HNF4 α expression. All values are normalized to control normal hepatocytes. Transplantation of HNF4 α Treated Human Hepatocytes from Cirrhotic Livers into Immune Deficient Mice FAH k/o Mice.

Control human hepatocytes and AAV-HNF4 α transduced hepatocytes are transplanted into immune-deficient FAH K/O (FRG or FRG-NOD) mice that provide a selective repopulation advantage to donor cells. FRG/N mice (6-12 week old), maintained on 2-(2-nitro-4-trifluoro-methyl-benzoyl)-1,3 cyclohexanedione (NTBC)-containing drinking water at 16 mg/L, receive 5 \times 10⁹ pfu Ad-uPA i.p. before transplantation (Lieber, A. et al. 1995 *Hum Gene Ther.* 6(8):1029-37; Azuma, H. et al. 2007 *Nature Biotechnology* 25(8):903-10). 106 viable human hepatocytes are then transplanted into the spleen for engraftment in the liver. NTBC is gradually decreased (1.6 mg/l, day 0-2; 0.8 mg/l, day 3-4; 0.4 mg/l, day 5-6) and completely withdrawn one week after transplantation. Two weeks after stopping NTBC, animals are placed back on the drug for 5 d and then taken off again. NTBC may need to be repeatedly restarted for 5 days each time the body weight decreases by 20 percent in order to allow expansion of transplanted hepatocytes. Human serum albumin level is used to non-invasively assess the extent to which engrafted donor hepatocytes function and expand in the non-cirrhotic FRG/N liver environment over time. 4-8 weeks after transplantation, when human serum albumin approaching 0.5 mg/ml indicates engraftment by human hepatocytes approximating 5-10% repopulation, hepatocytes are isolated by *in situ* collagenase perfusion (Berry, M N. et al. 1969 *PMCID:PMCID2107801*; Seglen P A, 1976 *Method Cell Biol.* 13:29-83). Isolated cells are placed in fresh media containing homogenitic acid (HGA), the intermediate metabolite in the pathway between 4-hydroxyphenylpyruvate dioxygenase and FAH, for 24 hrs. Donor cells that express FAH survive this treatment, whereas FAH-deficient cells do not survive (Kubo S. et al. 1998 *PNASUSA* 95(16):9552-7).

As predicted, it was found that FAH-deficient hepatocytes die in a dose-dependent fashion. As with hepatocytes derived from control and cirrhotic rats, human hepatocyte function: albumin secretion, urea synthesis, and qPCR is measured for expression of liver-specific genes including HNF4 α , baseline and induced cytochrome P450 activity (CYP3A4, 2C9, 1A1, 1A2), and evidence of replicative senescence (telomerase expression, functional telomerase activity, and telomere length) (Kitada T, et al. 1995 *Biochem Biophys Res Commun* 211(1):33-9; Rudolph L K. et al. Telomeres and telomerases in experimental liver cirrhosis. Chisari F V, et al. editors. In: *The Liver: Biology and Pathobiology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1000-10; Wiemann S U, et al. 2002, *FASEB J.* 16(9):935-42).

Differences between experimental and controls are analyzed statistically using ANOVA. At least 10 samples representing each group are required for comparison.

REFERENCES

- 60 1. F. Durand, D. Valla, *J Hepatol* 42 Suppl, S100 (2005).
2. P. Gines, A. Cardenas, V. Arroyo, J. Rodes, *N Engl J Med* 350, 1646 (Apr. 15, 2004).
3. D. Schuppan, N. H. Afdhal, *Lancet* 371, 838 (Mar. 8, 2008).
- 65 4. A. Martinez-Hernandez, J. Martinez, *Hepatology* 14, 864 (November, 1991).
5. S. L. Friedman, *J Hepatol* 38 Suppl 1, S38 (2003).

35

6. D. Pessayre, D. Lebrec, V. Descatoire, M. Peignoux, J. P. Benhamou, *Gastroenterology* 74, 566 (March, 1978).
7. M. Vaubourdolle et al., *Scand J Gastroenterol* 24, 467 (May, 1989).
8. P. M. Lopez, P. Martin, *Mt Sinai J Med* 73, 1056 (December, 2006).
9. S. Marro et al., *Cell Stem Cell* 9, 374 (Oct. 4, 2011).
10. K. Takahashi et al., *Cell* 131, 861 (Nov. 30, 2007).
11. N. Kobayashi et al., *Hepatology* 31, 851 (April, 2000).
12. J. Locker, in *Molecular Pathology of Liver Diseases*, S. P. Monga, Ed. (Springer, New York, 2011), pp. 193-2011.
13. F. M. Sladek, S. Seidel, in *Nuclear Receptors and Genetic Disease*, T. P. B. E. McCabe, Ed. (Academic Press, London, 2001).
14. L. Liu et al., *Hepatology* 55, 1529 (May, 2012).
15. C. Berasain et al., *Hepatology* 38, 148 (July, 2003).
16. P. B. Limaye et al., *Lab Invest* 88, 865 (August, 2008).
17. E. Bolotin et al., *Hepatology* 51, 642 (February, 2010).
18. H. Nagata et al., *Gastroenterology* 124, 422 (February, 2003).
19. H. Y. Yue et al., *Gut* 59, 236 (February, 2010).
20. I. Kyrmizi et al., *Genes Dev* 20, 2293 (Aug. 15, 2006).
21. D. T. Odom et al., *Mol Syst Biol* 2, 2006 0017 (2006).

36

22. G. P. Hayhurst, Y. H. Lee, G. Lambert, J. M. Ward, F. J. Gonzalez, *Mol Cell Biol* 21, 1393 (February, 2001).
23. F. Parviz et al., *Nat Genet* 34, 292 (July, 2003).
24. F. M. Sladek, W. M. Zhong, E. Lai, J. E. Darnell, Jr., *Genes Dev* 4, 2353 (December, 1990).
25. F. J. Gonzalez, *Drug Metab Pharmacokinet* 23, 2 (2008).
26. G. K. Michalopoulos, *Am J Pathol* 176, 2 (January, 2010).
27. N. Kobayashi et al., *Hepatology* 31, 851 (April, 2000).
28. J. B. O. Bures, J. P. Huston, in *Techniques and Basic Experiments for the Study of Brain and Behavior*. (Elsevier, New York, 1976), pp. 37-45.
29. M. N. Berry, D. S. Friend, *J Cell Biol* 43, 506 (December, 1969).
30. P. O. Seglen, *Methods Cell Biol* 13, 29 (1976).
31. R. M. Cawthon, *Nucleic Acids Res* 30, e47 (May 15, 2002).
32. T. Matsushita et al., *Gene Ther* 5, 938 (July, 1998).
33. D. Grimm et al., *J Virol* 82, 5887 (June, 2008).
- 20 Various publications, patents, patent applications, and GenBank Accession Nos. are cited herein, the contents of which are hereby incorporated by reference in their entireties.

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 80

<210> SEQ ID NO 1
<211> LENGTH: 4707
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

ggtttgaaag gaaggcagag agggcactgg gaggaggcag tgggaggggcg gagggccgggg       60
gccttcgggg tggcgccccca gggtagggca ggtggccgcg gcgtggaggc agggagaatg      120
cgactctcca aaaccctcggt cgacatggac atggccact acagtgtctgc actggaccca      180
gcctacacca ccctggaatt tgagaatgtg caggtgttga cgatggcaa tgacacgtcc      240
ccatcagaag gcaccaacccat caacgcgcac aacagectgg gtgtcagcgc cctgtgtgcc      300
atctgcgggg accggggccac gggcaaaacac tacgggtcct ctagctgtga cgggtgcaag      360
ggcttcttcc ggaggagcgt gggagaacaac cacatgtact cctgcagatt tagccggcag      420
tgcggtgtgg acaaagacaa gaggaaccag tgccgtact gcaggctcaa gaaatgttc      480
cgggtggca tgaagaagggc aatcggtccag aatgagccgg accggatcag cactcgaagg      540
tcaagctatg aggacacgcg cctgcccctcc atcaatgcgc tccgtcaggc ggaggtcctg      600
tcccacacca tcacccccc cgtctccggg atcaacggcc acattccggc gaagaagatt      660
gccagcatcg cagatgtgtg tgagtccatg aaggagcagc tgctgggtct cgttgagtgg      720
gccaagtaca tcccagctt ctgcgcgc cccctggaccc accagggtggc cctgctcaga      780
gccccatgtg gcgagcaccc gctgctggaa gcccaccaaga gatccatggt gttcaaggac      840
gtgctgctcc taggcaatga ctacattgtc cctcggact gcccggagct ggcggagatg      900
agccgggtgt ccatacgcac cttgtacgag ctgggtctgc cttccagga gctgcagatc      960
gatgacaatg agtatgccta cttcaaaagcc atcatcttct ttgaccaga tgccaagggg      1020
ctgagcgtc caggaaatgc caagcggtg cgttccagg tgcagggtgag cttggaggac      1080
tacatcaacg accggccacta tgactcgcgt ggccgcattt gaggactgt gctgctgtg      1140
ccccacccatgc agagcatcac ctggcagatg atcgagcaga tccagttcat caagcttcc      1200

```

-continued

ggcatggcca agattgacaa cctgttgag gagatgctgc tgggagggtc ccccagcgat 1260
 gcaaaaaatg cccaccaccc cctgcaccc cacctgtatc aggaacatata gggaaaccaac 1320
 gtcatcggtt ccaacacaat gcccactcac ctcagcaacg gacagatgtc caccctgag 1380
 accccacacgc cctcaccgccc aggtggctca gggtctgagc cctataagct cctgccggga 1440
 gccgtcgcca caatcgtaa gccccctctt gccatcccc agccgaccat caccaagcag 1500
 gaagttatct agcaagccgc tggggcttgg gggctccact ggctcccccc agccccctaa 1560
 gagagcacct ggtgtatcacg tggtcacggc aaaggaagac gtgtatgccag gaccagtccc 1620
 agagcaggaa tgggaaggat gaaggggcccg agaacatggc ctaaggccca catccactg 1680
 ccacccttga cgccctgctc tggataacaa gactttgact tggggagacc tctactgcct 1740
 tggacaacct ttctcatgtt gaagccactg cttcacctt caccttcatc catgtccaaac 1800
 ccccgacttc atcccaaagg acagccgcct ggagatgact tgaggcotta cttaaacccca 1860
 getcccttct tccttagcct ggtgttctc ctctccttagc cccctgtatc gtgtccagac 1920
 agagccctgt gagggtgggt ccaattgtgg cacttggggc accttgcctt tctttctgct 1980
 getgccccca cctctgtc ctcctctgc tgcacccctt ctcageccatc ccgttttctc 2040
 caacaccacc tctccagagg ccaaggaggg cttggaaacg attccccag tcattctggg 2100
 aacatgttgt aagcactgac tgggaccagg caccaggcag ggtctagaag gctgtggta 2160
 gggaaagacgc ctttctcctc caacccaacc tcatccttctc tcttcaggga cttgggtggg 2220
 tacttgggtg agatccctg aaggccttca acccgagaaa acaaaccagg gttggcact 2280
 gcaacaggaa cttggagtgg agaggaaaag catcagaaag aggccagacca tccaccaggc 2340
 ctttgagaaa gggtagaaatt ctggctggta gaggcgttgc gatgggacat tccaaagaac 2400
 agcctgagcc aaggcctagt ggttagtaaga atctagcaag aattgaggaa gaatggtgc 2460
 ggagagggat gatgaagaga gagagggcct gctggagacg atagggtctg gaacaccagg 2520
 ctggggctt gatcagcttc aaggagtagt cagggagctg ggcttcaga aatgaacac 2580
 agcagttctg cagaggacgg gaggctggaa gctggggatc cagggtgggt ggtatgatata 2640
 atgcgggtga gagtaatgag gcttggggct ggagaggaca agatgggtaa accctcacat 2700
 cagagtaca tccaggagga ataagctccc agggcctgtc tcaagetctt ccttactccc 2760
 aggcaactgtc ttaaggcatc tgacatgtc catctcattt aatccctccct tccctccat 2820
 taaccttagag attgttttttgc ttttttattc tccctccccc tccccggccct caccggcccc 2880
 actccctccct aaccttagaga ttgttacaga agctgaaatt gcgttctaag aggtgaagtgc 2940
 attttttttc tgaaactcac acaacttagga agtggctgag tcaggacttgc aaccctggc 3000
 tccctggatc agaacaggag ctcttaacta cagtggtga atagcttc caaaggctcc 3060
 ctgtgttctc accgtatca agttgggggg cttccggctc cttctacag cctcagaaac 3120
 cagactcggtt cttctggaa ccctgcccac tcccaggacc aagattggcc tgaggctgca 3180
 ctaaaattca cttagggtgc agcatcctgt ttgctgataa atattaagga gaattcatga 3240
 ctcttgacag ottttcttc ttcactcccc aagtcaaggg gaggggtggc aggggtctgt 3300
 ttccctggaaag tcaggctcat ctggcctgtt ggcattggggg tgggacagtgc tgacagtg 3360
 gggggcagggg gagggctaaag caggcctggg tttgagggtc gtcggggaga ccgtcactcc 3420
 aggtgcattc tggaaaggcatt agacccagg atggagcgcac cagcatgtca tccatgtgga 3480
 atcttgggtgg ctggaggac attctggaaa atgccactga ccagtgtgaa caaaaggat 3540

-continued

gtgttatggg gctggagggtg tgatttagta ggagggaaac tggggaccg actcctgcc	3600
cctgctcaac actgaccctt ctgagtggtt ggaggcagtg ccccaagtgc cagaaatccc	3660
accattagtg attgttttt atgagaaaga ggcgtggaga agtattgggg caatgtgtca	3720
gggaggaatc accacatccc tacggcagtc ccagccaagc ccccaatccc agcggagact	3780
gtgcccgtct cagagctccc aagecttccc ccaccaccc actcaagtgc ccctgaaatc	3840
cctgcccac ggctcagcct ggtctgcggt aaggcaggga ggctggaaacc atttctggc	3900
attgtggtca ttcccactgt gttcctccac ctccctccctc cagcgttgc cagacctctg	3960
tcttgggaga aagggttggaa taagaatgtc ccatggagtgc ccgtggccaa cagtggccct	4020
tcatgggaac aatctgttgg agcagggggt cagttctctg ctgggaatct acccccttct	4080
ggaggagaaa cccattccac cttataact ttattgtaat gtgagaaaca caaaacaaag	4140
tttacttttt tgactctaag ctgacatgtat attagaaaat ctctcgctct ctttttttt	4200
ttttttttt tttttggcta ctttagttgt ggtcctaaaa cataaaatct gatggacaaa	4260
cagagggttg ctggggggac aagcgtgggc acaatttccc caccaagaca ccctgatctt	4320
caggcgggtc tcaggagctt cttaaaatcc gcatggctct cctgagagtg gacagaggag	4380
aggagagggt cagaaatgaa cgctcttcta tttcttgtca ttaccaagcc aattactttt	4440
gccaatttt tctgtgatct gcccgttatta agatgaatttg tgaaatttac atcaagcaat	4500
tatcaaagcg ggctgggtcc catcagaacg acccacatct ttctgtgggt gtgaatgtca	4560
tttaggtcttg cgctgacccc tgagccccca tcactgcccgc ctgatggggc aaagaaacaa	4620
aaaacatttc ttactcttct gtgttttaac aaaagtttat aaaacaaaat aaatggcgca	4680
tatgtttct aaaaaaaaaaaaaaaa	4707

<210> SEQ_ID NO 2
<211> LENGTH: 4737
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

ggtttgaag gaaggcagag agggcactgg gaggaggcag tggggagggcg gagggcgffff	60
gccttcgggg tggcgccca gggtagggca ggtggccgcg gcgtggaggc agggagaatg	120
cgactctcca aaaccctcggt cgacatggac atggccgact acagtgtgc actggaccca	180
gcctacacca ccctggatt tgagaatgtc caggtgttgc cgatggccaa tgacacgtcc	240
ccatcagaag gcaccaacct caacgcgc aacagcctgg gtgtcagcgc cctgtgtgcc	300
atctgcccccc accggggccac gggcaaacac tacgggtcct cgagctgtga cggctgcaag	360
ggcttcttcc ggaggagcgt gccaagaacac cacatgtact cctgcagatt tagccggcag	420
tgcgtggtgg acaaagacaa gaggaaccag tgccgctact gcaggctcaa gaaatgttc	480
cgggctggca tgaagaagga agccgtccag aatgagcggg accggatcag cactcgaagg	540
tcaagctatg aggacagcag cctgcccctcc atcaatgcgc tcctgcagggc ggaggctctg	600
tcccgacaga tcacccccc cgtctccggg atcaacggc acatccgggc gaagaagatt	660
gccagcatcg cagatgtgtc tgagtccatg aaggagcgc tgctggttct cggtgagtg	720
gccaagtaca tcccagctt ctgcgagctc cccctggacg accaggtggc cctgctcaga	780
gccccatgtcg gggggccac gctgcgtcgg a cccaccaaga gatccatggt gttcaaggac	840
gtgcgtgtcc taggcaatga ctacattgtc cctcggcact gcccggagct ggcggagatg	900
agccgggtgt ccatacgcat ctttgacgag ctggcgtcgc cttccagga gctgcagatc	960

-continued

gatgacaatg agtatgccta cctcaaagcc atcatttct ttgaccaga tgccaagggg	1020
ctgagcgatc caggaaagat caagcggtc cggtcccagg tgcagggtgag ctggaggac	1080
tacatcaacg accggcagta tgactcgctg ggccgccttg gagagctgct gctgctgctg	1140
cccaccccttc agagcatcac ctggcagatg atcgagcaga tccagttcat caagctttc	1200
ggcatggcca agattgacaa cctgttgcag gagatgctgc tggggagggtc ccccgcgat	1260
gcacccccatg cccaccaccc cctgcaccct cacctgtatc aggaacatata gggaaaccac	1320
gtcatcggtt ccaacacaat gcccactac ctcagcaacg gacagatgtg tgagtggccc	1380
cgaccccgagg gacaggcagc cacccttagt accccacacg cctcaccggcc aggtggctca	1440
gggtctgagc octataagct cctgcccggg gccgtcgecca caatcgtaa gcccctctt	1500
gecatcccccc agccgaccat caccaagcag gaagttatct agcaagccgc tggggcttgg	1560
gggctccact ggctccccc agccccctaa gagagcacct ggtgatcagc tggtcacggc	1620
aaaggaagac gtgtatgcag gaccagtccc agagcaggaa tgggaaggat gaaggggcccg	1680
agaacatggc otaaggggca catccactg ccacccttga cgcctgctc tggataacaa	1740
gactttgact tggggagacc tctactgcct tggacaactt ttctcatgtt gaagecactg	1800
ccttcacccctt cacccatc catgtccaa ccccgacttc atcccaaagg acagccgcct	1860
ggagatgact tgaggcctta cttaaacccaa gctcccttc tcccttagcct ggtgttttc	1920
ctctccatgc ccctgtatc gtgtccagac agagccctgt gaggctgggt ccaattgtgg	1980
cacttggggc accttgcctc tccttctgt gctggcccca cctctgctgc ctccctctgc	2040
tgtcacccctt ctcagccatc ccgtcttc caacaccacc tctccagagg ccaaggagc	2100
cttggaaacg attcccccag tcattctggg aacatgttg aagactgac tgggaccagg	2160
caccaggcag ggtctagaag gctgtggta gggaaagacgc ctttctcc tcacccaaacc	2220
tcatccctt tcttcaggaa ctgggggtggg tactgggtt aggateccctg aaggectca	2280
acccgagaaa acaaacccag gttggcgact gcaacaggaa ctggagatgg agaggaaaag	2340
catcagaaag aggcagacca tccaccaggc ctttgagaaa gggtagatt ctggctgta	2400
gagcaggtga gatggacat tccaaagaac agcctgagcc aaggcctagt ggttagtaaga	2460
atctagcaag aattgaggaa gaatgggtg gtagggat gatgaagaga gagagggcct	2520
gttggagacg atagggtctg gaacaccagg ctgaggctt gatcagcttc aaggagtatg	2580
cagggagctg ggctccaga aaatgaacac agcagttctg cagaggacgg gaggctggaa	2640
gttggaggt caggtgggtt ggtatgatata atgcgggtga gagtaatgag gcttgggtct	2700
ggagaggaca agatggtaa accctcacat cagagtaca tccaggagga ataagctccc	2760
aggccctgtc tcaagctctt ctttactccc aggcaactgtc ttaaggcatc tgacatgcat	2820
catctcatattt aatccctccct tcctccctat taaccttagag attttttttt ttttttattc	2880
tcctccccc tccccccct caccggcccc actccctctt aaccttagaga ttgttacaga	2940
agctgaaatt gcgttctaag aggtgaagtg attttttttc tgaaactcac acaacttagga	3000
agtggctgag tcaggacttg aaccagggtc tccctggatc agaacaggag ctcttaacta	3060
cagtggctga atagcttctc caaaggctcc ctgtgttctc accgtatca agttgagggg	3120
cttccggctc ctttctacag cctcagaaac cagactcggtt ctgtggaa ccctgcccac	3180
tcccaggacc aagattggcc tgaggctgca ctaaaattca cttagggtgc agcatccgt	3240
ttgctgataa atattaagga gaattcatga ctcttgacag cttttctctc ttcactcccc	3300

-continued

aagtcaaggg gaggggtggc aggggtctgt ttcccttggaaag tcaggctcat ctggcctgtt	3360
ggcatggggg tgggacagtg tgacacagtgt gggggcaggg gagggctaag caggcctggg	3420
tttgagggt gctccggaga ccgtcactcc aggtgcattc tggaaagcatt agaccccagg	3480
atggagcgac cagcatgtca tccatgtgga atcttgggtt ctttggggac attctggaaa	3540
atgccactga ccagtgtgaa caaaaaggat gtgttatggg gctgggggtg tgatttagta	3600
ggaggggaaac tggggaccg actctctgccc cctgctcaac actgacccct ctgagtgggt	3660
ggaggcagtg ccccaactgccc cagaatccc accattagtg attgtttttt atgagaaaga	3720
ggcgtggaga agtattgggg caatgtgtca gggaggaatc accacatccc tacggcagtc	3780
ccagccaagc ccccaatccc agcggagact gtgcctgtct cagagctccc aagccttccc	3840
ccaccacccctc actcaagtgc ccctgaaatc cctgcccacag ggctcagcct ggtctgggt	3900
aaggcagggg ggctggaaacc atttctgggc attgtggtaa ttcccactgt gtctccac	3960
ctccctccctc cagcgttgct cagacccctg tcttgggaga aagggttggaa taagaatgtc	4020
cctatggatg cctgtggccaa cagtgccctt tcatgggaaac aatctgttgg agcagggggt	4080
cagttctctg ctgggaaatct accccctttctt ggaggagaaa cccattccac cttataact	4140
ttattgtaat gtgagaaaca caaaacaaaag ttactttttt tgactctaag ctgacatgat	4200
attagaaaat ctctcgctct cttttttttt tttttttttt tttttggcta ctttagtgt	4260
ggtcctaaaa cataaaatct gatggacaaa cagagggttg ctggggggac aagcgtggc	4320
acaatcccc caccaagacac ccctgatctt caggcgggtc tcaggagctt cttttttttt	4380
gcatggctct cctgagagtg gacagaggag aggagagggt cagaaatgaa cgctttctta	4440
tttcttgtaa ttaccaagcc aattactttt gccaaatttt tctgtgatct gcccgttta	4500
agatgaattt gaaaaattttt acatggcaat tatcaaagcg ggctgggtcc catcagaacg	4560
acccacatct ttctgtgggt gtgaatgtca tttaggtctt cgtgacccccc tgagccccca	4620
tcaactggcgc ctgatggggc aaagaaacaa aaaacatttc ttacttttctt gtgtttttaac	4680
aaaagtttat aaaacaaaat aaatggcgca tatgttttctt aaaaaaaaaa aaaaaaaaaa	4737

<210> SEQ ID NO 3
 <211> LENGTH: 1628
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

ggtttggaaag gaaggcagag agggcactgg gaggaggcag tggggagggcg gagggcgggg	60
gccttcgggg tggggggccca gggtagggca ggtggcccgcg gcgtggaggc agggagaatg	120
cgactctcca aaaccctcgatcgacatggac atggccgact acagtgtgc actggaccca	180
gcctacacca ccctggaaattt tgagaatgtg caggtgttga cgatgggcaa tgacacgtcc	240
ccatcagaag gcaccaaccc caacgcgcac aacagcctgg gtgtcagcgc cctgtgtgcc	300
atctgcgggg accggccac gggcaaacac tacgggtcctt cgagctgtga cggctgcac	360
ggcttcttcc ggaggaggcgt gcggaagaac cacatgtact cctgcagatt tagccggcag	420
tgcgtgggtt gaaaaagacaa gaggaaaccag tgccgtactt gcaggctcaa gaaatgcttc	480
cgggctggca tgaagaagga agccgtccag aatgagcggg accggatcag cactcgaagg	540
tcaagctatg aggacacgcg cctgcctcc atcaatgcgc tctgtcaggc ggaggctctg	600
tcccgacaga tcacccccc cgtctccggg atcaacggcg acattcgggc gaagaagatt	660
gccagcatcg cagatgtgtg tgagtccatg aaggagcagc tgctgggttctt cggtgagtg	720

-continued

gccaagtaca tcccagctt ctgcgagctc cccctggacg accaggtggc cctgctcaga	780
gccccatgtg gcgagcacct gctgctcgg a gccaccaaga gatccatggt gttcaaggac	840
gtgctgtcc taggcaatga ctacattgtc cctcggact gcccggagct ggccggagatg	900
agccgggtgt ccatacgcac ccttgacgag ctgggtgtc cttccagga gctgcagatc	960
gatgacaatg agtatgccta cctcaaagcc atcatcttct ttgaccaga tgccaagggg	1020
ctgagcgtac caggaaagat caagcggctg cgttcccagg tgcagggtgag cttggaggac	1080
tacatcaacg accgcacgt a tgactcgcgt ggccgctttg gagagctgt gctgtgtc	1140
cccaccttc acagcatcac ctggcagatg atcgagcaga tccagttcat caagctttc	1200
ggcatggcca agattgacaa cctgttgacg gagatgtgc tgggaggtcc gtgccaagcc	1260
caggaggggc ggggttggag tggggactcc ccaggagaca ggccctcacac agttagctca	1320
ccctcagct cttggcttc cccactgtc cgcttgggc aagttgttta acctgtctgt	1380
gcctcagtt cctcaccaga aaaatggaa caaggcaatg gtctatttgt tcaggcaccc	1440
agaaccttagc acgtgccagt cactgttcta agtgctggca attcagcaaa gaacaagatc	1500
tttgccctcg gggaggctgt gtgtgtgtga gtatgtatgg atgcgtggat atctgtgtat	1560
atgcccgtat gtgcgtcat gtgtatataa agcctcacat tttatgattt taaaataaac	1620
aggtaata	1628

<210> SEQ ID NO 4
<211> LENGTH: 4558
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4	
ggccatggtc agcgtgaacg cgccccctegg ggctccagtg gagagttctt acgacacgtc	60
cccatcagaa ggcaccaacc tcaacgcgc caacagcctg ggtgtcagcg ccctgtgtc	120
catctgcggg gaccgggcca cggggcaaca ctacggtgcc tcgagctgtg acggctgca	180
gggcttttc cggaggagcg tgccggaa ccacatgtac tcctgcagat ttageccgca	240
gtgcgtggtg gacaaagaca agaggaacca gtgccgtac tgcaggctca agaaatgctt	300
ccgggctggc atgaagaagg aagecgteca gaatgagcgg gaccggatca gcactcgaa	360
gtcaagctat gaggacagca gcctgcctc catcaatgcg ctccctgcagg cggaggctct	420
gtccccacag atcacctccc ccgtctcgg gatcaacggc gacattcggg cgaagaagat	480
tgccagcatc gcagatgtgt gtgagtccat gaaggagcag ctgctggc tcgttgagtg	540
ggccaagttac atcccaagtt tctgcgtac cccctggac gaccagggtgg ccctgctcag	600
agcccatgtc ggccgacacc tgctgctegg agccaccaag agatccatgg tggtaagga	660
cggtgtgtc ctagggaaatg actacattgt ccctcggcc tggccggagc tggccggagat	720
gagccgggtg tccatacgca tccttgacga gctgggtctg cccttcagg agctgcagat	780
cgatgacaat gagtatgcct acctcaaagg catcatctt tttgaccagg atgccaagg	840
gtgtgacatc ccaggaaaga tcaaggccgt gcttcccag gtgcagggtga gcttggagga	900
ctacatcaac gaccgcacgt atgactcgcg tggccgttt ggagagctgc tgctgtgtc	960
gccccacccctg cagagcatca cctggcagat gatcgacgac atccagttca tcaagcttt	1020
cgccatggcc aagattgaca acctgttgcg ggagatgtcg ctggggagggt cccccagcga	1080
tgcaccccat gcccaccacc ccctgcaccc tcacctgtatc caggaacata tggaaacca	1140

-continued

cgtcatcggt gccaacaccaa tgcccaactca cctcagaca ggacagatgt gtgagtgccc	1200
ccgaccggagg ggacaggcag ccacccctga gaccccaag ccctcaccgc caggggctc	1260
agggtcttagt ccctataaagc tcctggcccc agccgtcgcc acaatctca agccctctc	1320
tgcatecccc cagccgacca tcaccaagca ggaagttatc tagcaagccg ctggggctt	1380
ggggctccac tggctcccc cagccctca agagagcacc tgggtatcac gtggtaacgg	1440
caaaggaaaga cgtgtatgcga ggaccaggcc cagagcagga atggaaaggga tgaaggggcc	1500
gagaacatgg cctaaggggcc acatccact gccacccttgc acgcccgtct ctggataaca	1560
agactttgac ttggggagac ctctactgcc ttggacaact ttctcatgt tgaaggccact	1620
gccttcacct tcacccatcat ccatgtccaa ccccccgaact catccaaag gacagccgccc	1680
tggagatgac ttgaggccctt acttaaaaccc agtcccttc ttccctagcc tgggtcttct	1740
ccttccttag cccctgtcat ggtgtccaga cagagccctg tgaggctggg tccattgtg	1800
gcacttgggg caccttgctc ctccctctgc tgctgcccccc acctctgtg cctccctctg	1860
ctgtcacctt gtcagccat cccgtcttct ccaacaccac ctctccagag gccaaggagg	1920
ccttggaaac gattccccca gtcattctgg gaacatgttga taagactga ctgggaccag	1980
gcaccaggca gggcttagaa ggctgtggtg agggaaagacg ctttctctt ccaacccaaac	2040
ctcatccctcc ttcttcaggg acttgggtgg gtacttggg gaggatccct gaaggccctc	2100
aacccgagaa aacaaaccca gggtggcgac tgcaacagga acttggagtg gagagaaaa	2160
gcatcagaaa gaggcagacc atccaccagg cttttagaa aggtagaat tctggctgt	2220
agagcagggtg agatgggaca ttccaaagaa cagcctgagc caaggcttag tgtagtaag	2280
aatcttagcaa gaatttgggaa agaatgggtgt gggaggggaa tgatgaagag agagggggcc	2340
tgttggagag catagggctt ggaacaccag gctgaggtoe tgatcagttt caaggagttat	2400
gcagggagct gggcttccag aaaatgaaca cagcaggatcc gcaaggaggcc ggaggctgg	2460
agcttggagg tcaggtgggg tggatgatat aatgcgggtg agagtaatga ggcttggggc	2520
tggagaggac aagatgggta aaccctcaca tcagagtgc atccaggagg aataagctcc	2580
caggccctgt ctcaagctt ctccctactcc caggcaactgt ctttaaggcat ctgacatgca	2640
tcatcttatt taatccccc ttccctccata ttaaccttaga gattttttt gttttttatt	2700
ctccctctcc ctccccggcc tcacccggcc cactccctcc taaccttagat atttttacag	2760
aagctgaaat tgcgttctaa gaggtgaagt gatttttttt ctgaaactca cacaactagg	2820
aagtggctga gtcaggactt gaaccctaggat ctccctggat cagaacagga gctcttaact	2880
acagttggctg aatacttctt ccaaaggctc cctgtgttcc caccgtgtc aagttgggg	2940
gtttccggct cccttctaca gcctcagaaa ccagactgt tttctggat accctggccca	3000
ctcccccaggac caagattggc ctgaggctgc actaaaattt acttgggtc gagcatccctg	3060
tttgctgata aatattaagg agaattcatg actcttgcata gttttctctt cttcaactccc	3120
caagtcaagg ggaggggtgg caggggtctg tttcctggaa gtcaggctca tctggccctgt	3180
tggcatgggg gtggggacgt gtgcacagtg tggggggcagg ggagggctaa gcaggccctgg	3240
gtttgagggc tgctccggag accgtcactc caggtgcatt ctggaaagcat tagaccccaag	3300
gtatggggcga ccagcatgtc atccatgtgg aatcttggtg gttttggagga cattctggaa	3360
aatgccactg accagtgtga acaaaaggaa tgggttatgg ggctggaggt gtgatttaggt	3420
aggaggaaa ctgttggacc gactctgccc ccctgtctaa cactgacccctt tctgtttttt	3480
tggaggcagg gccccggatgc ccagaaatcc caccatttagt gattttttt tatgagaaag	3540

US 9,981,048 B2

49**50**

-continued

```

aggcgtggag aagtattggg gcaatgtgtc agggaggaat caccacatcc ctacggcagt    3600
cccagccaag cccccaatcc cagcggagac tgtgccctgc tcagagctcc caagccttcc    3660
cccaccacct cactcaagtg cccctgaaat ccctgccaga cggctcagcc tggctcgccg    3720
taaggcaggg aggcttggaaac catttcttggg catttgtgtc atttccactg ttttcttcca    3780
cctcctccct ccagegttgc tcagacctct gtcttggag aaagggtttag ataagaatgt    3840
cccatggagt gccgtggca acagtggccc ttcatggaaat caatctgtt gaggcggggg    3900
tcagttctt gctggaaatc taccctttc tggaggagaa acccattcca ccttaataac    3960
tttattgtaa ttttgagaaac acaaaaacaaa gtttactttt ttgactctaa gctgacatga    4020
tattagaaaa tctctcgctc tctttttttt tttttttt ttttttgct acttgagttg    4080
tggctctaaa acataaaaatc tttttttttt tttttttttt ttttttgct acttgagttg    4140
cacaatttcc ccaccaagac accctgtatct tcaggcgggt ctcaggagct tctaaaaatc    4200
cgcatggctc tcctgagagt ggacagagga gaggagggg tcagaaatga acgctttct    4260
atttcttgc attaccaagc caattacttt tgccaaattt ttctgtgatc tgccctgatt    4320
aagatgaatt gtgaaattna catcaagcaa ttatcaaagc gggcttgggc ccatcagaac    4380
gaccacatc tttctgtggg tttttttttt tttttttttt ttttttgct acttgagttg    4440
atcaactgccc cttttttttt tttttttttt ttttttgct acttgagttg    4500
caaaagttta taaaacaaaaaa taaaatggcgc atatgttttcaaaaaaaaaaaaaaaa    4558

```

<210> SEQ ID NO 5
<211> LENGTH: 4528
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

```

ggccatggtc agcgtgaacg cgccccctgg ggccgttgc gagagttttt acgacacgtc    60
cccatcgaa ggcaccaacc tcaacgcgcc caacagctt ggtgtcagcg ccctgtgtc    120
catctgggg gaccggggca cgggcaaaaca ctacgggtcc tcgagctgtg acggctgca    180
gggcttcttc cggaggagcg tgcggaaagaa ccacatgtac tcctgcagat ttgcggca    240
gtgcgtggg gacaaaagaca agaggaatca gtgcgttgc tgcaggctca agaaatgtt    300
ccgggtggc atgaagaagg aagccgttca gaatgagcg gacggatca gcactcgaa    360
gtcaagctat gaggacagca gcctgccttc catcaatgtc tcctgcagg cggagggtct    420
gtcccgacag atcacctccc ccgtctccgg gatcaacggc gacattcggg cgaagaagat    480
tgccagcatc gcagatgtgt gtgagttccat gaaggagcg ctgctgggtc tcgttgcgt    540
ggccaaatgtc atcccaatgt tctgcgttgc gcccctggac gaccagggtgg ccctgtctc    600
agcccatgtc ggccgttgc tgcgttgcgg agccaccaag agatccatgg tttcaaggg    660
cgtgtgtctc ttaggcaatg actacattgt ccctcggtac tgcccgagc tggcgagat    720
gagccgggtg tccatacgca tccttgacga gctgggtctg cccttccagg agctgcagat    780
cgatgacaat gatgtatgtt acctcaaaatc catcatcttc tttgacccag atgccaagg    840
gtgtgtgttgc tcaaggaaaga tcaagggttgc gctttccagg gtgcagggtga gcttggagga    900
ctacatcaac gaccggcgtt atgactcgcc tggccgttgc ggagagctgc tgctgtctc    960
gcccaccccttgc cagacatca cctggcgttgc gatcgagcgtt atccagttca tcaagcttt    1020
ggccatggcc aagattgaca acctgttgca ggagatgttgc ctggggggg cccccagcga    1080

```

-continued

tgcacccat gccccaccacc cccctgcaccc tcacctgatg caggaacata tggaaaccaa	1140
cgtcatcggtt gccaacacaaa tgcccactca cctcagcaac ggacagatgt ccacccctga	1200
gaccccacag ccctcaccgc cagggtggctc agggtctgag ccctataagc tcctgccgg	1260
agccgtcgcc acaatcgta agccctctc tgccatcccc cagccgacca tcaccaagca	1320
ggaagtattc tagcaagccg ctggggcttg ggggctccac tggctcccc cagcccccta	1380
agagagcacc ttgtgtatcac gtggtaeagg caaaggaaga cgtgtatgcca ggaccagtcc	1440
cagagcagga atgggaagga tgaaggccc gagaacatgg cctaaggccc acatcccact	1500
gccaccccttg acgcccgtct ctggataaca agactttgac ttggggagac ctctactgcc	1560
ttggacaact ttctctatgt tgaagccact gccttcacct tcacccatc ccatgtccaa	1620
cccccgactt catccaaag gacagccccc tggagatgac ttgaggccctt acttaaaccc	1680
agctcccttc ttccctagecc ttgtgtttct cctctcttag cccctgtcat ggtgtccaga	1740
cagagccctg tgaggctggg tccaaattgtg gcacttgggg caccttgctc ctccctctgc	1800
tgtgtcccccc acctctgtc cccccccttg ctgtcacctt gtcagccat cccgtttct	1860
ccaacaccac ctctccagag gccaaggagg ccttggaaac gattccccca gtcattctgg	1920
gaacatgttg taagcactga ctgggaccag gcaccaggca gggcttagaa ggctgtggtg	1980
agggaaagacg cctttctcct ccaacccaaac ctcatcctcc ttcttcaggg acttgggtgg	2040
gtacttgggt gaggatccct gaaggccctc aacccgagaa aacaaaccca gggtggcgac	2100
tgcaacagga acttggagtg gagagaaaa gcatcagaaaa gaggcagacc atccaccagg	2160
cctttgagaa agggtagaat tctggctgtt agagcaggtt agatgggaca ttccaaagaa	2220
cagcctgagc caaggccctag ttgttagtaag aatctagcaa gaattgagga agaatggtgt	2280
ggggaggggaa tgatgaagag agagagggcc tgctggagag catagggctt ggaacaccag	2340
gctgaggctcc tgatcagctt caaggagttt gcagggagct gggcttccag aaaatgaaca	2400
cagcaggctt gcagaggacg ggaggcttgg agctgggggg tcaagggttttggatgtat	2460
aatgcgggtt agagtaatga ggcttggggc tggagaggac aagatgggtt aaccctcaca	2520
tcaaggtgac atccaggagg aataagctcc cagggccctgt ctcaagctt tccttactcc	2580
caggcactgt ottaaggcat ctgacatgca tcatcttatt taatcctccc ttccctctta	2640
ttaacctaga gattttttt gttttttatt ctccctctcc ctcccccccc tcacccggcc	2700
cactccctcc taaccttagag attgttacag aagctgaaat tgcgttctaa gaggtgaagt	2760
gatttttttt ctgaaaactca cacaactagg aagtggctga gtcaggactt gaacccaggt	2820
ctccctggat cagaacagga gctcttaact acagtggctg aatagttctt ccaaaggctc	2880
cctgtgtttt caccgtgtatc aagttgaggg gcttccggctt cccttctaca gcctcagaaaa	2940
ccagactctt ttttctggga accctgcccc cttccaggac caagattggc ctgaggctgc	3000
actaaaattc acttagggtc gacatctgtt tttgctgata aatattaagg agaattcatg	3060
actcttgaca gctttctctt ctctactccc caagtcaagg ggaggggtgg caggggtctg	3120
ttccctggaa gtcaggctca tctggctgtt tggcatgggg gtggggacgt gtgcacagt	3180
tggggggcagg ggagggctaa gcaggccctgg gtttgagggc tgctccggag accgtcactc	3240
caggtgcatt ctggaaagcat tagacccctt gatggagcga ccagcatgtc atccatgtgg	3300
aatcttggtt gctttgagga cattctggaa aatgccactt accagtgtga aaaaaaggaa	3360
tgtgttatgg ggctggaggt gtgatttagt aggagggaaa ctgttgacc gactctgcc	3420
ccctgctcaa cactgacccc tctgatgtgtt tggaggcagt gccccagtgc ccagaatcc	3480

-continued

caccattagt gattgtttt tatgagaaaag aggctggag aagtattggg gcaatgtgc	3540
agggagaaat caccacatcc ctacggcagt cccagccaag cccccaatcc cagcgagac	3600
tgtgcctgc tcagagctcc caagcctcc cccaccacct cactcaagtg cccctgaaat	3660
ccctgccaga cggctcagcc tggctgccc taaggcaggg aggtggAAC catttctggg	3720
cattgtggtc attcccactg tggtcctcca cctcctccct ccagcgttgc tcagacctct	3780
gtcttggag aaaggttgag ataagaatgt cccatggagt gccgtggca acagtggccc	3840
ttcatggaa caatctgtt gagggggggg tcaagttctt gctggaaatc tacccttcc	3900
tggaggaa acccattcca ccttaataac ttatttgtaa tgtgagaaac aaaaaacaaa	3960
gtttactttt ttgactctaa gctgacatga tattagaaaa tctctcgctc tcttttttt	4020
ttttttttt tttttggct acttgagttt tggtcctaaa acataaaatc tgatggacaa	4080
acagagggtt gctggggggca caagcgtggg cacaatttcc ccaccaagac accctgatct	4140
tcaggcgggtt ctcaggagct tctaaaaatc cgcatggctc tcctgagagt ggacagagga	4200
gaggagaggg tcaaaaatga acgcttttctt atttcttgcatttcaaggc caattacttt	4260
tgccaaattt ttctgtgatc tgccctgatt aagatgaatt gtgaaattt catcaagcaa	4320
ttatcaaagc gggctgggtc ccatcagaac gaccacatc ttctgtggg tgtgaatgtc	4380
attaggctt gcgcgtaccc ctgagcccc atcaactgcgg cctgatgggg caaagaaaca	4440
aaaaacatttt cttactcttc ttttttttttcaaaaatggggcaaaaatggggcaaaaatggggca	4500
atatgttttcaaaaaaaaaaaaaaaa	4528

<210> SEQ ID NO 6
 <211> LENGTH: 1449
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

ggccatggc acgcgtgaacg cgccccctcg ggctccagtg gagagttttt acgacacgtc	60
cccatcagaa ggcaccaacc tcaacgcgc caacagectt ggtgtcagcg ccctgtgtgc	120
catctgcggg gaccggggca cgggcaaaaca ctacgggtcc tcgagctgtg acggctgca	180
gggcttcttc cggaggagcg tgcggaaagaa ccacatgtac tcctgcagat ttagecggca	240
gtgcgtggtg gacaaagaca agaggaacca gtgcgcgtac tgcaggctca agaaatgtt	300
ccgggctggc atgaagaagg aagccgtcca gaatgagcg gaccggatca gcactcgaa	360
gtcaagctat gaggacagca gcctgccttc catcaatgcg ctccctgcagg cggaggtcct	420
gtcccgacag atcacctccc ccgtctccgg gatcaacggc gacattcggg cgaagaagat	480
tgccagcatc gcagatgtgt gtgagttccat gaaggagcag ctgcgtggc tcgttgagtg	540
ggccaagtagt atcccaagtt tctgcgcgtt cccctggc gaccagggtgg ccctgctcag	600
agcccatgtt ggcgagcacc tgctgctcg agccaccaag agatccatgg ttttcaagga	660
cgtgctgttc ctaggcaatg actacattgt ccctcggcac tgcccgagc tggcgagat	720
gagccgggtt tccatacgca tccttgacga gctgggtgtt cccttcagg agctgcagat	780
cgtgacatgat gagtatgcct acctcaaaagc catcatcttc tttgacccag atgccaagg	840
gctgagcgat ccagggaaaga tcaagcggctt gcttcccag gtgcagggtga gcttggagga	900
ctacatcaac gaccggcagt atgactcgcc tggccgctttt ggagagctgc tgctgtgtc	960
gccccacccctt cagagcatca cctggcagat gatcgagcag atccagttca tcaagcttt	1020

-continued

cggcatggcc aagattgaca acctgttgc	aa ggagatgctg ctggggaggc	cgtgccaagc	1080
ccaggagggg cgggggttgg	a gttggactc cccaggagac	aggcctcaca cagtgagtc	1140
accctcagc tccttggctt	ccccactgtg cgc tttggg	caagttgctt aac tgc tctg	1200
tgcctcagtt tcctcaccag	aaaaatggga acaaggca	aat ggttattt gttcaggcacc	1260
gagaacctag cacgtgccag	tca ctgttct aagtgc tggc	aattcagcaa agaacaagat	1320
cttgcctc ggggaggctg	tgtgtgtgtg agtatgtat	gatgcgtgga tatctgtgt	1380
tatgcccgt	ta tgcgtgca tgcgtatata	aagcctcaca tt tttatgatt	1440
caggtaata			1449

<210> SEQ ID NO 7

<211> LENGTH: 464

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp	Met Ala Asp Tyr Ser	
1 5 10 15		

Ala Ala Leu Asp Pro Ala Tyr Thr	Leu Glu Phe Glu Asn Val Gln	
20 25 30		

Val Leu Thr Met Gly Asn Asp Thr	Ser Pro Ser Glu Gly Thr Asn Leu	
35 40 45		

Asn Ala Pro Asn Ser Leu Gly Val Ser Ala Leu Cys	Ala Ile Cys Gly	
50 55 60		

Asp Arg Ala Thr Gly Lys His Tyr Gly Ala Ser Ser Cys	Asp Gly Cys	
65 70 75 80		

Lys Gly Phe Phe Arg Arg Ser Val Arg Lys Asn His	Met Tyr Ser Cys	
85 90 95		

Arg Phe Ser Arg Gln Cys Val Val Asp Lys Asp Lys Arg	Asn Gln Cys	
100 105 110		

Arg Tyr Cys Arg Leu Lys Cys Phe Arg Ala Gly	Met Lys Lys Glu	
115 120 125		

Ala Val Gln Asn Glu Arg Asp Arg Ile Ser Thr Arg Arg	Ser Ser Tyr	
130 135 140		

Glu Asp Ser Ser Leu Pro Ser Ile Asn Ala Leu Leu Gln	Ala Glu Val	
145 150 155 160		

Leu Ser Arg Gln Ile Thr Ser Pro Val Ser Gly Ile Asn	Gly Asp Ile	
165 170 175		

Arg Ala Lys Lys Ile Ala Ser Ile Ala Asp Val Cys	Glu Ser Met Lys	
180 185 190		

Glu Gln Leu Leu Val Leu Val Glu Trp Ala Lys Tyr Ile	Pro Ala Phe	
195 200 205		

Cys Glu Leu Pro Leu Asp Asp Gln Val Ala Leu Leu Arg	Ala His Ala	
210 215 220		

Gly Glu His Leu Leu Leu Gly Ala Thr Lys Arg Ser Met	Val Phe Lys	
225 230 235 240		

Asp Val Leu Leu Leu Gly Asn Asp Tyr Ile Val Pro Arg	His Cys Pro	
245 250 255		

Glu Leu Ala Glu Met Ser Arg Val Ile Arg Ile Leu Asp	Glu Leu	
260 265 270		

Val Leu Pro Phe Gln Glu Leu Gln Ile Asp Asp Asn	Glu Tyr Ala Tyr	
275 280 285		

Leu Lys Ala Ile Ile Phe Phe Asp Pro Asp Ala Lys	Gly Leu Ser Asp	
---	-----------------	--

US 9,981,048 B2

57

-continued

290	295	300
Pro Gly Lys Ile Lys Arg Leu Arg Ser Gln Val Gln Val Ser Leu Glu		
305	310	315
Asp Tyr Ile Asn Asp Arg Gln Tyr Asp Ser Arg Gly Arg Phe Gly Glu		
325	330	335
Leu Leu Leu Leu Leu Pro Thr Leu Gln Ser Ile Thr Trp Gln Met Ile		
340	345	350
Glu Gln Ile Gln Phe Ile Lys Leu Phe Gly Met Ala Lys Ile Asp Asn		
355	360	365
Leu Leu Gln Glu Met Leu Leu Gly Gly Ser Pro Ser Asp Ala Pro His		
370	375	380
Ala His His Pro Leu His Pro His Leu Met Gln Glu His Met Gly Thr		
385	390	395
Asn Val Ile Val Ala Asn Thr Met Pro Thr His Leu Ser Asn Gly Gln		
405	410	415
Met Ser Thr Pro Glu Thr Pro Gln Pro Ser Pro Pro Gly Ser Gly		
420	425	430
Ser Glu Pro Tyr Lys Leu Leu Pro Gly Ala Val Ala Thr Ile Val Lys		
435	440	445
Pro Leu Ser Ala Ile Pro Gln Pro Thr Ile Thr Lys Gln Glu Val Ile		
450	455	460

<210> SEQ ID NO 8

<211> LENGTH: 474

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser		
1	5	10
Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gln		
20	25	30
Val Leu Thr Met Gly Asn Asp Thr Ser Pro Ser Glu Gly Thr Asn Leu		
35	40	45
Asn Ala Pro Asn Ser Leu Gly Val Ser Ala Leu Cys Ala Ile Cys Gly		
50	55	60
Asp Arg Ala Thr Gly Lys His Tyr Gly Ala Ser Ser Cys Asp Gly Cys		
65	70	75
Lys Gly Phe Phe Arg Arg Ser Val Arg Lys Asn His Met Tyr Ser Cys		
85	90	95
Arg Phe Ser Arg Gln Cys Val Val Asp Lys Asp Lys Arg Asn Gln Cys		
100	105	110
Arg Tyr Cys Arg Leu Lys Lys Cys Phe Arg Ala Gly Met Lys Lys Glu		
115	120	125
Ala Val Gln Asn Glu Arg Asp Arg Ile Ser Thr Arg Arg Ser Ser Tyr		
130	135	140
Glu Asp Ser Ser Leu Pro Ser Ile Asn Ala Leu Leu Gln Ala Glu Val		
145	150	155
Leu Ser Arg Gln Ile Thr Ser Pro Val Ser Gly Ile Asn Gly Asp Ile		
165	170	175
Arg Ala Lys Lys Ile Ala Ser Ile Ala Asp Val Cys Glu Ser Met Lys		
180	185	190
Glu Gln Leu Leu Val Leu Val Glu Trp Ala Lys Tyr Ile Pro Ala Phe		
195	200	205

58

US 9,981,048 B2

59**60**

-continued

Cys Glu Leu Pro Leu Asp Asp Gln Val Ala Leu Leu Arg Ala His Ala
210 215 220

Gly Glu His Leu Leu Leu Gly Ala Thr Lys Arg Ser Met Val Phe Lys
225 230 235 240

Asp Val Leu Leu Leu Gly Asn Asp Tyr Ile Val Pro Arg His Cys Pro
245 250 255

Glu Leu Ala Glu Met Ser Arg Val Ser Ile Arg Ile Leu Asp Glu Leu
260 265 270

Val Leu Pro Phe Gln Glu Leu Gln Ile Asp Asp Asn Glu Tyr Ala Tyr
275 280 285

Leu Lys Ala Ile Ile Phe Phe Asp Pro Asp Ala Lys Gly Leu Ser Asp
290 295 300

Pro Gly Lys Ile Lys Arg Leu Arg Ser Gln Val Gln Val Ser Leu Glu
305 310 315 320

Asp Tyr Ile Asn Asp Arg Gln Tyr Asp Ser Arg Gly Arg Phe Gly Glu
325 330 335

Leu Leu Leu Leu Pro Thr Leu Gln Ser Ile Thr Trp Gln Met Ile
340 345 350

Glu Gln Ile Gln Phe Ile Lys Leu Phe Gly Met Ala Lys Ile Asp Asn
355 360 365

Leu Leu Gln Glu Met Leu Leu Gly Gly Ser Pro Ser Asp Ala Pro His
370 375 380

Ala His His Pro Leu His Pro His Leu Met Gln Glu His Met Gly Thr
385 390 395 400

Asn Val Ile Val Ala Asn Thr Met Pro Thr His Leu Ser Asn Gly Gln
405 410 415

Met Cys Glu Trp Pro Arg Pro Arg Gly Gln Ala Ala Thr Pro Glu Thr
420 425 430

Pro Gln Pro Ser Pro Pro Gly Gly Ser Gly Ser Glu Pro Tyr Lys Leu
435 440 445

Leu Pro Gly Ala Val Ala Thr Ile Val Lys Pro Leu Ser Ala Ile Pro
450 455 460

Gln Pro Thr Ile Thr Lys Gln Glu Val Ile
465 470

<210> SEQ ID NO 9

<211> LENGTH: 417

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Met Arg Leu Ser Lys Thr Leu Val Asp Met Asp Met Ala Asp Tyr Ser
1 5 10 15

Ala Ala Leu Asp Pro Ala Tyr Thr Thr Leu Glu Phe Glu Asn Val Gln
20 25 30

Val Leu Thr Met Gly Asn Asp Thr Ser Pro Ser Glu Gly Thr Asn Leu
35 40 45

Asn Ala Pro Asn Ser Leu Gly Val Ser Ala Leu Cys Ala Ile Cys Gly
50 55 60

Asp Arg Ala Thr Gly Lys His Tyr Gly Ala Ser Ser Cys Asp Gly Cys
65 70 75 80

Lys Gly Phe Phe Arg Arg Ser Val Arg Lys Asn His Met Tyr Ser Cys
85 90 95

Arg Phe Ser Arg Gln Cys Val Val Asp Lys Asp Lys Arg Asn Gln Cys
100 105 110

-continued

Arg Tyr Cys Arg Leu Lys Lys Cys Phe Arg Ala Gly Met Lys Lys Glu
115 120 125

Ala Val Gln Asn Glu Arg Asp Arg Ile Ser Thr Arg Arg Ser Ser Tyr
130 135 140

Glu Asp Ser Ser Leu Pro Ser Ile Asn Ala Leu Leu Gln Ala Glu Val
145 150 155 160

Leu Ser Arg Gln Ile Thr Ser Pro Val Ser Gly Ile Asn Gly Asp Ile
165 170 175

Arg Ala Lys Lys Ile Ala Ser Ile Ala Asp Val Cys Glu Ser Met Lys
180 185 190

Glu Gln Leu Leu Val Leu Val Glu Trp Ala Lys Tyr Ile Pro Ala Phe
195 200 205

Cys Glu Leu Pro Leu Asp Asp Gln Val Ala Leu Leu Arg Ala His Ala
210 215 220

Gly Glu His Leu Leu Leu Gly Ala Thr Lys Arg Ser Met Val Phe Lys
225 230 235 240

Asp Val Leu Leu Leu Gly Asn Asp Tyr Ile Val Pro Arg His Cys Pro
245 250 255

Glu Leu Ala Glu Met Ser Arg Val Ser Ile Arg Ile Leu Asp Glu Leu
260 265 270

Val Leu Pro Phe Gln Glu Leu Gln Ile Asp Asp Asn Glu Tyr Ala Tyr
275 280 285

Leu Lys Ala Ile Ile Phe Phe Asp Pro Asp Ala Lys Gly Leu Ser Asp
290 295 300

Pro Gly Lys Ile Lys Arg Leu Arg Ser Gln Val Gln Val Ser Leu Glu
305 310 315 320

Asp Tyr Ile Asn Asp Arg Gln Tyr Asp Ser Arg Gly Arg Phe Gly Glu
325 330 335

Leu Leu Leu Leu Pro Thr Leu Gln Ser Ile Thr Trp Gln Met Ile
340 345 350

Glu Gln Ile Gln Phe Ile Lys Leu Phe Gly Met Ala Lys Ile Asp Asn
355 360 365

Leu Leu Gln Glu Met Leu Leu Gly Gly Pro Cys Gln Ala Gln Glu Gly
370 375 380

Arg Gly Trp Ser Gly Asp Ser Pro Gly Asp Arg Pro His Thr Val Ser
385 390 395 400

Ser Pro Leu Ser Ser Leu Ala Ser Pro Leu Cys Arg Phe Gly Gln Val
405 410 415

Ala

<210> SEQ ID NO 10

<211> LENGTH: 452

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr
1 5 10 15

Asp Thr Ser Pro Ser Glu Gly Thr Asn Leu Asn Ala Pro Asn Ser Leu
20 25 30

Gly Val Ser Ala Leu Cys Ala Ile Cys Gly Asp Arg Ala Thr Gly Lys
35 40 45

His Tyr Gly Ala Ser Ser Cys Asp Gly Cys Lys Gly Phe Phe Arg Arg
50 55 60

-continued

Ser Val Arg Lys Asn His Met Tyr Ser Cys Arg Phe Ser Arg Gln Cys
 65 70 75 80
 Val Val Asp Lys Asp Lys Arg Asn Gln Cys Arg Tyr Cys Arg Leu Lys
 85 90 95
 Lys Cys Phe Arg Ala Gly Met Lys Lys Glu Ala Val Gln Asn Glu Arg
 100 105 110
 Asp Arg Ile Ser Thr Arg Arg Ser Ser Tyr Glu Asp Ser Ser Leu Pro
 115 120 125
 Ser Ile Asn Ala Leu Leu Gln Ala Glu Val Leu Ser Arg Gln Ile Thr
 130 135 140
 Ser Pro Val Ser Gly Ile Asn Gly Asp Ile Arg Ala Lys Lys Ile Ala
 145 150 155 160
 Ser Ile Ala Asp Val Cys Glu Ser Met Lys Glu Gln Leu Leu Val Leu
 165 170 175
 Val Glu Trp Ala Lys Tyr Ile Pro Ala Phe Cys Glu Leu Pro Leu Asp
 180 185 190
 Asp Gln Val Ala Leu Leu Arg Ala His Ala Gly Glu His Leu Leu Leu
 195 200 205
 Gly Ala Thr Lys Arg Ser Met Val Phe Lys Asp Val Leu Leu Leu Gly
 210 215 220
 Asn Asp Tyr Ile Val Pro Arg His Cys Pro Glu Leu Ala Glu Met Ser
 225 230 235 240
 Arg Val Ser Ile Arg Ile Leu Asp Glu Leu Val Leu Pro Phe Gln Glu
 245 250 255
 Leu Gln Ile Asp Asp Asn Glu Tyr Ala Tyr Leu Lys Ala Ile Ile Phe
 260 265 270
 Phe Asp Pro Asp Ala Lys Gly Leu Ser Asp Pro Gly Lys Ile Lys Arg
 275 280 285
 Leu Arg Ser Gln Val Gln Val Ser Leu Glu Asp Tyr Ile Asn Asp Arg
 290 295 300
 Gln Tyr Asp Ser Arg Gly Arg Phe Gly Glu Leu Leu Leu Leu Pro
 305 310 315 320
 Thr Leu Gln Ser Ile Thr Trp Gln Met Ile Glu Gln Ile Gln Phe Ile
 325 330 335
 Lys Leu Phe Gly Met Ala Lys Ile Asp Asn Leu Leu Gln Glu Met Leu
 340 345 350
 Leu Gly Gly Ser Pro Ser Asp Ala Pro His Ala His His Pro Leu His
 355 360 365
 Pro His Leu Met Gln Glu His Met Gly Thr Asn Val Ile Val Ala Asn
 370 375 380
 Thr Met Pro Thr His Leu Ser Asn Gln Met Cys Glu Trp Pro Arg
 385 390 395 400
 Pro Arg Gly Gln Ala Ala Thr Pro Glu Thr Pro Gln Pro Ser Pro Pro
 405 410 415
 Gly Gly Ser Gly Ser Glu Pro Tyr Lys Leu Leu Pro Gly Ala Val Ala
 420 425 430
 Thr Ile Val Lys Pro Leu Ser Ala Ile Pro Gln Pro Thr Ile Thr Lys
 435 440 445
 Gln Glu Val Ile
 450

-continued

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Met	Val	Ser	Val	Asn	Ala	Pro	Leu	Gly	Ala	Pro	Val	Glu	Ser	Ser	Tyr
1						5				10					15

Asp	Thr	Ser	Pro	Ser	Glu	Gly	Thr	Asn	Leu	Asn	Ala	Pro	Asn	Ser	Leu
						20				25					30

Gly	Val	Ser	Ala	Leu	Cys	Ala	Ile	Cys	Gly	Asp	Arg	Ala	Thr	Gly	Lys
						35			40			45			

His	Tyr	Gly	Ala	Ser	Ser	Cys	Asp	Gly	Cys	Lys	Gly	Phe	Phe	Arg	Arg
						50			55			60			

Ser	Val	Arg	Lys	Asn	His	Met	Tyr	Ser	Cys	Arg	Phe	Ser	Arg	Gln	Cys
65						70			75			80			

Val	Val	Asp	Lys	Asp	Lys	Arg	Asn	Gln	Cys	Arg	Tyr	Cys	Arg	Leu	Lys
						85			90			95			

Lys	Cys	Phe	Arg	Ala	Gly	Met	Lys	Lys	Glu	Ala	Val	Gln	Asn	Glu	Arg
						100			105			110			

Asp	Arg	Ile	Ser	Thr	Arg	Arg	Ser	Ser	Tyr	Glu	Asp	Ser	Ser	Leu	Pro
						115			120			125			

Ser	Ile	Asn	Ala	Leu	Leu	Gln	Ala	Glu	Val	Leu	Ser	Arg	Gln	Ile	Thr
						130			135			140			

Ser	Pro	Val	Ser	Gly	Ile	Asn	Gly	Asp	Ile	Arg	Ala	Lys	Lys	Ile	Ala
145						150			155			160			

Ser	Ile	Ala	Asp	Val	Cys	Glu	Ser	Met	Lys	Glu	Gln	Leu	Leu	Val	Leu
						165			170			175			

Val	Glu	Trp	Ala	Lys	Tyr	Ile	Pro	Ala	Phe	Cys	Glu	Leu	Pro	Leu	Asp
						180			185			190			

Asp	Gln	Val	Ala	Leu	Leu	Arg	Ala	His	Ala	Gly	Glu	His	Leu	Leu	Leu
						195			200			205			

Gly	Ala	Thr	Lys	Arg	Ser	Met	Val	Phe	Lys	Asp	Val	Leu	Leu	Leu	Gly
						210			215			220			

Asn	Asp	Tyr	Ile	Val	Pro	Arg	His	Cys	Pro	Glu	Leu	Ala	Glu	Met	Ser
225						230			235			240			

Arg	Val	Ser	Ile	Arg	Ile	Leu	Asp	Glu	Leu	Val	Leu	Pro	Phe	Gln	Glu
						245			250			255			

Leu	Gln	Ile	Asp	Asp	Asn	Glu	Tyr	Ala	Tyr	Leu	Lys	Ala	Ile	Ile	Phe
						260			265			270			

Phe	Asp	Pro	Asp	Ala	Lys	Gly	Leu	Ser	Asp	Pro	Gly	Lys	Ile	Lys	Arg
						275			280			285			

Leu	Arg	Ser	Gln	Val	Gln	Val	Ser	Leu	Glu	Asp	Tyr	Ile	Asn	Asp	Arg
						290			295			300			

Gln	Tyr	Asp	Ser	Arg	Gly	Arg	Phe	Gly	Glu	Leu	Leu	Leu	Leu	Leu	Pro
						305			310			315			320

Thr	Leu	Gln	Ser	Ile	Thr	Trp	Gln	Met	Ile	Glu	Gln	Ile	Gln	Phe	Ile
						325			330			335			

Lys	Leu	Phe	Gly	Met	Ala	Lys	Ile	Asp	Asn	Leu	Leu	Gln	Glu	Met	Leu
						340			345			350			

Leu	Gly	Gly	Ser	Pro	Ser	Asp	Ala	Pro	His	Ala	His	His	Pro	Leu	His
						355			360			365			

Pro	His	Leu	Met	Gln	Glu	His	Met	Gly	Thr	Asn	Val	Ile	Val	Ala	Asn
						370			375			380			

Thr	Met	Pro	Thr	His	Leu	Ser	Asn	Gly	Gln	Met	Ser	Thr	Pro	Glu	Thr
						385			390			395			400

-continued

Pro Gln Pro Ser Pro Pro Gly Gly Ser Gly Ser Glu Pro Tyr Lys Leu
 405 410 415

Leu Pro Gly Ala Val Ala Thr Ile Val Lys Pro Leu Ser Ala Ile Pro
 420 425 430

Gln Pro Thr Ile Thr Lys Gln Glu Val Ile
 435 440

<210> SEQ ID NO 12

<211> LENGTH: 395

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

Met Val Ser Val Asn Ala Pro Leu Gly Ala Pro Val Glu Ser Ser Tyr
 1 5 10 15

Asp Thr Ser Pro Ser Glu Gly Thr Asn Leu Asn Ala Pro Asn Ser Leu
 20 25 30

Gly Val Ser Ala Leu Cys Ala Ile Cys Gly Asp Arg Ala Thr Gly Lys
 35 40 45

His Tyr Gly Ala Ser Ser Cys Asp Gly Cys Lys Gly Phe Phe Arg Arg
 50 55 60

Ser Val Arg Lys Asn His Met Tyr Ser Cys Arg Phe Ser Arg Gln Cys
 65 70 75 80

Val Val Asp Lys Asp Lys Arg Asn Gln Cys Arg Tyr Cys Arg Leu Lys
 85 90 95

Lys Cys Phe Arg Ala Gly Met Lys Lys Glu Ala Val Gln Asn Glu Arg
 100 105 110

Asp Arg Ile Ser Thr Arg Arg Ser Ser Tyr Glu Asp Ser Ser Leu Pro
 115 120 125

Ser Ile Asn Ala Leu Leu Gln Ala Glu Val Leu Ser Arg Gln Ile Thr
 130 135 140

Ser Pro Val Ser Gly Ile Asn Gly Asp Ile Arg Ala Lys Lys Ile Ala
 145 150 155 160

Ser Ile Ala Asp Val Cys Glu Ser Met Lys Glu Gln Leu Leu Val Leu
 165 170 175

Val Glu Trp Ala Lys Tyr Ile Pro Ala Phe Cys Glu Leu Pro Leu Asp
 180 185 190

Asp Gln Val Ala Leu Leu Arg Ala His Ala Gly Glu His Leu Leu Leu
 195 200 205

Gly Ala Thr Lys Arg Ser Met Val Phe Lys Asp Val Leu Leu Leu Gly
 210 215 220

Asn Asp Tyr Ile Val Pro Arg His Cys Pro Glu Leu Ala Glu Met Ser
 225 230 235 240

Arg Val Ser Ile Arg Ile Leu Asp Glu Leu Val Leu Pro Phe Gln Glu
 245 250 255 265

Leu Gln Ile Asp Asp Asn Glu Tyr Ala Tyr Leu Lys Ala Ile Ile Phe
 260 265 270

Phe Asp Pro Asp Ala Lys Gly Leu Ser Asp Pro Gly Lys Ile Lys Arg
 275 280 285

Leu Arg Ser Gln Val Gln Ser Leu Glu Asp Tyr Ile Asn Asp Arg
 290 295 300

Gln Tyr Asp Ser Arg Gly Arg Phe Gly Glu Leu Leu Leu Leu Pro
 305 310 315 320

Thr Leu Gln Ser Ile Thr Trp Gln Met Ile Glu Gln Ile Gln Phe Ile

US 9,981,048 B2

69**70**

-continued

325 330 335

Lys Leu Phe Gly Met Ala Lys Ile Asp Asn Leu Leu Gln Glu Met Leu
 340 345 350

Leu Gly Gly Pro Cys Gln Ala Gln Glu Gly Arg Gly Trp Ser Gly Asp
 355 360 365

Ser Pro Gly Asp Arg Pro His Thr Val Ser Ser Pro Leu Ser Ser Leu
 370 375 380

Ala Ser Pro Leu Cys Arg Phe Gly Gln Val Ala
 385 390 395

<210> SEQ ID NO 13

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 13

atggacatgg ctgactacag tgct

24

<210> SEQ ID NO 14

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 14

acagcttgag gctccgtagt gttt

24

<210> SEQ ID NO 15

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 15

tctagagggc ctggagttca

20

<210> SEQ ID NO 16

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 16

tcactgtctg gcctgttgag

20

<210> SEQ ID NO 17

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 17

ttcaatgtcc ctgccccatgtta

20

<210> SEQ ID NO 18

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 18
catctccaga gtccagcaca 20

<210> SEQ ID NO 19
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 19
ttgctgacag gatgcagaag 20

<210> SEQ ID NO 20
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 20
cagtgaggcc aggatagagc 20

<210> SEQ ID NO 21
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 21
gcccgacata cgaagaaaac a 21

<210> SEQ ID NO 22
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 22
tctcttgtc tggaaaggatt cct 23

<210> SEQ ID NO 23
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 23
tctgcacact cccagacaag 20

<210> SEQ ID NO 24
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 24
agtcacccat caccgtcttc 20

```

-continued

<210> SEQ ID NO 25
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 25

ggcaaggatt tcatggagaa

20

<210> SEQ ID NO 26
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 26

cccgagttctc tggacaaaagg

20

<210> SEQ ID NO 27
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 27

acatggaaaca agcctccaag

20

<210> SEQ ID NO 28
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 28

tggccaccac agctatatca

20

<210> SEQ ID NO 29
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 29

tgaaccgcctt ctgggattac

20

<210> SEQ ID NO 30
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 30

tgtgtgactt gggagctctg

20

<210> SEQ ID NO 31
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 31

ggaggatctg agggaaagacc

20

<210> SEQ ID NO 32

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 32

ggcagcagat cctttcagag

20

<210> SEQ ID NO 33

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 33

tttggtgcca cacagcttg

19

<210> SEQ ID NO 34

<211> LENGTH: 22

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 34

atggaataaca cctgcgttaac gg

22

<210> SEQ ID NO 35

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 35

gaaggcctaa gcacaacacg

20

<210> SEQ ID NO 36

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 36

aagcacttga ccctggtacg

20

<210> SEQ ID NO 37

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 37

gccagaaga ctggatggataa

20

<210> SEQ ID NO 38

-continued

<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 38

aacacccctct gctgcgtctc

20

<210> SEQ ID NO 39
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 39

gctcagatct ttgcgaattc

20

<210> SEQ ID NO 40
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 40

cgcttcgatt tctgtctcc

19

<210> SEQ ID NO 41
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 41

tggtcctcaa ggtttccaag

20

<210> SEQ ID NO 42
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 42

ttaccagctt ccccatcatc

20

<210> SEQ ID NO 43
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 43

tgcagaaaat ggttgcttg

20

<210> SEQ ID NO 44
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 44

-continued

gctttcctga ttgccgttaag 20

<210> SEQ ID NO 45
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 45

atggagatca cagcccaagt 20

<210> SEQ ID NO 46
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 46

cgcatcttcctc ctgcagtttc 20

<210> SEQ ID NO 47
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 47

tgagaatggt gaatgccagt 20

<210> SEQ ID NO 48
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 48

gagtcatctc cgccttcatc 20

<210> SEQ ID NO 49
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 49

taacccaggaa ggaagcacac 20

<210> SEQ ID NO 50
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 50

cttcatttgca ctccctctcc 20

<210> SEQ ID NO 51
<211> LENGTH: 20
<212> TYPE: DNA

-continued

```

<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 51

ccatccgtca ttctctctcc                                20

<210> SEQ ID NO 52
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 52

tcgaacatgt tgccagagt                                20

<210> SEQ ID NO 53
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 53

gacgtctcca ggtctcaacc                                20

<210> SEQ ID NO 54
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 54

cacccgtgtt agtgaacgtg                                20

<210> SEQ ID NO 55
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 55

ctcaccctca gctggatagg                                20

<210> SEQ ID NO 56
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 56

ccctttggag tagctgcttg                                20

<210> SEQ ID NO 57
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 57

aatgcaatcc gtttttggaaag                                20

```

-continued

<210> SEQ ID NO 58
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 58

gccagagatt tgaggtctgc

20

<210> SEQ ID NO 59
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 59

catcgtggac aacatgaagg

20

<210> SEQ ID NO 60
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 60

cagggtctgt aggcaggttc

20

<210> SEQ ID NO 61
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 61

ttgaagggtc tggaagagga

20

<210> SEQ ID NO 62
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 62

tcatcgaaca agcagagcag

20

<210> SEQ ID NO 63
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 63

gcatctgacc cgagtctctc

20

<210> SEQ ID NO 64
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 64

gaatggcctg agctttcag

20

<210> SEQ ID NO 65

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 65

aatggagatg gcaaagagga

20

<210> SEQ ID NO 66

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 66

gagagccgaa cagtttgaag

20

<210> SEQ ID NO 67

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 67

ggactctcca cctgc当地

20

<210> SEQ ID NO 68

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 68

gactggcgag ccttagttt

20

<210> SEQ ID NO 69

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 69

ggttccctgg cataatctga

20

<210> SEQ ID NO 70

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 70

atggctgaac agggaaacac

20

-continued

<210> SEQ ID NO 71
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 71

tggacgttgg aggaaaagaag

20

<210> SEQ ID NO 72
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 72

tcccaggcga caataaaatgc

20

<210> SEQ ID NO 73
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 73

tgtgcaacctt tgtggagagg

20

<210> SEQ ID NO 74
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 74

aattgcaacc cagggtggtag

20

<210> SEQ ID NO 75
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 75

tcgtactgga aggctttgg

20

<210> SEQ ID NO 76
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 76

gtaggagtag gggctgagca

20

<210> SEQ ID NO 77
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 77

ggttttgag ggtgagggtg agggtgaggg tgagggt

37

<210> SEQ ID NO 78

<211> LENGTH: 39

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 78

tcccgactat ccctatccct atccctatcc ctatcccta

39

<210> SEQ ID NO 79

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 79

cagcaagtgg gaagggtgtaa tcc

23

<210> SEQ ID NO 80

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 80

ccccattctat catcaacggg tacaa

25

The invention claimed is:

1. A method of treating hepatic failure in a human subject, comprising administering intravenously, to a human subject having liver failure, a therapeutically effective amount of a pharmaceutical composition comprising a therapeutic adeno-associated virus vector comprising a nucleic acid encoding a human HNF4 α , protein operably linked to a promoter, wherein administration of said nucleic acid results in expression of the human HNF4 α protein and improved liver function.

- 40
2. The method of claim 1, wherein the improved liver function is indicated by an increase in serum albumin.
 3. The method of claim 1, wherein the improved liver function is indicated by decreased serum ammonia level.
 4. The method of claim 1, wherein the improved liver function is indicated by a decrease in total bilirubin.
 5. The method of claim 1, wherein the improved liver function is indicated by an improved encephalopathy score.
 6. The method of claim 1, wherein the administration of
- 45
- said nucleic acid treats Child-Pugh Class B or C.

* * * * *